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Chromothripsis and focal copy number alterations determine poor outcome in malignant
melanoma
T Gaiser,4,1 MR Gaiser,3 D Hirsch,1 R Kemmerling,2 S Davis,1 PS Meltzer1 and T Ried1 1 Genetics
Branch, National Institutes of Health, Bethesda, MD, 2 Institute of Pathology, Paracelsus
Medical University, Salzburg, Austria, 3 Department of Dermatology, University of
Heidelberg, Heidelberg, Germany and 4 Institute of Pathology, University Medical Center
Mannheim, Mannheim, Germany
Genetic changes during tumorigenesis are usually acquired sequentially. However, a recent study
showed that in 2 to 3% of all cancers a single catastrophic event, termed chromothripsis, can lead
to massive genomic rearrangements confined to one or a few chromosomes. In order to explore
whether the degree of genomic instability and chromothripsis influences prognosis in cancer, we
retrospectively applied array comparative genomic hybridization (aCGH) to 20 malignant melanomas
(MM) that showed, despite comparable conventional clinical and pathological parameters, a pro-
foundly different clinical course. We compared 10 patients who died of MM 3.7 years (median,
range 0.9 to 7.6 years) after diagnosis with 10 patients who had a median disease-free survival of
14.8 years (range 12.5 to 16.7 years; P = 0.00001). We observed a striking association between the
degree of chromosomal instability, both numerical and structural, and outcome. MM associated
with good prognosis showed only few chromosomal imbalances (mean 1.6 alterations per case),
predominantly whole chromosome or chromosome arm gains and losses while MM with poor prog-
nosis harbored significantly more chromosomal aberrations (13.9 per case; P = 0.008). aCGH showed
that these aberrations were mostly focal events, which culminated in two cases in a pattern con-
sistent with the phenomenon of chromothripsis, which was confirmed by paired-end sequencing.
This is the first description of chromothripsis in primary MM. Our study therefore links focal copy
number alterations and chromothripsis with poor outcome in MM patients (P = 0.0002) and pro-
vides a genetic approach to predict outcome in MM.
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REC8 is aberrantly expressed in melanoma and may act as a driver of genomic instability
SF Lindsey, M Eller, J Escandon, M Sanchez and JM Grichnik Department of Dermatology,
University of Miami Miller School of Medicine, Miami, FL
Melanomas include a subpopulation of cells with stem/germ cell-like features. To examine whether
the expression of germ cell proteins plays a role in the development of chromosomal instability in
melanoma, we studied a protein known to be crucial for meiotic division, REC8. REC8 is a major
subunit of the meiotic cohesin complex, and is involved in sister chromatid cohesion and crossover
events during meiosis. While one would expect this protein to be limited to germ cells, we found
increased levels of REC8 RNA in melanoma tissue compared to normal tissues by qPCR analysis
(p=0.03). We also compared protein levels in vitro and found increased REC8 expression in multi-
ple melanoma cell lines as compared to normal human melanocytes and fibroblasts. We hypothe-
sized that the aberrant expression of this protein during mitosis would lead to defects in chromo-
somal segregation. To further explore this hypothesis, we constructed a REC8-GFP fusion protein
under the constitutive expression of the ubiquitin promoter. As a control, GFP alone under the
ubiquitin promoter was utilized. These recombinant DNAs were co-transfected with histone H2B
tagged with mCherry into HEK293T cells. While the control GFP + cells primarily revealed normal
appearing nuclei, the cells that were cotransfected with the REC8-GFP fusion protein demonstrated
DNA bridging and polyploidy. In summary, we have shown that a meiosis protein known to be
involved in chromosomal cohesion is inappropriately expressed in melanoma. Overexpression leads
to nuclear abnormalities suggestive of failed normal segregation. Taken together, these results sug-
gest that the aberrant expression of the meiosis protein REC8 during mitosis may act as a driver for
chromosomal instability.
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An attempt to assess the expression of desmogleins 2 and 3 with fluorescent in situ hybridiza-
tion and immunohistochemistry in basal cell carcinomas
M Dmochowski,1 J Gornowicz-Porowska,1 P Pietkiewicz,1 E Kaczmarek,2 A Seraszek-Jaros2 and
M Bowszyc-Dmochowska1 1 Cutaneous Histopathology and Immunopathology Section,
Department of Dermatology, Poznan University of Medical Sciences, Poznan, Poland and 2
Department of Bioinformatics and Computational Biology, Poznan University of Medical
Sciences, Poznan, Poland
The abnormal expression of desmogleins (DSG) in basal cell carcinomas (BCC) is reported. How-
ever, there are no data on their simultaneous expression profile at the various levels of biosynthe-
sis. Here, we comparatively examined the expression of DSG2 and DSG3 with fluorescent in situ
hybridization (FISH) and immunohistochemistry (IHC) in BCC nests. Altogether, frozen sections from
47 patients with various clinical/histological subtypes of BCC were analyzed using IHC with mon-
oclonal antibodies against human DSG2 and DSG3, and FISH with fluorescent-labeled oligonu-
cleotide probes for the human DSG2 and DSG3 mRNA. The sequences of human DSG2 and DSG3
mRNA were obtained from GenBank. The probes were used: DSG2 (5’-6-FAM/5-TAMRA-AAAgT-
gTAgCTgCTgTgTTCCTCTCTgTCCAA-3’), DSG3 (5’-6-FAM-AgTTgTTCATAATCTAgAgCCTTCAC-
CACTTTCAggA-3’). IHC data suggested that at the protein level there is a quantitatively significant
overexpression of DSG2 and underexpression of DSG3 in BCC nests. Moreover, it appears that
with the use of FISH and semiquantitative expression evaluation there are no changes in DSG2 and
DSG3 mRNA expression in BCC nests. Thus, it seems that there are differences between the
DSG2/DSG3 protein and mRNA expression in BCC nests. This data might provide evidence that
the possible mechanism which regulates biosynthesis of DSG2/DSG3 in BCC nests could be induced
through local-dependent translational control/locus control element. The discrepancy in the
DSG2/DSG3 expression between mRNA and protein in BCC nests could be due to the posttran-
scriptional/translational modification of DSG2/DSG3 associated with the complex synthesis and
transport of DSG (inactive precursors in the cytoplasm/biologically active mature proteins within
desmosomes on the cell surface).
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Autophagy controls p38 activation to promote cell survival under UVB stress
L Qiang,1 C Wu,1,2 M Ming,1 B Viollet3,4,5 and Y He1 1 Dermatology/Medicine, University of
Chicago, Chicago, IL, 2 Radiation Oncology, China Medical University, Chicago, China, 3
Inserm, U1016, Institut Cochin, Paris, France, 4 Cnrs, UMR8104, Paris, France and 5 Univ
Paris Descartes, Paris, France
Deregulated cell survival under carcinogen-induced genotoxic stress is vital for cancer develop-
ment. One of the cellular processes critical for cell survival under metabolic stress and energy star-
vation is autophagy, a catabolic process involved in capture and delivery of cytoplasmic compo-
nents to lysosomes for degradation. However, the role of autophagy following carcinogen-induced
genotoxic stress remains unclear. Here we show that UVB radiation, a known human skin carcinogen
that operates by causing DNA damage, induced autophagy and autophagic flux through AMPK acti-
vation. Autophagy deficiency sensitizes cells to UVB-induced apoptosis through increasing p62-
dependent activation of the stress-activated protein kinase p38. As compared with normal human
skin, autophagy was activated in human squamous cell carcinomas, in association with decreased
phosphorylation of p38, and increased phosphorylation of ATR and formation of gamma-H2AX,
two markers of DNA damage response. Our results demonstrate that autophagy promotes cell sur-
vival through suppressing p62-mediated p38 activation and thus may facilitate tumor development
under genotoxic stress. These findings suggest that autophagy plays an oncogenic role in epithelial
carcinogenesis by promoting cell survival.
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Targeting PI3K/mTOR signaling in cutaneous angiosarcoma
M Wada,1 M Horinaka,2 T Sakai,2 M Masuzawa3 and N Katoh1 1 Department of Dermatology,
Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan,
2 Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical
Science, Kyoto Prefectural University of Medicine, Kyoto, Japan and 3 Department of
Regulation Biochemistry, Kitasato University School of Allied Health Sciences, Kanagawa,
Japan
Angiosarcoma is a rare and aggressive malignant neoplasm of endothelial cells. Recent data have
shown that the mTOR pathway is also aberrantly activated in cutaneous angiosarcoma. Since the
prognosis of this disease is still poor, new therapeutic strategies are required. We investigated the
sensitivity of inhibitors for PI3K/AKT/mTOR pathway in ISOS-1 and ISO-HAS cutaneous angiosar-
coma cell lines. In both cells, PI3K inhibitor and mTOR inhibitor, not AKT inhibitor demonstrated
the growth inhibition in a dose-dependent manner. Interestingly, PI3K inhibitor more effectively
caused cell cycle arrest at the G1 phase with downregulation of cyclinD1 expression than mTOR
inhibitor in ISOS-1 cells. Taken together, PI3K inhibition rather than mTORC1 inhibition might be
the appropriate strategy to treat cutaneous angiosarcoma, and therefore PI3K inhibitor is promising
for the therapy.
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UAB30, a novel synthetic RXR retinoid, is an effective chemopreventive agent against UVB-
induced nonmelanoma skin cancers
GH Nguyen, SC Chaudhary, RK Srivastava, CA Elmets and M Athar Department of Dermatology,
University of Alabama at Birmingham, Birmingham, AL
Systemic retinoids are useful for the chemoprophylaxis of basal cell carcinomas (BCCs) and squa-
mous cell carcinomas (SCCs) in high risk populations, but significant toxicities currently limit their
long-term use. UAB30 is a unique synthetic retinoid with low toxicity due to its high selectivity for
activating retinoid X receptors (RXR), while having no significant retinoic acid receptor (RAR)-bind-
ing activity. Our aim was to investigate whether UAB30 is effective at inhibiting UVB-induced skin
carcinogenesis in a relevant murine model. We used genetically engineered Ptch+/-/SKH-1 hairless
mice because they recapitulate the pathogenesis of human nonmelanoma skin cancer development
following chronic ultraviolet B (UVB) exposure. The animals were divided in half, with one group
receiving UAB30 through oral gavage, while another group received a vehicle control. Both groups
were chronically irradiated with UVB (180 mJ/cm2; twice per week) for 30 weeks. Compared to
controls, the UAB30 treated group showed a 48% reduction in tumor number and a 78% reduc-
tion in tumor volume. The number of papillomas, BCCs, and SCCs were reduced by 33%, 74%,
and 76%, respectively. In addition, treatment with UAB30 diminished UVB-induced skin hyper-
plasia, and enhanced differentiation of suprabasal epidermal cells. UAB30 also decreased prolif-
eration and increased apoptosis of tumor cells, as demonstrated by increased expression of pro-
apoptotic proteins and decreased expression of cell cycle regulatory proteins. Moreover, target genes
of the sonic hedgehog signaling pathway, which is constitutively activated in >90% of BCCs, were
downregulated in the UAB30 treatment group. In summary, UAB30 is a potent chemopreventive
agent for blocking skin photocarcinogenesis, and holds great promise in the chemoprevention of
nonmelanoma skin cancers among high risk populations, such as in solid organ transplant recipi-
ents and individuals with chronic actinic damage.
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GLI2 induces genomic instability in human keratinocytes by inhibiting apoptosis
E Pantazi,1 E Gemenetzidis,1 G Trigiante,1 G Warnes,2 L Shan,3 E Mao,3 M Ikram,3 G Neill,1
M Teh,4 Y Lu3 and M Philpott1 1 Centre for Cutaneous Research, Institute of Cell and Molecular
Science,Barts and The London School of Medicine and Dentistry, Queen Mary University of
London, LONDON, United Kingdom, 2 Imaging and Flow Cytometry Core facilities, Institute
of Cell and Molecular Science,Barts and The London School of Medicine and Dentistry,
Queen Mary University of London, LONDON, United Kingdom, 3 Centre for Molecular
Oncology, Barts Cancer Institute, Barts and The London School of Medicine and Dentistry,
Queen Mary University of London, LONDON, United Kingdom and 4 Department of
Diagnostic and Oral Sciences, Institute of Cell and Molecular Science, Barts and The London
School of Medicine and Dentistry, Queen Mary University of London, LONDON, United
Kingdom
Abnormal Sonic Hedgehog (SHH) signalling leads to increased transcriptional activation of its down-
stream effector, GLI2, which is implicated in the pathogenesis of a variety of human cancers. How-
ever, the mechanisms underlying the tumorigenic role of GLI2 remain elusive. We demonstrate that
overexpression of GLI2ΔN in human keratinocytes, is sufficient to induce numerical and structural
chromosomal aberrations, such as tetraploidy/aneuploidy and chromosomal translocations, respec-
tively. This is coupled with suppression of cell-cycle regulators 14-3-3σ and p21WAF1/CIP1, and
strong induction of the anti-apoptotic signaling which reduces the ability to eliminate genomically
unstable cells. We demonstrate that, forced overexpression of GLI2ΔN renders human keratinocytes
resistant to apoptosis mediated by ultraviolet (UV) B, one of the most important etiological factors
in BCC formation, while inhibition of the anti-apoptotic BCL-2 protein restores endogenous (genomic
instability) and exogenous (UVB) DNA damage-induced apoptosis. This study reveals a novel role
and associated mechanisms of GLI2 in the generation of genomic instability, a hallmark of human
tumors, and may provide new opportunities in designing novel forms of cancer therapeutic strate-
gies by targeting GLI2 itself or relevant mechanisms.
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Langerhans cell contribution to UV-induced DNA damage and carcinogenesis
M Freudzon, J Lewis, R Filler and M Girardi Dermatology, Yale University School of Medicine,
New Haven, CT
Resident epidermal dendritic cells, called Langerhans cells (LC), were recently shown to facilitate
DMBA/TPA-induced chemical carcinogenesis. LC contribution to UV-induced carcinogenesis, how-
ever, remains to be elucidated. In this study, we used genetically engineered hairless LC-deficient
and LC-intact mice to characterize early and late effects of DNA damage in epidermis following
exposure to UVB light. We find that LC density in LC-intact mice remains unchanged at 1hr and
24hr post 100 J/m2 UVB (0hr: 861.4±68.4, 1hr: 894.2±126.4, 24hr: 848.2±101.7 /mm2). Thus, LC
are poised to affect the surrounding epidermal cells following acute UVB exposure. Using confo-
cal microscopy, LC-intact mice showed >2x (8556±3561 vs 4255±1320; P<0.0098) the area occu-
pied by keratinocytes containing mutated p53, a tumor suppressor protein highly associated with
squamous cell carcinoma, after 9 weeks of UVB. Since mutant p53 arises from unrepaired DNA
damage, we examined early DNA damage following UVB exposure. At 1hr post 100 J/m2 UVB
exposure, LC-intact mice showed significantly greater keratinocytes containing γH2AX (130.6±15.4
vs 75.7±7.1 /mm2, P=0.0030), a phosphorylated histone indicative of non-specific DNA damage;
therefore, LC impart substantial influences on UVB induced keratinocyte DNA-damage. However,
when we quantified cyclobutane pyrimidine dimers, the pathognomonic direct UV-induced DNA
lesions, LC-intact and LC-deficient skin showed no differences at 1 and 24 hours following 100 J/m2
UVB exposure. Taken together, these results suggest that LC influence UVB-induced DNA-damage
and clonal expansion in adjacent keratinocytes, supporting an hypothesis of “cooperative carcino-
genesis.” Collectively, these data give new insight into the previously unknown role of LC in UV-
induced carcinogenesis, and may facilitate the development of novel preventive and therapeutic
targets against skin cancer.
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Activated p-AKT, but not MDM2, drives malignant progression in Ras/Fos/PTENnull skin car-
cinogenesis via p53/p21 loss and cyclin D1/E2 over-expression
FH Macdonald, Y Denggao, JA Quinn and DA Greenhalgh Dermatology, Glasgow University
Medical School, Glasgow, United Kingdom
Tumour progression depends on a complex combination of the genetic mutation milieu pitted against
the sentinel systems that have evolved to resist carcinogenesis at each specific stage. To investigate
tumour progression mechanism in transgenic mouse skin carcinogenesis, inducible PTEN ablation
[Δ5PTEN] was introduced into the epidermis of mice expressing activated rasHa/fos oncogenes.
RU486-treated HK1.ras/fos-Δ5PTEN mice exhibited accelerated papillomatogenesis but malignant
conversion was delayed due to compensatory p53/p21 expression. Following p53 loss, malignant
progression was limited to well-differentiated squamous cell carcinoma via persistent p21 expres-
sion and down regulation of cyclin E2. Analysis of AKT activity during papillomatogenesis showed
reduced p-AKT expression, associated with fos/PTEN feedback, which returned following p53 loss
to circumvent/antagonise p21 expression; co-operate with MAPK signalling [i.e. elevated ERK1/2
expression]; and accelerate tumour progression via increased cyclin D1 and E2 expression. In con-
trast elevated, suprabasal MDM2 expression in p53-positive papillomas was lost and paralleled
that of p53; hence sustained MDM2-mediated p53 ubiquination does not appear to influence this
progression mechanism. These data suggest p53/p21 counter deregulated MAPK signalling during
papillomatogenesis and help minimise consequences of PTEN loss via p-AKT inhibition. Stepwise
p53/p21 loss subsequently facilitates ras/MAPK/fos co-operation with PTEN/AKT activities to accel-
erate malignant progression via major failures in cell cycle control. The interplay between these
common mutations thus create unique tumours contexts and insight for therapies geared to reacti-
vating p53/p21 functions or that target ras/MAPK/fos and PTEN/AKT signalling pathways.
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Intercellular contact-dependent induction mechanism of podoplanin in squamous cell car-
cinoma
M Fujii, M Honma, H Takahashi, AI Yamamoto and H Iizuka Dermatology, Asahikawa Medical
University, Asahikawa, Japan
Podoplanin (PDPN), a transmembranous glycoprotein, is expressed in various human tumors includ-
ing cutaneous neoplasms, and plays an important role in tumor invasion and metastasis. Recent
reports show that PDPN-inhibition using neutralizing antibodies and specific inhibitory chemicals
prevents tumor progression in animal models. However, detailed regulatory mechanism of PDPN-
expression has not been fully elucidated. Here, we investigated an intercellular contact-mediated
regulatory mechanism of PDPN-expression and the related signaling pathway in human squamous
cell carcinoma (SCC) cell lines. PDPN-expression was upregulated along with increased cell den-
sity in highly EGFR-expressing SCC cell-lines, such as A431, HSC2 and HSC4, but not in a less
EGFR-expressing cell-line, HSQ89. This cell density-dependent PDPN-induction was accompanied
by increased cell motility, which was reversed by PDPN-silencing using shRNA, suggesting an essen-
tial role of PDPN in the enhanced cell motility. In the confluent culture condition, phospho-EGFR
and -STAT3 was also upregulated and an EGFR-specific inhibitor, AG1478 and STAT3-silencing
using shRNA abolished the cell density-dependent PDPN-induction. In addition, exogenous EGF
or soluble EGF ligand did not induce PDPN expression, and then EGFR activation due to increased
cell-cell contact was thought to be important for PDPN induction. In human SCC lesions, PDPN
was co-localized with phosphor-EGFR and phosphor-STAT3 at invading front, suggesting a crucial
role of EGFR-STAT3 signaling pathway in the PDPN-induction mechanism both in vitro and in
vivo. The novel cell density-dependent PDPN-induction might significantly be involved in pro-
gression process of SCC and could be a possible target for SCC treatment.
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TLR4 is a negative regulator of keratinocyte proliferation
G Iotzova-Weiss, SN Freiberger, I Kleiber Schaaf, PJ Dziunycz, LE French and HF Günther
University Hospital Zurich, Dermatology Clinic, Zurich, Switzerland
Our current study investigates the role of TLR4 in the proliferation capacity of normal keratinocytes.
Our preliminary results using a blocking monoclonal antibody (HTA125) against TLR4 showed an
unexpected, pronounced proliferation of keratinocytes, assessed by BrDU proliferation assay. In
addition, we abrogated the interaction between TLR4 and its accessory protein MDII using a spe-
cific blocking peptide for MDII and we detected an induction of proliferation. We observed that
with the subsequent growing of normal primary keratinocytes and keratinocytes derived from patients
with SCC up to full confluence and differentiation, the expression of TLR4 increased significantly.
This correlates with the differential TLR4 expression within the layers in normal skin and skin from
patients with SCC In addition, we detected that the blocking HTA125 antibody induces the phos-
phorylation of SAPK/JNK and ERK1/2 in primary keratinocytes. Furthermore, we found that the tumor
SCC13 cell line, stably expressing TLR4 showed lower proliferation capacity and higher motility.
Our results show that TLR4 is a negative regulator of keratinocyte proliferation and may be associ-
ated with the progression of SCC of the skin. Better understanding of the regulatory role for TLR4 is
the basis for a later use in a therapeutic setting to stop keratinocyte proliferation such as in squa-
mous cell carcinoma of the skin and to induce keratinocyte proliferation such as in wound healing.
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Inducible ROCK 2 activation increases primary keratinocyte differentiation but co-operates
with rasHa activation in transgenic mouse skin carcinogenesis
SF Masre,1 MF Olson2 and DA Greenhalgh1 1 Section of Dermatology, Glasgow University
Medical School, Glasgow, United Kingdom and 2 Beatson Institute for Cancer Research,
Glasgow, United Kingdom
To investigate ROCK 2 signalling in epidermal differentiation and co-operation with rasHa activa-
tion in squamous cell carcinogenesis [SCCs], transgenic mice expressing a conditionally active, 4-
hydroxytamoxifen (4HT)-regulated, human ROCK2 transgene from a keratin 14 promoter
[K14.ROCKer] were crossed with mice expressing activated rasHa exclusively in epidermal transit
amplifying keratinocytes [HK1.ras]. 4HT-treatment of K14.ROCKer alone cohorts for 12 weeks
induced epidermal and follicular hyperplasia but no papillomas. Western analysis of primary
K14.ROCKer keratinocyte differentiation showed elevated K1 expression following calcium chal-
lenge in vitro, consistent with a role in differentiation, whereas little K6 expression was detectable
in 4-HT treated K14.ROCKer hyperplasia in vivo; an unusual result for epidermal hyperplasia. In
addition hyperplastic anagen follicles expressed elevated collagen deposits in the hair bulb/IRS
regions, a result also observed in bi-genic K14.ROCKer/HK1.ras papillomas. Here, 4-HT treatment
for 12-14 weeks had little apparent effect on HK1.ras papillomatogenesis, with tumours appearing
by approx 8-10 wks in treated and untreated cohorts. However K14.ROCKer/HK1.ras histotype
was quite different, with increased collagen deposits appearing in the connective tissue of papillo-
mas, which now expressed K6 but at lower levels and in an atypical, supra-basal fashion compared
to untreated, bi-genic controls. Further, the basal layer architecture was also disturbed and now 4-
HT treated K14.ROCKer/HK1.ras papillomas taken at 12-14 weeks displayed areas of malignant
conversion with both carcinoma in situ and overt SCC. These interesting data demonstrate signifi-
cant roles for ROCK 2 in epidermal differentiation and identify unique epidermal responses to its
deregulated signalling and novel early-stage co-operation with HK1.ras in skin carcinogenesis.
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Cytokine-induced senescence arrests cancers by activating the p16Ink4a/Rb pathway
M Hahn, K Braungart, S Assmann, E Brenner, T Wieder, H Braumüller and M Röcken Department
of Dermatology, University Medical Center Tuebingen, Tuebingen, Germany
Survival of metastatic melanoma after immunotherapy is associated with a stable growth arrest and
not with deletion of metastases. Dysfunctional cell cycle regulation frequently caused by impaired
p16Ink4a/Rb regulation is a key feature of cancers. RIP1-Tag2 mice (RT2) selectively express the
SV40 large T antigen (Tag) under the control of the rat insulin promoter (RIP). Tag inactivates p53
function and partially inhibits the p16Ink4a/Rb pathway what leads to neuroendocrine cancers.
Treatment with Tag-specific T helper 1 cells (Th1) inhibits tumor cell proliferation in vivo and pro-
longs the lifetime of RT2 mice. Here we found that Th1 treatment causes strong induction of p16Ink4a
expression in cancer cells. As MHC class II deficient cancers can not be directly recognized by Th1
cells, the in vivo data suggests that the Th1 cytokines IFNγ and TNF may restore the p16Ink4a/Rb
mediated cell cycle arrest in cancers. Indeed, in vivo treatment with IFNγ and TNF arrested the β
cancer cells in the G0/G1 phase of the cell cycle as determined by flow cytometry. Simultaneously,
the two cytokines increased the p16Ink4a protein levels as shown by Western Blot analysis of
p16Ink4a. To determine whether the cytokine-induced p16-protein is relevant for cell cycle arrest,
we silenced p16Ink4a and p19Arf via transduction of cancer cells with Mscv vectors containing
p16Ink4a/p19Arf- or control-shRNA. Control-shRNA did not affect the induction of a stable growth
arrest by IFNγ and TNF. In sharp contrast, IFNγ and TNF failed to induce growth arrest in cancer
cells where p16Ink4a/p19Arf was silenced. These data show that IFNγ and TNF induced growth
arrest in neuroendocrine cancers trough cytokine-mediated activation of the p16Ink4a/Rb senes-
cence pathway. This may be of general validity, as modern immunotherapies of melanomas may
arrest melanoma growth through induction of melanoma senescence.
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Drug-resistant basal cell carcinomas maintain hedgehog pathway output by activating aPKC
signaling
SX Atwood, JY Tang and AE Oro Program in Epithelial Biology, Stanford University School of
Medicine, Stanford, CA
Basal cell carcinomas (BCC) are dependent on high levels of Hedgehog (Hh) signaling for tumor
growth. Smoothened (Smo) inhibitors effectively treat BCCs, although 20% of patients develop drug-
resistant tumors indicating a need for additional therapeutic targets downstream of Smo. Previ-
ously, we identified atypical Protein Kinase C iota/lambda (aPKC) as a novel BCC oncogene essen-
tial for Hh signaling. How aPKC mediates its effects on the pathway and its role in tumorigenesis
remains unclear. Here we show aPKC operates downstream of Smo to phosphorylate and activate
Gli1, resulting in high affinity DNA binding and Hh activation. aPKC and Gli1 form a complex as
recombinant aPKC and Gli coimmunoprecipitate. Purified aPKC directly phosphorylates Gli1 in
vitro and in vivo with the majority of the phosphorylation occurring in the zinc finger DNA bind-
ing region of Gli1. We performed a mutagenesis screen of the DNA binding domain to determine
the site of aPKC phosphorylation and found that two residues in the DNA binding domain appear
to mediate aPKC effects. Phospho-mimetic Gli1 bound to target DNA just as well as wild-type phos-
phorylated Gli1 and possesses reduced sensitivity to PSI in BCC cells, suggesting these sites are func-
tional aPKC sites. Flag:Gli1 ChIP in BCC cells show that PSI-treated tumor cells left Gli1 nuclear
protein levels unchanged but reduced the association with chromatin. Application of a topical aPKC
inhibitor suppresses Hh signaling and tumor growth in naïve primary murine BCC tumors, suggesting
BCCs are dependent on aPKC pathway activation. Consistent with this notion, we demonstrate that
patients harboring Smo antagonist-resistant BCCs overexpress active aPKC and pharmacological
inhibition of aPKC in drug-resistant BCC cells suppresses proliferation. These results demonstrate
aPKC pathway activation is critical for Hh-dependent processes and suggest aPKC may be a new
therapeutic target for the treatment of naïve and resistant BCCs.
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MicroRNA-9 causes expansion of cancer stem cells in skin squamous cell carcinoma metas-
tasis
A Reddi,1,2 R White,2 J Neiman,2 G Han,2 D Roop1 and X Wang1,2 1 Dermatology, University of
Colorado School of Medicine, Denver, CO and 2 Pathology, University of Colorado School of
Medicine, Denver, CO
Epidermal stem cells of the hair follicle bulge are capable of tumor initiation but an unresolved ques-
tion is if they retain tumorigenic pluripotency and contribute to metastasis. We show that by tar-
geting mouse K15+ epidermal stem cells with KrasG12D and Smad4 mutations, two frequent muta-
tions in human squamous cell carcinoma (SCC), resulted in multi-lineage tumors including metastatic
SCC. In this mouse model, SCC metastasis was associated with increased microRNA-9 (miR-9)
expression that correlated with the expansion of side-population (SP+) but not SP-/CD34+/CD49+
cancer stem cells. Transplanting SCC cells overexpressing miR-9 in vivo resulted in SCC lung metas-
tases in mice. Conversely, knockdown of miR-9 inhibited metastasis in vivo. We found that miR-9
targeted the adherence junction protein α-catenin, facilitating β-catenin nuclear translocation as
well as β-catenin-mediated expression of ATP binding cassette (ABC) transporters (a molecular deter-
minant of the SP+ phenotype). Inhibition of miR9 or β-catenin abrogated both murine ABC trans-
porter gene expression and multidrug resistance protein 1 (MDR1) (a protein encoded by an ABC
transporter gene). In a human SCC tissue array, we detected miR-9 in metastatic SCC lesions but
rarely in primary SCC. Additionally, in human SCC, miR-9 expression correlated with loss of mem-
brane α-catenin as well as increased expression of MDR1. Our data reveal that the combination of
KrasG12D mutation and Smad4 deletion converts K15+ bulge stem cells to cancer stem cells pro-
moting SCC metastasis by a mechanism involving miR9.
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Identification of a distinct microRNAome and tumor suppressive role of microRNA-125b in
cutaneous squamous cell carcinoma
N Xu,1 L Zhang,2 F Meisgen,1 M Harada,3 J Heilborn,1 B Homey,4 D Grandér,3 M Ståhle,1
E Sonkoly1 and A Pivarcsi1 1 Department of Medicine, Karolinska Institutet, Stockholm,
Sweden, 2 Tianjin Life Science Research Center and Basic Medical School, Tianjin Medical
University, Tianjin, China, 3 Department of Oncology-Pathology, Karolinska Institutet,
Stockholm, Sweden and 4 Department of Dermatology, Heinrich-Heine-University,
Düsseldorf, Germany
MicroRNAs (miRNA) are ~22 nt single-stranded noncoding RNAs, which play important roles in
gene regulation. The role of miRNAs in skin cancers is not well understood. To identify tumor sup-
pressor and oncogenic miRNAs involved in the pathogenesis of skin cancers, we performed miRNA
expression profiling in two most common skin cancers, squamous cell carcinoma (SCC) and basal
cell carcinoma (BCC), as well as healthy skin by TaqMan MicroRNA Low Density Array. We found
that the miRNAome of SCC and BCC differs from that of healthy skin and from each other. In SCC,
4 miRNAs were found to be up-regulated compared with healthy skin (miR-31, miR-135b, miR-21
and miR-223) and 54 miRNAs were down-regulated, such as miR-375, miR-125a/b family, let-
7a/b/c/d/f/g family, miR-99a/b/100 family, many of which have been implicated in various cancers.
Moreover, we found that SCC and BCC display distinct miRNA profiles: 15 up-regulated and 10
down-regulated miRNAs were identified in SCC compared with BCC. MiR-125b is one of the top
down-regulated miRNAs in SCC compared with healthy skin or BCC; therefore, its function was
further studied in SCC. We demonstrated that overexpression of miR-125b suppresses proliferation,
migration and invasion capacity of human SCC cells. Moreover, we identified matrix metallopep-
tidase 13 (MMP13) as a direct target gene suppressed by miR-125b. Knockdown of MMP13 expres-
sion in SCC cells phenocopied the effects of miR-125b over-expression. Together our data indicate
that miRNAs are deregulated in SCC and BCC, and these tumors have disctinct miRNAomes. More-
over, our study identified miR-125b as a potential tumor suppressor in SCC.
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Stat1-signaling in cancer cells critically controls senescence and metastases spreading
E Brenner, H Braumüller, K Schielbach, T Wieder and M Röcken Dermatology, University
Tübingen, Tübingen, Germany
Immunotherapy with tumor-specific Th1 cells reduces tumor burden in humans with melanoma and
in mice with neuroendocrine cancers. In RIP1-Tag2 (RT2) mice, expression of oncogenic large T
antigen 2 of the Simian virus 40 under the rat insulin promoter 1 leads to the development of neu-
roendocrine cancers. Previous data showed that cancer control by Th1 cells strictly depends on
interferon-γ (IFNγ), as in the presence of anti-IFNγ mAb, Th1 cells paradoxically promote multistage
carcinogenesis. To investigate the mechanisms underlying IFNγ-mediated cancer control, we gen-
erated RT2 mice lacking Stat1, the signal transducers and activator of transcription of IFNs. While
Th1 cells were capable of doubling life span of RT2 mice, Th1 cells failed to prolong the survival
of RT2xStat1.ko double transgenic mice. Histology revealed that RT2xStat1.ko mice developed the
same number of islet carcinomas, and the blood glucose decreased as rapidly as compared with
RT2 control mice. Importantly, RT2 mice never develop metastases (<1%). In sharp contrast, 50%
of RT2xStat1.ko mice developed metastasis into the mesenteric lymph nodes within 12 weeks. As
the data suggested that STAT1 deficient cancer cells have an increased potential to metastasize, we
generated β-cancer cells generated from RT2 and RT2xStat1.ko mice and injected the cancer into
NOD-SCIDxIL2Rcγ.ko mice. Such RT2 cancer cells grew rapidly and increased the serum insulin
levels. Importantly, senescent RT2 cancer cells from STAT1-competent mice failed to grow when
injected into NOD-SCIDxIL2Rcγ.ko mice. Whereas, RT2xStat1.ko cancer cells did not undergo
senescence, neither upon in vivo treatment with Th1 cells, nor after in vitro treatment with IFNγ and
TNF, and grew rapidly upon transfer into immune deficient hosts. Thus, intact IFNγ and STAT1 sig-
naling is a key event required for tumor growth arrest and the control of metastatic spreading of can-
cer.
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Role of survivin in the development and progression of squamous cell carcinoma: In vivo mod-
els
R Lotti, T Petrachi, K Dallaglio, F Truzzi, A Saltari, P Morandi, A Marconi and C Pincelli
Dermatology, University of Modena and Reggio Emilia, Modena, Italy
Survivin is a bifunctional protein, as it inhibits apoptosis and regulates the cell cycle. Survivin is
overexpressed in most tumors, while it identifies keratinocyte stem cells (KSC) in humans. Because
epithelial tumors originate from KSC, we wanted to evaluate the role of survivin in the develop-
ment and progression of squamous cell carcinoma (SCC). We first showed that survivin is highly
expressed in poorly differentiated SCC, and survivin overexpressing keratinocytes display a more
pronounced ability to migrate. Moreover, survivin silencing in SCC keratinocytes results in a decreased
proliferation and reduced ability to form colonies. To test whether survivin is involved in SCC
development, we separated a subpopulation of neoplastic keratinocytes based on their ability to
adhere to a type IV collagen through b1-integrin. When seeded in a silicone chamber grafted onto
the back of NOD SCID mice, rapidly adhering (RAD) cells, expressing high levels of survivin, formed
tumor 2-4 fold bigger than those derived from NON RAD cells. To better clarify if survivin is asso-
ciated with tumor initiation, we induced carcinogenesis in SCID mice by injecting human ker-
atinocytes retrovirally transduced with oncogenic HRas G12V and IkB-alpha, in the presence or
absence of survivin. First, HRas/IkB-alpha overexpressing keratinocytes proliferate and migrate to a
greater extent, as compared to HRas/IkB-alpha keratinocytes in which survivin is silenced, in vitro.
In SCID mice, tumors derived from HRas G12V and IkB-alpha overexpressing keratinocytes were
significantly more aggressive than tumors where survivin was silenced (mitotic index: 10,2 +/- 2,28
vs. 5,4 +/- 1,81). In these tumors, vascular endothelial growth factor and hypoxia-inducible factor-
1 alpha were overexpressed. On the other hand, these markers were reduced when survivin was
silenced. All in all, survivin silencing induced a less aggressive pathologic phenotype. The study
suggests that survivin plays a crucial role in the development and invasiveness of SCC.
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Tumor cell associated receptor tyrosine kinase, EphB2 modulates gene expression signatures
involved in migration and invasion of tumor cells
M Farshchian,1 L Nissinen,1 E Siljamäki,1 A Kivisaari,1 P Riihilä,1 R Ala-aho,1 T Pihlajaniemi,2
R Heljasvaara,2 R Grénman,3 J Peltonen4 and V Kähäri1 1 Department of Dermatology, and
MediCity Research Laboratory, University of Turku, Turku, Finland, 2 Department of Medical
Biochemistry, University of Oulu, Oulu, Finland, 3 Department of Otorhinolaryngology, Head
and Neck Surgery, University of Turku, Turku, Finland and 4 Department of Anatomy and Cell
Biology, University of Turku, Turku, Finland
Cutaneous SCC is the second most common cutaneous malignancy in white population. We have
studied the role of Eph receptors, the largest family of receptor tyrosine kinases in skin SCC. Spe-
cific upregulation of EphB2 was noted in SCC cell lines (n=8) and tumors (n=6) compared with nor-
mal human epidermal keratinocytes (n=5) and normal skin (n=7) using Affymetrix-based expres-
sion profiling, SOLiD™ whole transcriptome analysis, quantitative RT-PCR, Western blotting and
immunofluorescence staining. Immunohistochemistry revealed tumor cell-specific overexpression
of EphB2 in Bowen’s disease (n=56) and cutaneous SCC (n=68) compared with actinic keratoses
(n=69) and normal skin (n=12) (p<0.001). Moreover, upregulation of EphB2 expression was noted
in DMBA-TPA-induced mouse skin SCCs (n=19) compared with normal skin (n=13) (p<0.001).
EphB2 knockdown with specific siRNA showed inhibition of proliferation, migration and invasion
of skin SCC cells. Microarray analysis identified 2460 differentially expressed genes (P<0.05) in SCC
cell lines (n=3) following EphB2 knockdown. Gene expression profile after EphB2 knockdown was
subjected to Ingenuity Pathway Analysis (FC (log2) >0.75 and P<0.05). Over 11% of downregu-
lated genes belonged to peptidases classification. Invasion of tumor cells (z-score= -2.099, p<0.001)
and migration of tumor cells (z-score= -2.358, p<0.001) were among the top biofunctions signifi-
cantly decreased after EphB2 knockdown. Together these findings highlight the role of EphB2 in pro-
gression of cutaneous SCC and particularly in invasion and migration of SCC cells, suggesting it as
a therapeutic target in these invasive and metastatic tumors.
346
Interventions for cutaneous Bowen’s disease: A systematic review
RN Matin,1,4 J Leonardi-Bee,2 D Wilkinson3 and F Bath-Hextall4 1 Dermatology, Oxford
University Hospitals NHS Trust, Oxford, United Kingdom, 2 Division of Epidemiology and
Public Health, University of Nottingham, Nottingham, United Kingdom, 3 School of
Medicine, University of Queensland, Brisbane, QLD, Australia and 4 Centre of Evidence
Based Dermatology, University of Nottingham, Nottingham, United Kingdom
The relative effectiveness of the available treatments for cutaneous Bowen’s disease is not known.
A systematic review was undertaken to assess which is the most effective therapeutic intervention
for cutaneous Bowen’s disease with the least side effects. We searched the following databases up
to September 2012: the Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE, EMBASE
and LILACS including online trials registers. Inclusion criteria were all RCTs assessing interventions
used in Bowen’s disease, preferably histologically proven. Primary outcome measures were com-
plete clearance of lesions after the first treatment cycle and recurrence rate at 12 months. Second-
ary outcomes included cosmetic outcome and adverse outcomes as reported by consumer and cli-
nician. Two authors independently carried out study selection and assessment of methodological
quality. Nine studies were identified. Clearance was significantly better when methyl aminolevuli-
nate with photodynamic therapy (MAL-PDT) was compared to placebo-PDT or cryotherapy, how-
ever there was no significant difference in clearance when compared to 5-fluorouracil (5-FU). One
study found significantly greater clearance rates (RR 20.19, 95% CI, 1.29 - 319.17) in favour of
imiquimod when compared to placebo. No recurrences were reported in the imiquimod group but
at 18 months, 2/16 participants in the placebo group had developed early invasive squamous cell
carcinoma. Overall, there has been little good quality research on treatments for Bowen’s disease.
The lack of quality data for surgery and topical therapies has limited the scope largely to a review
of PDT studies; 5-FU appears equivalent in efficacy to PDT and cryotherapy whereas MAL-PDT
appears to be more efficacious than cryotherapy. The age group, number and size of lesions and
site(s) affected may all influence therapeutic choice.
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RSK activation of translation factor eIF4B drives deregulated Laminin γ2 expression during
epithelial neoplastic progression
M Degen,1 E Natarajan,2 HR Widlund1 and JG Rheinwald1 1 Dermatology, Brigham and
Women’s Hospital, Boston, MA and 2 Oral Health and Diagnostic Sciences, U. Conn. School
of Dental Medicine, Farmington, CT
The basement membrane protein Laminin-332 is essential for normal basal epithelial cell adhesion
and also plays a key role in migration and hypermotility. Abnormal expression of its γ2 subunit
(Lamγ2) is detectable immunohistochemically in premalignant epidermal and oral dysplasias and
invasive squamous cell carcinomas (SCC). We recently we reported that deregulated Lamγ2 expres-
sion results from EGFR/MAPK signal pathway hyperactivity. To fully elucidate the molecular mech-
anism of abnormal Lamγ2 expression, here we have examined archival pathology specimens of
oral dysplasia immunohistochemically and have compared normal primary human oral and epi-
dermal keratinocytes with cell lines initiated from premalignant dysplasias and SCCs in culture. We
immunostained dysplasias for molecular biomarkers that identify and distinguish between MAPK
and mTOR pathway activation states, finding that both become hyperactive at the same time dur-
ing epithelial neoplastic progression and that Lamγ2 overexpression occurs in a subset of cells within
regions of signal pathway hyperactivity. Pharmacological kinase inhibitors revealed that, in cultured
cells, expression of Lamγ2, as well as MYC, are limited only by MAPK/RSK-dependent activation
of the translation factor eIF4B, independent of PI3K/mTOR pathway kinases and their translation
factor targets. Lentiviral-mediated eIF4B shRNA knockdown in SCC cells reduced expression of both
Lamγ2 and MYC, consistent with the known function of eIF4B in initiating translation of mRNAs
having long, complex 5’ UTR sequences. In reporter assays, translation of a luciferase mRNA con-
taining the Lamγ2 5’UTR was RSK- and eIF4B-sensitive. Our data demonstrate that MAPK-depend-
ent RSK activation of eIF4B, leading to increased Lamγ2 translation, are early events during neo-
plastic progression to SCC. These results have potential application as prognostic biomarkers of
preinvasive stages of SCC and as targets for early intervention therapy.
347
The rs2910164 G>C polymorphism in microRNA-146a is associated with the pathogenesis
of malignant melanoma
S Fukushima, J Yamashita, T Iwakiri, M Jinnin, A Miyashita, J Aoi, H Kanemaru, A Ichihara, Y Inoue
and H Ihn Dermatology and Plastic Surgery, Kumamoto University, Kumamoto, Japan
MicroRNA-146a (miR-146a) is one of the microRNAs (miRNAs) implicated in the pathogenesis of
various cancers. Recently, single nucleotide polymorphisms (SNPs) located in miRNAs themselves,
so-called MIRSNPs, have attracted attention for their possible involvement in the pathogenesis of
various diseases. Such MIRSNPs may have functional roles due to the alteration of the miRNA. In
this study, we investigated whether MIRSNP rs2910164 in miR-146a is involved in the pathogene-
sis of malignant melanoma (MM). DNA samples were collected from 50 patients with MM and 107
controls and genotyped by polymerase chain reaction (PCR)-restriction fragment. In patients with
MM, the genotype distributions were 15 CC (30.0%), 35 CG (70.0%) and 0 GG (0.0%). The CG
genotype was significantly increased in patient compared with controls (p=0.02). The minimum free
energy between miR-146a and its complementary strand with the G allele was estimated to be -
26.8 kcal/mol, while that of C allele was -24.0 kcal/mol, suggesting that the change from C to G
may increase the stability of the miR-146a. However, there was no significant difference between
the CC and CG genotypes in terms of the relative expression levels of miR-146a. Human melanoma
cell lines with the G allele showed significantly higher proliferation, migration and invasion than
those with the C allele. In conclusion, miR-146a may be involved in the pathogenesis of MM, and




The expression of B-defensins, cathelicidin (LL-37) in skin tumors
Y Park,1 K Whang2 and J Lee3 1 Dermatology, Soonchunhyang university hospital, Bucheon,
Republic of Korea, 2 Dermatology, Soonchunhyang university hospital, Seoul, Republic of
Korea and 3 Dermatology, Soonchunhyang university hospital, Cheonan, Republic of Korea
Antimicrobial peptides (AMPs), which is a kind of innate immune system, are produced by ker-
atinocytes during differentiation. Among them, B-defensins and LL-37 are the major human antimi-
crobial peptides. Because B-defensins and LL-37 are critically involved keratinocyte migration and
proliferation, we hypothesized that both peptides also have an influence on differentiation and pro-
liferation of skin tumors originated from keratinocytes. We studied the expressions of AMPs by tis-
sue array techniques in benign and malignant skin tumors. The expression of AMPs was examined
by immunohistochemical staining of 31 specimens of skin tumors including 4 cases of seborrheic
keratosis, 4 cases of keratoacanthomas, 4 cases of basal cell carcinomas (BCC), 16 cases of squa-
mous cell carcinomas (SCC) and 3 cases of malignant melanomas (MM). Immunohistochemical
analysis of the skin tumor samples revealed a high expression of B-defensin and cathelicidin (LL-
37) in benign skin tumors such as keratoacanthomas and seborrheic keratosis than in malignant
tumors such as SCCs, BCCs and MMs. Among malignant tumors, BCCs and MMs showed lower
expression fo AMPs than SCCs, in which their expression was shown to be decreased with increased
dysplasia of tumor cells. These findings showed that AMPs have a negative association with the
malignancies of the skin tumors and suggested the role of AMPs in the protection of loss of differ-
entiation and dysplasia of skin tumors.
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The specific expression of PDGF-B and CD34 in dermatofibrosarcoma protuberans implies
the underlying pathogenesis with involvement of its mesenchymal stem cell origin
D Utsumi,1 I Nakamura,1 E Okada,2 M Yasuda,2 O Ishikawa,2 H Uezato1 and K Takahashi1 1
Dermatology, University of Ryukyus, Nakagami, Japan and 2 Dermatology, University of
Gunma, Maebashi, Japan
Dermatofibrosarcoma protuberans (DFSP) is an intermediate grade malignancy of subcutis with
frequent local recurrences. The most characteristic cytogenetic feature of DFSP is the chromosomal
translocation, causing a fusion of the platelet derived growth factor beta (PDGF-B) and collagen
type 1 (COL1) genes. We previously reported a novel gene fusion between PDGF-B and COL1A2
besides the known COL1A1 gene, and our discovery reaffirmed the essential role of PDGF-B expres-
sion in DFSP pathogenesis. DFSP, as well as dermatofibroma, is dermal mesenchymal tumor and
the expression of hematopoietic stem cell marker; CD34 in DFSP is reliable diagnostic clue to dis-
tinguish them. The DFSP tumor cells are thus proposed to originate from one of mesenchymal stem
cells (MSC). PDGF-B, a pathogenic fusion protein in DFSP, acts as a ligand for PDGF-Rα at MSC,
and plays an important role in recruitment of MSC. To ascertain the origin of DFSP cells as MSC lin-
eage, we studied 23 DFSP and 20 dermatofibroma samples for their expression of PDGF-B as well
as various stem cell or differentiation markers including CD34, PDGF-Rα and, α-SMA and S-100.
CD34 was expressed in 96.3% of DFSP cases, but also expressed in only 10% of dermatofibroma.
Consistently, we found that 92.6% DFSP tumors expressed PDGF-B, whereas dermatofibroma did
not express PDGF-B at all, and the specificity of PDGF-B for DFSP was much higher than CD34
among various mesenchymal tumors. Meanwhile, DFSP showed lesser immunoreactivity to α-SMA
and S-100 than dermatofibroma. PDGF-Rβ was cooperatively expressed in all DFSP cases with dif-
ferent degree, which suggested the autocrine or paracrine PDGF-B stimulations might cause the
PDGF-Rβ internalization. Our results suggest that DFSP tumor cells exhibit a distinct feature simi-
lar to MSC, and to lesser extent for cell differentiation as compared with dermatofibroma.
351
Diagnostic markers for Sézary syndrome
M Vermeer,1 M Bagot,2 S Whittaker,3 R Willemze,1 S Boonk,1 W Zoutman,1 K Tensen1 and L van
der Fits1 1 Dermatology, Leiden University Medical Center, Leiden, Netherlands, 2
Dermatology, Hopital Saint-Louis, Paris, France and 3 Dermatology, St John’s Institute of
Dermatology, Paris, France
Sézary syndrome (SS) is an aggressive type of cutaneous T-cell lymphoma with a poor prognosis.
Differentiation between SS and other conditions presenting with erythroderma, including benign
inflammatory dermatoses, may be extremely difficult. Also identification and quantification of tumor
cells is often difficult, thereby hampering (early) diagnosis and monitoring of progression. Previous
studies reported several biomarkers for Sézary cells but these have not been evaluated in inde-
pendent studies. In this prospective, multicenter study we evaluate the diagnostic and prognostic
value of these potential markers that were previously described in literature. We collected periph-
eral blood mononuclear cells, cDNA and genomic DNA from SS patients (as defined by WHO cri-
teria, 2008) and patients with benign erythroderma. CD4+ T cells were analyzed for expression of
cell surface proteins by flow cytometry. Gene expression and copy number alterations were evalu-
ated by using custom made quantitive PCR platforms. Experimental data are correlated with clini-
cal information at inclusion of the study and after 12, 24, 36, and 48 months follow up. During the
first two years of this study, samples from 105 individuals were included and clinical data from 86
patients have been collected. Characteristic alterations in copy number for MYC and MNT were
observed in respectively 44% and 65% of the SS patients. Flow cytometry revealed aberrant expres-
sion of CD2, CD7, CD26, CD158b and/or CD45RA in >90% of patients. In addition, upregulation
of DNM3, EPHA4, PLS3 and TWIST1 and downreguation of STAT4 in 65 to 95% of SS patietns was
confirmed by RT-qPCR. Our data demonstrate that Sézary cells can be identified by (combinations
of) specific biomarkers using different techniques. The prognostic significance of those markers is
currently under investigation with the sample data of all included patients.
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Protein kinase D1 plays a unique role in enhancing tumor promotion in chemically-induced
skin carcinogenesis
M Rashel, T Gaddapara and S Ghazizadeh Oral Biology and Pathology, Stony Brook University,
Stony Brook University, NY
Protein kinase D (PKD) isoforms are novel diacylglycerol-regulated serine/threonine protein kinases
that can be activated by a multitude of stimuli and are implicated in the regulation of diverse cel-
lular functions. The role of PKDs in skin however, is poorly understood. We and other have previ-
ously shown that treatment of keratinocytes with a tumor promoter, 12-Otetradecanoyl phorbol-
13-acetate (TPA), induced a rapid phosphorylation/ activation of PKD1 in a protein kinase C
(PKC)-dependent manner. However, it is not known how PKD1 contributes to TPA-induced responses
including tumor promotion. To investigate the role of PKD1 in normal and stress-induced epider-
mis, we have used a conditional gene knockout system to specifically delete PKD1 in mouse epi-
dermis (cKO-PKD1). These mice exhibited no abnormalities in epidermal growth and differentia-
tion in vivo, although the proliferation rate of PKD1-null keratinocytes in culture was significantly
increased. A single topical application of PKD1-null epidermis with TPA resulted in a significantly
reduced epidermal hyperplasia and inflammation when compared to control PKD1-floxed litter-
mates. Moreover, the cKO-PKD1 mice exhibited resistance to tumor formation in two-stage chem-
ically-induced skin carcinogenesis. The resistant to tumor formation was consistent with the sup-
pressed effects of tumor promoter, not a consequence of a general impairment in proliferative
responses of PKD1-null keratinocytes . Interestingly, despite higher expression of PKD2 and PKD3
in keratinocytes, they failed to play a compensatory role for PKD1 during TPA induced hyperpla-
sia/ tumor promotion. These data demonstrated a unique role for PKD1 as a critical mediator of
PKC signaling in carcinogenesis, and suggests a potential target for skin cancer therapeutics.
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The E3 ubiquitin ligase Trim32 has a functional role in the development and progression of
cutaneous squamous cell carcinoma
AM Wortham, Y Liu, Y Wang, J Lagowski, E Swanzey, R Bridges, T West and MF Kulesz-Martin
Dermatology Research Division, Oregon Health and Science University, Portland, OR
Cutaneous squamous cell carcinoma (cSCC) is the second most common type of cancer in the United
States with over half a million new cases each year. Although SCC is usually detected at an early
stage, surgical excision often causes morbidity, and the presence of metastases at diagnosis is asso-
ciated with a poor five-year survival. We detected overexpression of the E3 ubiquitin ligase Tripar-
tite Motif protein 32 (Trim32) in a clonal mouse model of cSCC and in human cSCC patient sam-
ples. TRIM family scaffold proteins have been associated with cancer, innate immunity, and inborn
genetic disorders affecting muscle and other organ sites, suggesting roles in multiple signaling
pathways. We have previously shown that Trim32 binds and ubiquitylates the E3 SUMO ligase Piasy,
leading to Piasy’s degradation via the proteasomal pathway, reversal of Piasy’s inhibition of the
transcription factor NF-κB, and an increase in epidermal cell survival in response to genotoxic and
cytokine stress. Similarly, others have demonstrated that Trim32 can promote cell growth and migra-
tion by facilitating the degradation of Abl-interactor 2 (Abi2), a putative tumor suppressor. Together,
these studies suggest that Trim32 promotes the development of cancer in vitro by down-regulating
tumor suppressors. In order to determine if deficiencies in the expression of Trim32 altered tumor
development in vivo, we performed a two stage chemical carcinogenesis experiment and compared
Trim32+/- and Trim32-/- mice to their wild type littermates. We observed a delay in tumor formation
and a decrease in tumor multiplicity in the Trim32+/- and Trim32-/- mice. Total tumor burden was
also decreased in the Trim32+/- and Trim32-/- mice. These results indicate that ablation of Trim32
inhibits tumor growth and suggests an oncogenic role for Trim32. Investigations are underway to
determine whether regulation of oncogenic/tumor suppressor pathways and/or innate immunity
pathways underlie Trim32’s ability to enhance tumor growth.
354
Potential involvement of mitochondrial DNA damage elicited by oxidative stress in arsenic
carcinogenesis in skin
C Lee,1,2 S Wu,5 C Hong,3,4 G Chen,2 Y Wei5,6 and H Yu2 1 Dermatology, Kaohsiung Municipal
Hsiao-Kang Hospital, Kaohsiung, Taiwan, 2 Dermatology, Kaohsiung Medical University,
Kaohsiung, Taiwan, 3 Dermatology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan,
4 Dermatology, National Yang-Ming University, Taipei, Taiwan, 5 Biochemistry and Molecular
Biology, National Yang-Ming University, Taipei, Taiwan and 6 Medicine, Mackay Medical
College, Taipei, Taiwan
Arsenic causes several human cancers. Arsenic-induced Bowen’s disease (As-BD), the most com-
mon arsenical cancers, is characterized by increased proliferation,full-layer epidermal dysplasia,
and individual cell apoptosis, all of which involve mitochondria. We reported arsenic causes aber-
rant keratinocyte proliferation via mtTFA-mediated mitochondrial biogenesis in As-BD. Increasing
mitochondrial biogenesis render cells undergo oxidative stresses. However, how arsenic induces
oxidative stress and causes mitochondrial DNA (mtDNA) damage in arsenical cancers remains
largely unknown. Using tissues from As-BD patients and arsenic-treated keratinocytes, we deter-
mined the oxidative stress, antioxidant enzymes, DNA repair enzymes, and 8-OHdG level in mtDNA
by immunofluorescence, real-time PCR, and Western blot. The results showed that oxidative stress
was enhanced in both As-BD and arsenic-treated keratinocytes. Antioxidant enzymes including Mn-
SOD and Cu/Zn-SOD and DNA repair enzymes were upregulated concomitantly in tissues and
cells. In arsenic-treated keratinocytes, increased mitochondrial oxidative stress and the 8-OHdG
level in mtDNA was attenuated by pretreatment with ascorbic acid, a potent antioxidant. Further,
we found several consistent somatic mutations in the ND4, ND5, and ND6 genes of mtDNA in
lesional but not in perilesional skin from As-BD patients. The results suggest oxidative damage and
mutations to mitochondria might be involved in progression of carcinogenesis in arsenical cancers
in the context of mitochondrial biogenesis.
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Periostin expression induced by wound healing process promotes metastasis of melanoma
cells
K Fukuda,1,2 E Sugihara,2 M Amagai1 and H Saya2 1 Department of dermatology, Keio University
School of Medicine, Tokyo, Japan and 2 Division of Gene Regulation, Institute for Advanced
Medical Research, Keio University School of Medicine, Tokyo, Japan
Tissue injury has been reported to stimulate metastasis in a number of cancers. However, it remains
unknown how wound healing process induces metastasis. Recently, periostin (POSTN), an extra-
cellular matrix (ECM) protein, which facilitates the re-epithelialization during cutaneous wound
healing, has been demonstrated to initiate the colonization of cancer cells. Therefore, we aimed to
investigate if ECMs associated with the wound healing promote the metastasis of melanoma to the
wound. We experienced a patient with melanoma on the right sole and metastatic lesion on the
right heel that appeared one month after trauma. Comparative genome-wide microarray analysis of
the patient revealed that mRNA of ECM proteins relevant to wound healing, such as POSTN,
fibronectin 1 (FN1) and collagen-I (COL-I) were expressed over 4-fold in metastatic lesion com-
pared with those in the primary lesion. Using human melanoma cell line MeWo and murine
melanoma cell line B16BL6, we performed adhesion assay with those ECMs. Compared with FN
and COL-I, melanoma cells on POSTN became more rounded shape and significantly attenuated
adhesion, suggesting that POSTN reduces the cell binding affinities. Next, cellular motility was eval-
uated by transwell migration assay. We found that POSTN promotes cell migration significantly
higher than FN or COL-1. To examine whether wound healing predisposes to metastasis in vivo, we
injected B16BL6 cells into footpad of nude mouse and created full-thickness excisional punch
wounds on the thigh 3 days after the inoculation. Whereas 4 out of 6 mice with wounds developed
metastasis on the wound region in 3 weeks after injection, no metastasis was detected in all 6 mice
without wound. Immunohistochemistry revealed POSTN expression was higher in the wounded
skin at day 4, 7, and 10 than the intact skin. These data suggest that POSTN induced by tissue injury
is involved in promotion of melanoma metastasis to the wound.
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Dissecting T-helper-cell-mediated anti-angiogenesis from T cell-induced cancer cell senes-
cence
H Braumüller, E Brenner, K Braungart, S Weidemann, V Galinat, M Hahn, T Wieder and M Röcken
Dermatology, University Medical Center, Tübingen, Germany
Anti-tumoral effects of T helper 1 lymphocytes critically depend on the simultaneous signaling of
two cytokines: interferon-gamma (IFN-γ) and tumor-necrosis-factor (TNF). In RIP1-Tag2 mice, adop-
tive transfer of tumor-specific Th1 cells prevent multistage carcinogenesis, significantly reduce tumor
size, tumor cell proliferation and doubles survival. This T cell-induced tumor dormancy in beta-cell
cancers is associated with a pronounced reduction of blood vessel density within the solid Langer-
hans islet tumors and a strong induction of anti-angiogenic chmokines CXCL9 and CXCL10. Inhibit-
ing IFN-γ by the monoclonal antibody XMG1.2 in vivo abrogates the expression of the anti-angio-
genic chemokines. Mice treated with Th1 cells even develop significantly more vessels than
sham-treated mice. Besides the pronounced anti-angiogenic effect, the combined action of IFN-γ
and TNF also arrest cancer growth by inducing senescence through the upregulation of the tumor
suppressor protein p16Ink4a. This raised the question whether Th1 cells arrested cancer growth pri-
marily by reducing angiogenesis. To dissect the anti-angiogenic effects from the senescence-induc-
ing effects we isolated cancer cells from the pancreas and downregulated p16INK4a by short hair-
pin RNA (shRNA). Following the treatment with IFN- γ and TNF we analyzed senescence in β-cancer
cells and quantified CXCL9 and CXCL10 proteins in the supernatant. p16ink4a shRNA completely
blocked the capacity of IFN-γ and TNF to induce senescence while it did not abrogate the capac-
ity of beta cancer cells to produce high amounts of CXCL9 and CXCL10. Importantly, following
transplantation into immunocompromized NOD-SCID mice, senescent cancer cells remained growth
arrested even in the absence of anti-angiogenic chemokines while β-cancer cells showed rapid
metastatic growth.
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ABCB5 identifies a chemorefractory cell population in Merkel cell carcinoma 
N Lee,1 S Kleffel,1 MC Lezcano,2 K Sobolewski,1 A DoRosario,3 MH Frank,1,4 L Wang,1,3
GF Murphy2 and T Schatton1,4 1 Department of Dermatology, Brigham and Women’s Hospital,
Boston, MA, 2 Department of Pathology, Brigham and Women’s Hospital, Boston, MA, 3
Dana-Farber/Brigham and Women’s Cancer Center, Boston, MA and 4 Transplantation
Research Center, Children’s Hospital, Boston, MA
Merkel cell carcinoma (MCC) is a rare and highly aggressive cutaneous neuroendocrine carcinoma
that, on a case-by-case basis, is more deadly than melanoma. Responses to systemic therapy are
often not durable, and patients experience disease relapse, usually with fatal outcomes. Thus, elu-
cidating the mechanisms of MCC therapeutic resistance is critical for improving patient survival.
Here we show that ATP–binding cassette member B5 (ABCB5) identifies a subset of MCC cells that
preferentially resists first-line chemotherapy with carboplatin and etoposide. PCR analysis revealed
ABCB5 mRNA expression in established MCC lines, MKL-1, MKL-2, MS-1 and WaGa, as well as in
83 of 87 clinical MCC specimens. ABCB5 protein expression ranged from 1-15% of cells in MCC
lines and was also detected in 63 of 72 MCC patient samples. As in other cancers, ABCB5(+) MCC
cells exhibited preferential positivity for additional cancer stem cell antigens, including CD271. In
vitro treatment of MCC cells with the standard-of-care agents carboplatin or etoposide resulted in
>1500- and >100-fold upregulation of ABCB5 expression among surviving cells, respectively. Com-
pared to vehicle-controls, treatment of MCC xenograft-bearing mice with carboplatin or etoposide
resulted in markedly increased ratios of ABCB5(+) vs. ABCB5(-) cells when residual disease was
detected. Consistent with these findings, analysis of successive, patient-matched MCC biopsies
revealed enhanced frequencies of ABCB5(+) MCC cells after treatment with carboplatin and etopo-
side. Mechanistically, ABCB5 blockade sensitized MCC cells to carboplatin and etoposide-induced
killing. Our results establish ABCB5 as a novel chemoresistance mechanism in MCC and identify a
potential therapeutic target and biomarker for monitoring treatment responsiveness in this malig-
nancy.
360
Status of autophagy and mTOR associate with mortality and cell survival of angiosarcoma
T Takahashi, K Yamasaki and S Aiba Dermatology, Tohoku University Graduate School of
Medicine, Sendai, Japan
Angiosarcomas(AS) are rare sarcomas of endothelial cell origin with a poor prognosis. Recent use
of sorafenib and pazopanib, broad-spectrum tyrosine-kinase inhibitors targeting VEGF receptors,
have limited efficacy. Autophagy is a homeostatic “self-eating” process, which is regulated through
mTOR and digests cytoplasmic components via the lysosomal pathway to render cells nutrient for
stress or starvation including lack of growth factor receptor signaling. We hypothesized that the
autophagy system is involved in AS cell survival and aimed to examine the status of autophagy and
mTOR. Compared with benign hemangioma (4 cases), AS (9 cases) exhibited more intensive expres-
sion of phospho-p70 S6 Kinase (p-p70S6K) (9/9) suggesting mTOR signal activation and increase
in autophagy-related molecules including microtubule-associated proteins 1A/1B light chain 3 (LC3)
(9/9) and ATG12 (9/9). Although no significant difference in lysosome-associated membrane pro-
tein (LAMP)-1 and LAMP-2 amounts between hemangioma and AS was observed, we confirmed
the co-localization of LC3 and LAMP-2 in AS but not hemangioma, suggesting the autophagy sys-
tem is constitutively activated in AS tissue. The cases with high p-p70S6K and weak expressions of
LC3 before treatment had higher mortality rate, and the expression of these molecules altered after
chemotherapy. Using mouse AS endothelial cell lines A221a and MS1, immunoblotting demon-
strated increase in p-p70S6K, LC3, and ATG5-ATG12 conjugates under serum starvation in vitro.
0.03 to 0.3 μM of mTOR inhibitor pemetrexed and 1 to 10 mM of autophagy inhibitor 3-MA dose-
dependently induced apoptosis measured as caspase-3/7 activity to both AS cell line. In contrast,
sorafenib showed little effect for survival of both cells, and combination with 3-MA and pemetrexed
efficiently induced apoptosis of both cells treated with sorafenib. These suggested that mTOR and
autophagy system dictate AS cell survival and mortality of AS individuals and that control of mTOR
and autophagy system is a key for the successful treatment of AS with tyrosine kinase inhibitors.
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Potential driver genes in the development and progression of cutaneous T-cell lymphoma
X Ni, M Goswami and M Duvic The University of Texas MD Anderson Cancer Center,
Houston, TX
Mycosis fungoides (MF) and Sézary syndrome (SS), two most common forms of Cutaneous T-cell
lymphoma (CTCL), are still mostly incurable. Limited knowledge of tumorigenesis prevents us from
developing curable therapies. To identify driver genes in the development and progression of CTCL,
we used the Human Cancer Pathway Finder PCR Array. Representative (T1-T4) stage skin lesions
were biopsied from 26 newly diagnosed MF/SS patients. T stages were according to the ISCL/EORTC
revised criteria. Normal skin (HD) and psoriatic skin (PS) lesions were controls. Total RNA was
extracted from the paraffin embedded tissue sections, and cDNAs were synthesized using the RT2
PreAMP cDNA Synthesis Kit. The Human Cancer Pathway PCR was assayed to profile the expres-
sion of 84 genes across 6 biological pathways involved in cancer transformation and tumorigene-
sis. The gene changes were considered significant with > 2-fold change and a p-value of <0.05.
There were 28 genes dysregulated in MF/SS lesions including 6 genes in angiogenesis, 7 genes in
invasion & metastasis, 4 genes in cell cycle control and DNA damage repair, 6 in apoptosis and
cell senescence, 2 in signal transduction and transcription, and 3 in adhesion pathway. All were
up-regulated except SERPINB5 or Maspin, a tumor suppressor gene lost in breast cancer cells, never
before implicated in MF/SS. Fourteen genes were up-regulated only in T1 lesions, and 10 genes only
in T3 tumors. Expression in 4 genes was abnormal in both T1 and T3 lesions including, SERPINB5,
JUN, ITGA3, and TNFRSF10B. Further real-time-PCR analysis for SERPINB5 in all MF/SS lesions
confirmed a dramatic down-regulation in late stage lesions (T3, T4) compared to early stage (T1,
T2) and controls (HD, PS). The overexpression of Twist1 was seen in T3 lesions (p<0.01) confirm-
ing our previous work by IHC in MF/SS lesions (Goswami et al, JCP, 2012). Our preliminary study
identified unique cancer pathway gene sets in early or/and late stage lesions. Further validation of
gene expression and their relevance to tumorigenesis of CTCL is in progress.
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The development of cutaneous squamous lesions in patients treated with vemurafenib: A
possible role for human papillomavirus in addition to activated RAS
K Purdie,1 A South,2 M Sommerlad,3 I Leigh,2 C Proby2 and C Harwood1,3 1 Centre for Cutaneous
Research, Queen Mary University of London, London, United Kingdom, 2 Division of Cancer
Research, University of Dundee, Dundee, United Kingdom and 3 Department of
Dermatology, Barts Health NHS Trust, London, United Kingdom
Approximately half of metastatic melanomas have an activating mutation in the BRAF oncogene.
The BRAF inhibitor vemurafenib is associated with the de novo development of benign and malig-
nant squamoproliferative lesions in up to 25% of patients. The putative mechanism involves para-
doxical increased MAPK signalling by BRAF inhibitors in the context of mutated or activated RAS.
However, cutaneous SCC (cSCC) have been reported to develop in association with wart-like lesions
and upregulation of the MAPK pathway is known to facilitate human papillomavirus (HPV) repli-
cation, suggesting a possible role for HPV in the pathogenesis of these lesions. We have examined
RAS mutational status and presence of HPV DNA in 30 skin biopsies from 4 patients receiving vemu-
rafenib (20 benign squamoproliferative lesions; 7 SCC; 3 normal skin samples). A high proportion
(90%; 27 /30) were positive for beta (EV-associated) HPV; a subset (15%; 4/27) were also positive
for cutaneous alpha HPV. HPV DNA was detected at high levels in only a minority (19%; 5/27) of
positive lesions, all of which were identified clinicopathologically as viral warts. HRAS mutations
were detected in 8/20 (40%) samples (6/16 benign squamoproliferative lesions and 2/3 cSCC). No
mutations were identified in the NRAS or KRAS genes. Five of 8 (63%) HRAS mutations were in
codon 61, a mutational hotspot previously reported as characteristic of vemurafenib-associated
cSCC. The high frequency of HRAS mutations in our sample series together with the rapid timeframe
of lesion development support the hypothesis that these mutations are pre-existing and confer a
selective advantage in the context of vemurafenib therapy. The role of HPV in these lesions merits
further investigation.
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Acantholysis is the poor prognostic factor in squamous cell carcinoma, which is predictable
by the anomalies of cytoskeletal-adhesion molecules
R Awazawa,1 M Yasuda,2 E Okada,2 Y Kariya,1 O Ishikawa,2 H Uezato1 and K Takahashi1 1
Dermatology, University of Ryukyus, Okinawa, Japan and 2 Dermatology, Gunma University,
Maebashi, Japan
Squamous cell carcinoma of skin (SCC) shows the wide spectrum of histological characteristics,
including the highly keratinized, adenoid, acantholytic or mesenchymal variants even in a same
tumor. SCCs usually take rather non-progressive clinical prognosis after surgical excision, however,
in some contents, SCC lesions can progress and metastasize rapidly. We analyzed the various char-
acteristics including the histological subtypes and clinical prognosis of the independent 81 SCC
cases treated at 2005-08. 26 SCC cases showed acantholytic changes, and 5 cases developed metas-
tasis. Three cases with metastasis and 3 cases with the repeated recurrence harbored the acantholytic
changes; meanwhile only 2 cases did metastasize among 55 SCCs without acantholysis. The acan-
tholysis is thus considered as the potent poor prognostic factor, and we further analyzed the build-
ing of cytoskeleton and adhesion molecules. Keratin 8 (K8) or K18 were ectopically expressed in 5
SCC cases with acantholysis, in contrast no cases in non-acantholytic SCCs. Besides, vimentin
were expressed in 3 cases with acantholysis, whereas no cases in other SCCs, and the expression
of vimentin and K8/18 tends to overlap in each tumor cells. Desmoplakin is the other marker of
acantholysis, and locates at the cell periphery in non-acantholytic SCCs with two exceptional cases.
In contrast, in the examined 11 SCC cases with acantholysis, 8 cases showed the cytoplasmic loca-
tion of desmoplakin. Acantholysis in SCCs seems to be caused by the several distinct pathogene-
sis, such as by the epithelial mesenchymal transformation in K18 and vimentin positive SCC or by
the debilitated desmosome adhesion in K16 positive SCC. Finding out the cellular markers that
involves in the acantholytic phenotypes and thus leads to poor prognosis, enables the more ade-
quate therapeutic strategy.
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Cell surface CD74 expression is a key mediator of melanoma cell survival in response to the
cytotoxic effect of IFN-γ
K Tanese,1,2 S Ekmekcioglu1 and EA Grimm1 1 Melanoma Medical Oncology, MD Anderson
Cancer Center, Houston, TX and 2 Dermatology, Keio University School of Medicine, Tokyo,
Japan
Intensive analysis of the molecular pathogenesis revealed that tumor cell specific BRAF, NRAS and
c-KIT gene mutations activate the ERK1/2 MAPK and AKT signaling pathways to control growth and
survival of human melanoma. However, new data indicates that additional drivers in the microen-
vironment are bypassing these specific mutations. Here, we hypothesize that certain molecules on
the tumor cells are likely to respond to local inflammatory cytokines and directly regulate these
growth and survival pathways. In this study, we identified cell surface CD74 as of one such mole-
cules, which is upregulated in response to interferon-γ (IFN-γ). Immunohistochemical (IHC) analy-
sis of melanocytic tumor samples in a tissue microarray revealed that expression of CD74 serve as
a progression marker of melanocytic tumors. In the analysis of six melanoma cell lines with differ-
ent subtypes representing the spectrum of currently targeted somatic mutations, five cells showed
CD74 cell surface expression and all cells expressed its ligand, macrophage migration inhibitory
factor (MIF). The MIF-CD74 interaction functions in cell survival manner by regulating AKT Ser473
phosphorylation, secreting interleukin-6 and -8, and expressing antiapoptotic proteins. Patient
sample analysis by IHC staining of CD74 on tumor cells correlated with plasma IFN-γ levels. IFN-
γ upregulated the transcription and cell surface expression of CD74 and augmented MIF-CD74 inter-
action promoting survival. The role of IFN-γ in cancer has been reported to be both pro-and anti-
tumorigenic, and its effect depends on the tumor specificity and signaling intensity. The result of the
present study provides a plausible explanation of pro-tumorigenic effects of IFN-γ via CD74 which
contributes to the selection of more aggressive melanoma cell phenotypes.
363
Gene expression analysis in CTCL patients validates the clinical importance of novel onco-
genes and tumor suppressor genes
IV Litvinov,1 Y Zhou,2 K Pehr,1 TS Kupper3 and D Sasseville1 1 Dermatology, McGill University
Health Centre, Montreal, QC, Canada, 2 Dermatology, University of British Columbia,
Vancouver, BC, Canada and 3 Dermatology, Brigham and Women’s Hospital, Boston, MA
Cutaneous T-cell Lymphoma (CTCL) is the most common lymphoma of the skin. Unfortunately, the
molecular pathogenesis of this disease remains poorly understood. The cancer often presents in early
stages and remains indolent in the majority of patients. However, in 10-20% of cases it progresses
towards advanced stages, where it exhibits high morbidity and mortality. Previously, we performed
a microarray and RT-PCR analyses of lesional skin from a cohort of CTCL patients in order to iden-
tify novel molecular prognostic markers. Unfortunately, this initial analysis failed to include a num-
ber of genes that were previously reported to play an important role in CTCL pathogenesis. In the
current work we test by RT-PCR the expression of 160 additional putative tumor suppressor genes
and oncogenes in 60 CTCL patients, 21 benign inflammatory dermatoses and 6 normal skin sam-
ples and correlate our findings with 6 years of clinical follow up in CTCL patients. These findings
demonstrate that loss of a number of tumor suppressor genes (e.g., BCL7A, DLEU1 and CDKN1C)
or upregulation of several oncogenes(e.g., JUNB, TOX1 and TCF3) correlates with disease progres-
sion. Furthermore, comparison of expression of inflammatory response genes between CTCL and
benign inflammatory dermatoses documents that a number of genes (e.g. CCL 26, CCL18 and IL-
22) were upregulated in CTCL, but not in eczema, psoriasis or pityriasis rubra pilaris. In summary,
our findings combined with previous reports provide clinical confirmation for the importance of
the above described putative oncogenes and tumor suppressor genes in CTCL. Furthermore, our
study helps delineate inflammation observed in CTCL from other benign inflammatory responses.
364
Stromal fibroblasts impaired in TGFβ signaling support oncogenic transformation of adja-
cent epithelia
M Tan,1 M Sng1 and N Tan1,2 1 School of Biological Sciences, Nanyang Technological
University, Singapore, Singapore and 2 Institute of Molecular and Cell Biology, Singapore,
Singapore
Skin morphogenesis, maintenance and homeostasis require tightly regulated complex epithelial-
mesenchymal interactions involving primarily the keratinocyte and fibroblast, the principle cell type
of epidermis and dermis layers respectively. Epithelial cancers arise when the homeostatic interac-
tion between epithelial cells and stromal fibroblasts is perturbed, and the latter can support the
development of a tumor microenvironment by providing the necessary oncogenic signals. TGFβ,
which signals through the canonical Smad cascade and non-canonical TAK1 cascades, is an impor-
tant cytokine that regulates tumor-stroma interactions. However, the effects of TAK1 and Smad sig-
naling in the stromal fibroblasts on the oncogenic potential of adjacent epithelial remain unclear.
We observed that the expression of TGFβRII, Smad3 and TAK1 are frequently altered in cancer-asso-
ciated fibroblasts from human squamous cell carcinomas compared with normal fibroblasts. Organ-
otypic cocultures constructed using fibroblasts-deficient in TGFβRII, Smad3 and TAK1 led to increased
proliferation of the overlying epithelia. We observed that intracellular reactive oxygen species was
increased in the fibroblast knockdown concomitant with increased extracellular H2O2. Prolonged
exposure of keratinocytes to H2O2 was sufficient to induce colony formation in soft agar, i.e.
tumor transformation. Furthermore, conditioned media from the various OTCs contained elevated
levels of mitogenic factors that were differentially regulated by Smad3 and TAK1. Our study has
delineated the tumor-suppressive function of stromal TGFβ signaling that includes modulating the
microenvironment’s redox state and may aid the identification of novel therapeutic targets to reverse
or delay cancer progression.
365
Mouse Tumor Biology Database (MTB): A centralized resource on mouse models for human
skin and adnexal cancers
DA Begley, DM Krupke, SB Neuhauser, JE Richardson, CJ Bult, JT Eppig and JP Sundberg The
Jackson Laboratory, Bar Harbor, ME
Mouse models of human cancer are significant tools for studying the biological mechanisms and
genetic predispositions of cancer and developing new methods of treatment. The scientific com-
munity is generating an increasing number of novel models and associated data from these mod-
els. The Mouse Tumor Biology Database (MTB) is a public access database that provides tools to
identify, access, and analyze these data. MTB captures data on endogenously arising tumors (both
spontaneous and induced) in genetically defined mice (inbred, hybrid, mutant, and genetically engi-
neered mice) and provides freely available web access to these data (http://tumor.informatics.jax.org).
Data in MTB includes tumor classification, frequency, latency, tumor associated quantitative trait
loci (QTL), pathologic descriptions and images, references, genetic data, strain susceptibility data,
and much more on mouse models for human cancer. MTB is integrated with the Mouse Genome
Informatics database (MGI) and provides links to other related online resources. MTB contains sig-
nificant amounts of dermatology related pathology data. Data are available on over 2640 skin, hair
follicle, and nail neoplasias. MTB also includes immunohistochemistry data on over 410 antibod-
ies that work or do not work on mouse tissues presented with accompanying images of positive con-
trol samples and links to the respective vendors. MTB encourages direct submission of mouse tumor
data and photomicrographs from the cancer research community and has developed a web-based
system to facilitate submission of pathology data.
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Low-dose of ionizing radiation impairs DNA repair system in human primary keratinocytes
and human skin 3D model
M Rovere,2 M Menneteau,1 O Damour,2 M Diserbo,3 S Sauvaigo1 and W Rachidi1 1 CEA, Joseph
Fourier University-Grenoble 1, Grenoble, France, 2 Hospices Civils de Lyon, LYON, France
and 3 Institut de recherche biomédicale des armées, La Tronche, France
The effects of low-doses of ionizing radiation in humans are of growing concern, especially in the
context of current radiation techniques such as medical imaging. The biological response of healthy
tissue to low dose of 1-10 cGy in vivo is largely unknown. In this project, we propose firstly to
study the effects (long and short-term) of low-doses on cell proliferation, apoptosis, and capacity to
obtain a cohesive and stratified epidermis after irradiation. Secondly, we will evaluate the carcino-
genesis risk by measuring the modulation of the DNA repair/damage systems after low-dose expo-
sure. For short-term radiosensitivity, cell viability was determined by MTT assay after 24, 48 and 72
h post irradiation, we also performed an in vivo colony-forming assay, which measures the radia-
tion toxicity after 2 weeks. DNA repair system and damage was assessed by different techniques
available in our laboratory (DNA repair chips, modified comet assay …). Finally, organogenesis
potential was determined by the capacity of normal exposed keratinocytes to form a pluristratified
epithelium in 3D organotypic cultures. We showed that low-dose of ionizing radiation increases 2
fold the oxidative DNA damage (p=0.01) without any activation of the base excision repair path-
way, an important pathway to repair oxidative DNA damage. Moreover, we showed that low-dose
affects the organogenesis potential of keratinocytes and impairs the proliferation-differentiation
balance in the reconstructed skin. We postulate that when the dose or dose rate is very low the
radiation damage sensors (ATM or ATR) are not activated, and the repair machinery is not induced.
Hence damage could be accumulated in the genome of a cell until eventually it become malig-
nant.
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Thymocyte selection-associated high mobility group box protein TOX is a novel diagnostic
and prognostic marker for mycosis fungoides and Sézary syndrome
Y Huang,1 I Litvinov,2 Y Wang,1 M Su,1 D Sasseville2 and Y Zhou1 1 Dermatology and Skin
Science, University of British Columbia, Vancouver, BC, Canada and 2 McGill University,
Montreal, QC, Canada
The objective of this study is to test the utility of TOX (an early T cell development regulator) as a
diagnostic and prognostic marker for mycosis fungoides (MF) and Sézary syndrome (SS), which do
not have reliable molecular markers at present. Skin biopsies were obtained from 116 individuals
with MF, 25 with benign inflammatory dermatoses (BID), and 11 with normal skin (NS). Peripheral
blood CD4+ T lymphocytes were prepared from 12 SS patients and 27 subjects with BID or NS.
TOX mRNA was measured using quantitative polymerase chain reaction, and TOX protein was visu-
alized using immunofluorescence (IF) microscopy. Receiver operating characteristic (ROC) was used
to evaluate the diagnostic potential of TOX, whereas Kaplan-Meier method with Log rank test was
used to test TOX’s utility to predict MF/SS patients’ risk of disease progression and mortality. MF
skin biopsies expressed 11.3 times more TOX mRNA than non-MF skin biopsies (p=0.00001). Sim-
ilarly, the peripheral blood CD4+ cells in SS patients contained 4.6 times more TOX mRNA than
benign CD4+ T cells (p=0.000008). In IF analysis, TOX protein was specifically detected in the
nucleus of CD4+ cells in MF biopsies, but not in the CD4+ T cells of non-MF biopsies. Further, in
ROC analyses TOX accurately diagnosed MF subjects (with 100% specificity and 91.7% sensitiv-
ity) and SS subjects (with 100% specificity and 66.7% sensitivity). Finally, increased TOX expres-
sion strongly correlated with increased risk of disease progression for MF patients (p=0.003), and
increased disease specific mortality for both MF (p=0.042) and SS patients (p=0.049). In conclu-
sion, TOX is a novel molecular marker for the malignant CD4+ T cells in MF/SS, the most common
forms of cutaneous T cell lymphoma. Not only can it be used to establish MF/SS diagnosis, it can
also be used to predict long term clinical outcomes of MF/SS patients.
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Squamous cell carcinoma cell line (DJM-1) inhibits the growth of Merkel cell polyomavirus-
positive Merkel cell carcinoma cell line in collagen gel matrix culture
K Nagase,1 S Koba,1 S Aoki,2 S Ikeda,2 S Toda2 and Y Narisawa1 1 Division of Dermatology,
Department of Internal Medicine, Saga University, Saga, Japan and 2 Department of
Pathology and Microbiology, Saga University, Saga, Japan
Merkel cell carcinoma (MCC) is a highly aggressive skin cancer linked to a contributory virus, Merkel
cell polyomavirus (MCPyV). MCPyV DNA has been confirmed to be present in approximately 80%
of MCCs. We rarely have cases of combined MCC and Squamous cell carcinoma (SCC), although
the combined tumors account for a minor portion of MCCs. To our best knowledge, at least over
30 cases, including our cases, of combined MCC and SCC with MCPyV status of the MCC com-
ponent have been reported, and those all are MCPyV-negative. Thus, we hypothesized that there
are differences of the cell characteristics between MCPyV-positive and -negative MCCs in a coex-
istence environment with SCC. To address the effects of SCC on MCC growth and survival, we exam-
ined the growth and apoptosis of MCPyV-positive MCC cell line (MKL-1) and MCPyV-negative cell
line (MCC13) in coculture with SCC cell line (DJM-1), using a three-dimensional collagen gel matrix
culture with a cutaneous environmental factor, air exposure. The growth was estimated by the uptake
of bromodeoxy-uridine (BrdU) for 24 h. The BrdU indices of MKL-1 cells and MCC13 cells in cell-
free conditions were 6.57 % ± 1.53 % and 13.3 % ± 1.15 %, respectively, whereas the BrdU index
of MKL-1 cells and MCC13 cells in the gel with overlying DJM-1 cells were 2.74 % ± 0.49 % and
11.1 % ± 1.44 %. Cell apoptosis was detected with antibody specifically recognizing active cleaved
caspase-3. aIn conclusion, these findings indicated that squamous cell carcinoma cell line (DJM-
1) inhibit the growth of MCPyV-positive MCC cell line (MKL-1), but not MCPyV-negative MCC
(MCC13).
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Akt and intermediate filaments inhibit autophagy and promote tumorigenesis through Beclin
1/14-3-3 sequestration
RC Wang,1 Y Wei,3 Z An,3 Z Zou,3 M White,2 J Reichelt4 and B Levine3 1 Dermatology, UT
Southwestern, Dallas, TX, 2 Cell Biology, UT Southwestern, Dallas, TX, 3 Center for Autophagy
Research, UT Southwestern, Dallas, TX and 4 Institute of Cellular Medicine, Newcastle
University, Newcastle upon Tyne, United Kingdom
Aberrant signaling through the class I phosphatidylinositol 3-kinase (PI3K)-Akt axis is one of the
most frequent alterations in human cancers. Here we show that Beclin 1, an essential autophagy
and tumor suppressor protein, is a target of Akt. The Akt oncogene inhibits autophagy by promot-
ing phosphorylation of Beclin 1 on S234 and S295. Phosphorylated Beclin forms an inactive com-
plex with 14-3-3 and intermediate filament proteins. The disruption of this complex through deple-
tion of vimentin or keratin 10 in vitro and in vivo results in increased autophagy. Moreover, the
disruption of this complex through the expression of a Beclin 1 mutant resistant to phosphorylation
by Akt increases autophagy, reduces anchorage-independent growth in vitro, and inhibits Akt-medi-
ated tumorigenesis in vivo. Finally, Beclin 1 colocalizes with vimentin and keratin intermediate fil-
aments. Thus, Akt-mediated phosphorylation of Beclin 1 functions in autophagy inhibition and onco-
genesis, and leads to the formation of an autophagy-inhibitory Beclin 1/14-3-3/intermediate filament
complex. These findings suggest broader roles for Akt signaling and intermediate filament proteins
in the direct regulation of autophagy, cell growth, and cancer.
372
Nuclear receptor status of cancer-associated fibroblasts modifies squamous cell carcinoma
gene expression signature
J Chan,1 M Sng1 and N Tan1,2 1 School of Biological Sciences, Nanyang Technological
University, Singapore, Singapore and 2 Cancer genetics and therapeutics, Institute of
Molecular and Cell Biology (A*STAR), Singapore, Singapore
Recent advances in cancer research have highlighted the importance of the tumour stroma in sup-
plying a conducive microenvironmental niche enabling several hallmarks of cancer. Cancer-asso-
ciated fibroblasts (CAFs) which are featured prominently in the surrounding milieu of a neoplastic
lesion have been shown to facilitate cancer progression towards malignancy. CAFs are known to
promote tumorigenesis via a heterotypic paracrine fashion involving secreted chemokine and cytokine
networks. Yet, the transcriptional control of the pro-tumour phenotype of CAFs remains elusive.
Nuclear receptors, which are environmentally-responsive, ligand-activated transcription factors, are
expected to play a major role in CAF-mediated cancer progression. We profiled the expression lev-
els of all 48 known nuclear receptors in CAFs relative to normal dermal fibroblasts isolated from
human squamous cell carcinoma (SCC) biopsies. We further revealed that the nuclear receptor sta-
tus of CAFs profoundly impacts the gene expression signature of SCC. Our work suggests that selec-
tive targeting of nuclear receptors in CAFs perturbs cancer cell behaviour and thus positions drugs
targeting nuclear receptor as potential anticancer agents.
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Redox-based apoptosis induced by amino endoperoxides in tumors
R Wang,1 P Zhu1 and N Tan1,2 1 School of Biological Sciences, Nanyang Technological
University, Singapore, Singapore and 2 Institute of Molecular and Cell Biology, Singapore,
Singapore
Majority of human cancer deaths are due to metastases which are resistant to conventional thera-
pies. Anoikis resistance is a pivotal characteristic of metastatic cancer cells. Tumor cells exhibit
excessive and persistent elevation of reactive oxygen species (ROS) and utilize a redox-based mech-
anism to evade death by anoikis. Recent findings showed that tumor cells maintain a relatively high
O2-:H2O2 ratio to confer resistance to anoikis. We hypothesize those therapeutic treatments that
alter this redox ratio will minimize or prevent metastasis. Endoperoxides-containing compounds
have long been proposed as anti-cancer drugs. However, due to instability and complexity in syn-
thesis procedure, few have been employed clinically. We were able to synthesize novel amino
endoperoxides and their derivatives with good yields and stabilities. Our finding showed that our
amino-endoperoxide selectively targets high-Nox4 expressing tumor, reducing O2-:H2O2 ratio and
increasing hydroxyl radical level. Furthermore, we observed that cancer-associated fibroblasts
undergo apoptosis in vitro, suggesting a redox-mediated mechanism is important to sustain their
tumor-promoting phenotype.
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Nuak2 amplification coupled with Pten deficiency confers tumorigenicity to melanomas via
cdk2
T Namiki,1 JC Valencai,1 SG Coelho,1 L Yin,1 M Kawaguchi,1 WD Vieira,1 Y Kaneko,2 A Tanemura,3
I Katayama,3 Y Kawakami,4 H Yokozeki5 and VJ Hearing1 1 Laboratory of Cell Biology, National
Cancer Institute, National Institutes of Health, Bethesda, MD, 2 Research Institute for Clinical
Oncology, Saitama Cancer Center, Saitama, Japan, 3 Department of Dermatology, Osaka
University Graduate School of Medicine, Osaka, Japan, 4 Institute for Advanced Medical
Research, Keio University School of Medicine, Tokyo, Japan and 5 Department of
Dermatology, Tokyo Medical and Dental University Graduate School and Faculty of
Medicine, Tokyo, Japan
NUAK2 has a pivotal role in regulating melanoma growth and the survival of patients with melanomas,
and inhibition targeting NUAK2 itself and/or its downstream pathway would be promising thera-
pies. In this study, we explored genomic aberrations in addition to NUAK2 amplification and cell
cycle regulation by those genomic aberrations, and we characterized an efficient molecular target
to suppress melanoma growth. We found that a deficiency of PTEN is coupled with amplification
at the genomic area around NUAK2 using array-CGH data and immunohistochemical studies
using clinical specimens also verified that p-Akt expression has a significant correlation with NUAK2
expression (P=0.005) in acral melanomas. Inactivation of the PI3K pathway reduced the S-phase
population by up-regulating p21 expression. Both knockdown of NUAK2 and inactivation of the
PI3K pathway efficiently control CDK2 expression, and inactivation of CDK2 specifically abrogates
the growth of both NUAK2-amplified and PTEN-deficient melanoma cells compared to melanoma
cell without those genomic aberrations. Immunohistochemical studies also verified those results by
a high percentage (81.40%) of CDK2 expression in both NUAK2 and p-Akt expressing melanomas.
We further show that an inhibitor targeting CDK2 suppresses the growth of both NUAK2-amplified
and PTEN-deficient melanoma cells in vitro and in vivo. These results emphasize the importance
of CDK2 in cell cycle regulation of melanoma cells and suggest that CDK inhibitors targeting CDK2
are promising therapies for cutaneous melanomas.
373
Diagnostic utility of CD10 immunohistochemical staining in squamous cell carcinoma and
precursor lesions: Evaluation using tissue microarray
J Yun,1 J Choi,1 J Lee,1 S Park2 and J Roh1 1 Dermatology, Gachon University, Graduate School
of Medicine, Incheon, Republic of Korea and 2 Pathology, Ewha Womans University, School
of Medicine, Seoul, Republic of Korea
Cutaneous squamous cell carcinoma (cSCC) is widely accepted to be the result of a transformation
from precancerous lesions. Recent studies have suggested that CD10 expression is associated with
tumor progression and metastasis in malignant melanoma. This study examined whether CD10
expression in cSCC is associated with tumor progression and other clinicopathologic data. A total
of 25 cSCC cases were retrieved from the archives and a 2-mm tissue core was obtained from the
each specimen for the generation of the tissue microarray (TMA) blocks. In addition, 28, 28 and 29
cases of actinic keratosis, Bowenoid actinic keratosis and Bowen’s disease, respectively, were
immunostained for CD10 for comparison. The total area and intensity of the immunostain were arbi-
trarily defined as follows: area of staining 0 (<5%), 1 (5~25%), 2 (26%~50%), 3 (51%~75%) and 4
(>75%); and intensity 0 (none), 1 (faint/barely), 2 (weak to moderate) and 3 (strong). The variables
were multiplied and classified from 0 to 12 grades. Eight of 25 cases of cSCC (32%) showed CD10
expression, whereas no CD 10 expression was observed in the precursors. There was a positive
relationship between CD10 expression and grade of differentiation (P< 0.05). Although the cases
with recurrence or metastasis of tumor showed the high CD10 score, this was not statistically sig-
nificant (p= .093, p= .081, respectively). In conclusion, CD10 expression appears to be a late event
in cSCC carcinogenesis and is probably associated with tumor progression in cSCC.
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The cross talk between p53 and NFκB determines the response to UVB in keratinocytes
I Mueller, S Beissert and D Kulms Experimental Dermatology, University of Dresden, Dresden,
Germany
The susceptibility towards apoptosis-inducing stimuli depends on the intracellular balance of pro-
and anti-apoptotic factors. In response to DNA-damaging agents, this balance is shifted towards
up-regulation of pro-apoptotic factors via activation of p53. In contrast, activation of the transcrip-
tion factor NFκB dislocates the balance towards expression of anti-apoptotic genes. Thus, the cross
talk between p53 and NFκB significantly governs the cell fate. Putting the role of NFκB into a dif-
ferent perspective, our recent studies revealed that IL-1-induced NFκB activation enhanced UVB-
induced apoptosis. This effect was mediated via NFκB-dependent repression of anti-apoptotic genes
and coincided with a prolonged expression of TNF. Secreted TNF subsequently activated TNF-R1
in an autocrine fashion to additively enhance apoptosis. Elevated TNF production was due to per-
sistent NFκB activation resulting from disruption of the negative feedback loop, which involves re-
synthesis of its inhibitor IκB. Investigateing the role of p53 in UVB responsiveness the p53mut car-
rying keratinocyte cell line HaCaT and the p53wt carrying cell line SCL-1 were compared. Surprisingly,
only HaCaT but not SCL-1 cells responded with apoptosis induction. Additionally, only HaCaT cells
showed enhanced apoptosis when co-stimulated with IL-1. These results question the island posi-
tion of p53 in mediating DNA damage-induced apoptosis. Further evidence was provided by the
finding that exchanging the genotype of HaCaT cells into p53-ko via stable knock down and fur-
ther into p53wt by stable re-expression only feeble changes in short term UVB responses (24 h apop-
tosis assays) were noted, while no influence on clonogenic outgrowth or colony formation after 3
weeks of cultivation was seen. Strikingly, p53-ko cells were no longer able to conduct IL-1-induced
and NFκB-dependent enhancement of apoptosis and TNF production. This strongly indicates that
NFκB and p53 closely collaborate in generating a proper apoptotic response to UVB, an important
finding regarding the development of new antitumoral treatment strategies.
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RNA trans-splicing molecules for targeted suicide gene delivery into cancer cells
C Gruber,1 U Koller,1 S Hainzl,1 EM Murauer,1 C Hüttner,1 AP South,2 H Hintner1 and JW Bauer1
1 Department of Dermatology, Division of Experimental Dermatology and EB House Austria;
Paracelsus Medical University, Salzburg, Austria and 2 Medical Research Institute, Division of
Cancer Research;Ninewells Hospital and Medical School, University of Dundee, Dundee,
United Kingdom
Patients suffering from the severe form recessive dystrophic EB (RDEB-sev gen), have an increased
risk to develop aggressive squamous cell carcinoma (SCC). In this context we are evaluating a gene
therapy approach for tumor treatment, by inducing toxin-mediated death of the tumor cells. In this
study spliceosome-mediated RNA trans-splicing is used to specifically target tumor marker genes,
overexpressed in RDEB-associated tumor cells with the aim to introduce a suicide gene and elim-
inate the cells by its expression. We chose the solute carrier organic anion transporter family mem-
ber 1B3 (SLCO1B3), which is strongly upregulated in RDEB tumor cells. We designed and evalu-
ated different RNA trans-splicing molecules (RTMs) in order to improve the specificity of the
trans-splicing process and to reduce unwanted side effects including ectopic expression of the toxin.
Cell death inducing RTMs contain a specific binding domain for SLCO1B3 and the suicide gene
thymidine kinase from herpes simplex virus (HSV-tk). The trans-splicing efficiency of each RTM was
evaluated after co-transfection with a SLCO1B3 minigene (SLCO1B3-MG) in HEK293 cells. Accu-
rate trans-splicing leads to the generation of a chimeric SLCO1B3-tk fusion construct exhibiting
suicide gene activity after ganciclovir (GCV) treatment. Correct expression of the trans-spliced
SLCO1B3-tk mRNA and its protein was detected by semi-quantitative RT-PCR and Western blot
analysis, respectively. Furthermore, MTT and TUNEL assays confirmed that the constructed RTMs
induce toxin-mediated apoptosis in SLCO1B3-MG expressing cells. RTMs with high trans-splicing
specificity and efficiency are needed to successfully induce cell death in tumor cells. To conclude,
our inducible cell-death system provides a powerful tool to identify optimal RTMs for suicide gene
therapy approaches.
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Diverse roles for laminin 332 subunits in squamous cell carcinoma
MP Caley, V Martins, K Moore, JF Marshall and EA O’Toole Barts and the London SMD, Queen
Mary University of London, London, United Kingdom
The basement membrane zone (BMZ), present in all epithelia, plays an important role in cancer
spread acting not only as a barrier to invasion but also signalling through cell surface receptors.
Components of the skin BMZ include collagens IV, VII and XVII as well as laminin 332 (Lam332),
which is secreted in copious amounts by cancer cells. Patients with severe epidermolysis bullosa
(EB) caused by mutations in BMZ components suffer from an increased incidence of aggressive squa-
mous cell carcinoma (SCC). The role of Lam332 and collagen XVII in tumour development is
poorly understood. This study dissects the effect of loss of individual subunits of Lam332 or colla-
gen XVII on SCC. We have generated using lentiviral shRNA, 4 stable cutaneous SCC cell lines
each lacking a different BMZ component including collagen XVII and the three constituent parts of
Lam322, LamA3, LamB3 and LamC2. Using our cell lines we studied their role in cell attachment,
proliferation, motility, in vitro and in vivo invasion, and invadopodia. Loss of ColXVII increased
cell attachment whereas loss of any of the Lam332 chains reduced cell attachment. Loss of any of
the BM components reduced cell proliferation. The loss of LAMA3 and LAMC2 increased cell motil-
ity whereas loss of LAMB3 and ColXVII had no significant effect on motility. We demonstrated
increased invasion in both in vitro collagen gels and in vivo xenografts with loss of LAMA3, LAMC2
and ColXVII with distinct patterns of invasion seen in each cell line. An increased number of invadopo-
dia were observed in LAMA3, LAMC2 and ColXVII cell lines as well as more invadopodia positive
cells compared to control. LAMC2 invadopodia but not LAMA3 and ColXVII were Src dependent.
Finally we have used QPCR and Western blotting to identify changes in signalling pathways known
to be involved in cancer progression such as EMT (epithelial to mesenchymal transition), integrin
signalling and tight junction formation. In conclusion this study further refines the role of laminin
332 and ColXVII in SCC invasion and proliferation in vitro and in vivo.
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Characterisation of the peritumoral immune infiltrate in human primary cutaneous squamous
cell carcinomas
C Lai,1 R Behar,1 S August,1 C McGuire,1 M Polak,1 J Theaker,2 A Al-Shamkhani3 and E Healy1 1
Dermatopharmacology, University of Southampton, Southampton, United Kingdom, 2
Histopathology, University Hospital Southampton NHS Foundation Trust, Southampton,
United Kingdom and 3 Cancer Sciences, University of Southampton, Southampton, United
Kingdom
Defective immunity plays a major role in the pathogenesis of cutaneous squamous cell carcinoma
(SCC) as evidenced by the significantly increased incidence of this malignancy (up to 250-fold) in
immunosuppressed individuals. In immunocompetent patients, a peritumoral immune cell infiltrate
is commonly found in cutaneous SCC but is unable to destroy the tumour. We have previously shown
that FOXP3+ regulatory T cells (Tregs) are present in skin SCCs, and that Tregs from SCCs suppress
peritumoral effector T cell proliferation in vitro. Here we show, using immunohistochemical quan-
tification of Tregs in cutaneous SCCs (n=36), that increased FOXP3+ Treg numbers are present in
primary tumours from patients who subsequently developed metastases compared with tumours
that did not metastasise (28.6% versus 11.9% of immune cell infiltrate respectively, p=0.010), fur-
ther implicating Tregs as pathogenic in SCC. We also demonstrate a deficiency in CD8+ T cell func-
tion in skin SCCs, despite there being more CD8+ T cells in the tumour than in the peripheral blood
of subjects with skin SCCs (40.0% versus 18.3% of CD3+ population respectively; p=0.001). For
example, phytohaemagglutinin-stimulated FACS-isolated CD8+ T cells from SCC proliferated sig-
nificantly less than CD8+ T cells from peripheral blood (mean cpm 3,215 versus 5,576, n=8, p=0.017),
suggesting that CD8+ T cells accumulate in SCC but are dysfunctional. FACS quantification of the
inhibitory receptor, PD-1, demonstrated increased PD-1 expression on CD8+ T cells in SCC com-
pared with CD8+ T cells from peripheral blood (16.9% versus 2.9% of CD8+ population, n=4,
p=0.004). Overall, our results indicate that a combination of defective immune responses are pres-
ent in skin SCCs, and suggest that these play a fundamental role in the development of these tumours.
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Targeting Fyn restores cell-cell adhesion in Ras-transformed HaCaT cells and inhibits UV
skin tumorigenesis
MF Denning1,2 and SE Fenton2 1 Pathology, Loyola University Chicago, Maywood, IL and 2
Molecular Biology Program, Loyola University Chicago, Maywood, IL
Ras oncogene activation is a common feature of human cancers, including cutaneous squamous
cell carcinoma (SCC). However, directly targeting Ras activity has not proven to be clinically effec-
tive. Active Ras mediates its oncogenic effects via multiple effector pathways. We recently identi-
fied PI3K/Akt/Fyn signaling as an important Ras effector pathway involved in the migration and inva-
sion of H-Ras(G12V)-transformed HaCaT cells (HaCaT-Ras). HaCaT-Ras cells selectively over-express
the Src family kinase Fyn at the transcriptional level, and have undergone an epithelial-to-mes-
enchymal transition. We investigated the effects of Dasatinib, an approved Src family kinase inhibitor
currently used to treat leukemias, as a potential targeted therapy for SCCs using HaCaT-Ras cells as
a model. Although Dasatinib inhibited the growth and proliferation of HaCaT and HaCaT-Ras cells
with equal potency, it dramatically enhanced cell-cell adhesion and partially reversed the mes-
enchymal morphology of HaCaT-Ras cells. Dasatinib has similar effects on the morphology of Fyn-
transformed HaCaT cells. The Dasatinib-stimulated increase in HaCaT-Ras cell-cell adhesion was
associated with enhanced membrane localization of desmoplakin and N-cadherin, implicating both
desmosomes and adherens junctions. Dasatinib also significantly inhibited HaCaT-Ras cell migra-
tion, consistent with the role of Fyn in HaCaT-Ras cell migration. To determine if Dasatinib could
be effective in treating SCC, we performed a UV skin carcinogenesis experiment in SKH1 mice
exposed to broadband UVB three times per week. Mice treated topically with Dasatinib (1 μmole)
immediately after each UV exposure had significantly lower overall tumor burden, primarily due
to reduced tumor multiplicity. Overall, these results indicate that targeting Fyn activity with small
molecule inhibitors, such as Dasatinib, can reverse the migratory phenotype of Ras-transformed
cells and is a promising approach for the treatment of SCC.
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Crosstalk between Desmoglein-2 and Hedgehog signaling in skin tumorigenesis: Dsg2 mod-
ulates Gli expression in keratinocytes
DM Brennan, NA Riobo and MG Mahoney Thomas Jefferson University, Philadelphia, PA
The desmosomal cadherin, desmoglein 2 (Dsg2) is upregulated in various cancers, including basal
and squamous cell carcinomas (BCC, SCC). Furthermore, we recently demonstrated that Dsg2
enhances cell growth and survival and transgenic (Tg) mice overexpressing Dsg2 in the skin develop
a hyperproliferative epidermis and are more susceptible to chemical-induced tumor development.
Here we demonstrate that the mechanism by which Dsg2 regulates these phenotypic changes may
involve the Hedgehog (Hh) signaling pathway. Canonical Hh signaling is a key developmental path-
way characterized by the activation of Gli transcription factors which are regulated by Smoothened
(Smo). The Hh signaling cascade is initiated upon the binding of Hh ligands to Patched (Ptc), which
alleviates Ptc suppression of Smo. The Hh pathway is aberrantly activated in various skin cancers;
and in fact, improper activation of Hh signaling is the underlying cause of virtually all BCC. qPCR
analysis of Dsg2-Tg mice reveals a correlation between Dsg2 and the expression of Gli transcrip-
tional targets Gli1 and Ptc1. Additionally, immunohistochemical staining shows a correlation between
Dsg2 and Gli1 expression in human BCC. Furthermore, RNAi knockdown of Dsg2 results in a con-
comitant decrease in Gli expression in keratinocytes. We obtained PtcLacZ reporter mice, in which
a portion of the Ptc1 gene has been replaced with LacZ, rendering Ptc non-functional and making
them efficient reporters of Hh activity. These heterozygous mice are primed for Hh activation, and
thus are an ideal model for cancer studies. To assess the effects of deregulating both Dsg2 and Hh
signaling in vivo, we crossed the Dsg2-Tg mice with the PtcLacZ reporter mice. As expected, mice
overexpressing Dsg2 exhibit a hyperplastic epidermis and abnormal differentiation; furthermore,
these phenotypes are enhanced on the Ptc heterozygous background. Taken together, this data sup-
ports a role for Dsg2 in enhancing Hedgehog signaling, potentially through the regulation of Gli
expression.
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Determination of genes involved in the resistance of squamous cell carcinoma to photody-
namic therapy
A Juarranz,1 L Milla,2 A Damian,1 N Salazar,1 E Carrasco,1 S Gonzalez,3 V Jesus4 and Y Gilaberte4
1 Biology, Autonomous University of Madrid, Madrid, Spain, 2 Molecular Biology, Universidad
Nacional de Río Cuarto, Río Cuarto, Argentina, 3 Dermatology Service, Memorial Sloan-
Kettering Cancer Center, New York, NY and 4 Pathology and Dermatology, Hospital de San
Jorge de Huesca, Huesca, Spain
Photodynamic therapy (PDT) is widely used to treat actinic keratosis and in situ squamous cell car-
cinoma (SCC). However, the main problem about PDT, as well as other current treatments against
cancer, is the appearance of resistant population cells that would be responsible for relapses and
metastatic processes. By the use of comparative genomic hybridization (CGH) we have investi-
gated genomic alterations that might be implicated in resistance of the SCC-13 cell line to methyl
derivative of δ-aminolevulinic acid (MAL-PDT). SCC-13 original cell population (Parental) and resist-
ant SCC populations obtained by repeated treatment with MAL-PDT (5th and 10th PDT-generations)
were analyzed performing an array CGH (aCGH) to determine the potential genomic differences
between the three cells types. The differential selected genes were validated in extracts of Parental
and resistant SCC-13 cells using western blot and in histological sections of tumors induced by
injecting the SCC-13 cells in immunodeficient mice. The results obtained indicated that all three
cell types, Parental, 5th and 10th PDT-resistant cells, showed amplicons in 3p12.1 CADM2, 7p11.2
EFGR and 11q13.3 CCND1 genes. However, 5th and 10th PDT-resistant cells showed an amplicon
in 5q11.2 MAP3K1 and genomic losses in 5q14q23, 15q and 21q among others. As a first approach,
the changes detected by aCGH on CCND1, EFGR and MAP3K1 were evaluated by immunohisto-
chemistry in the tumors induced by inoculation in mice of Parental, 5th or 10th PDT-resistant cells
and in human biopsies obtained from persistent tumors after being subjected to MAL-PDT. An
increase in the expression of Cyclin D1, EFGR and MAP3K was detected. In conclusion genomic
imbalances related with CCND1, EFGR and MAP3K1 seems to be involved in the development of
resistance to PDT of SCC.
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Gene expression profiling of primary fibroblasts isolated from multiple self-healing squamous
epithelioma
Y Ng,1,2 I Szeverényi,1 L Lacina,1 P Benny,1 A Gerdes,3 S Broesby-Olsen4 and EB Lane1 1 Institute
of Medical Biology, A*STAR, Singapore, Singapore, 2 University of Dundee, Dundee, United
Kingdom, 3 Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark and 4
Odense University Hospital, Odense, Denmark
We have recently identified disease-specific spectrum of mutations in TGFBR1 gene to be basis of
the genetic skin cancer disorder called multiple self-healing squamous epithelioma (MSSE). MSSE,
also historically known as Ferguson-Smith disease, is characterized by multiple well-differentiated
keratoacanthoma-like tumours, which appear and grow rapidly, mainly on sun-exposed body sites.
The onset of this disease varies greatly, from 8-80 years of age. These tumours undergo spontaneous
regression and involution, leaving considerable scarring. The reason for such tumour behaviour
remains unclear. To understand the contribution of the microenvironment to the tumour progres-
sion and regression, global gene expression analysis was performed using Affymetrix Human Genome
U133 2.0 Plus Array on total RNA isolated from primary fibroblasts. The fibroblasts were derived
from the unaffected skin, peri-tumour and tumour tissues of a Danish MSSE patient. The control
fibroblasts were isolated from a healthy Danish family member. Preliminary data from gene expres-
sion analysis revealed 119 differentially expressed genes with functions related to skin, cancer devel-
opment and TGF-β signalling pathway.
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TRAIP expression is quantitatively and spatially regulated in epithelial cells
C Chapard,1,2 D Hohl1,2 and M Huber1,2 1 Dermatology, CHUV, Lausanne, Switzerland and 2
Biology and Medicine, UNIL, Lausanne, Switzerland
The TRAF-interacting protein (TRAIP, TRIP) is a RING-type E3 ubiquitin ligase that interacts with the
deubiquitinase CYLD, a tumor suppressor whose functional inactivation leads to skin appendage
tumors. TRAIP is required for embryonic development since removal of TRAIP either in Drosophila
or mice by mutations or knock-out is lethal due to aberrant regulation of cell proliferation and apop-
tosis. Furthermore, shRNA-mediated knock-down of TRAIP in human epidermal keratinocytes (HEK)
repressed cell proliferation and induced a G1/S phase block in the cell cycle. To investigate the cel-
lular localization of TRAIP, lentiviral vectors (LV) were constructed driving expression of a TRAIP-
GFP fusion protein (TRAIP-GFP) from the CMV promoter. Transduction of HeLa cells or HEK with
TRAIP-GFP followed by immuno-fluorescence analysis demonstrated that TRAIP-GFP is localized
to the nucleolus during interphase. TRAIP1-289 or TRAIP289-469 GFP fusion proteins expressed in
HeLa cells localized to the cytosol or the nucleus, respectively, indicating that the N-terminal part
specifies nucleolar localization whereas the C-terminal region determines nuclear transfer. Analy-
sis of the expression levels of TRAIP-GFP or GFP in stably transduced HeLa cells and HEK revealed
that the level of TRAIP protein was significantly lower compared to GFP although their mRNA lev-
els were comparable. Determination of the half-life using cycloheximide showed that TRAIP has a
half-life of 3.2+/-1.2 hours (n=5) suggesting that it is an unstable protein. These results indicate that
the level and sub-cellular localization of TRAIP protein is highly regulated which might be impor-
tant for control of cell proliferation.
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The newly developed vinegar “Izumi” inhibits the proliferation of human squamous cell car-
cinoma cells by inducing programmed cell necrosis
N Baba, Y Higashi and T Kanekura Kagoshima University Graduate School of Medical and
Dental Sciences, Kagoshima, Japan
Kurozu (Japanese black vinegar), a traditional product made from unpolished rice, contains bene-
ficial organic materials and minerals. The new vinegar that contains large amounts of such con-
stituents was produced by the improvement in the manufacturing process and named “Izumi”. Since
antioxidative effect of Kurozu is well elucidated, we examined the anticancer activity of Izumi on
human squamous cell carcinoma (SCC) cell line, HSC-5. HSC-5 cells were treated with Izumi or
the ordinary grain vinegar, which were adjusted to 4.2% acidicity. MTT assay and the trypan blue
dye exclusion test showed that Izumi significantly inhibited the proliferation of HSC-5 cells com-
pared to ordinary grain vinegar. Propidium iodide (PI) flow cytometry and annexin V/PI staining
revealed that among cells treated or untreated with Izumi or ordinary grain vinegar there was no
difference in the number of apoptotic cells. Recently, a new form of necrosis, programmed necro-
sis or necroptosis, has been proposed. Programmed necrosis is mediated by the receptor-interact-
ing serine-threonine kinase 3 (RIPK3) as a key signaling molecule and results in the release of cel-
lular danger-associated molecular patterns (DAMPs). When HSC-5 cells were treated with Izumi,
the cellular level of RIPK3 protein and the amount of high-mobility group protein B1 (HMGB1),
one of the DAMPs, released into culture media were remarkably increased. These findings indicate
that Izumi inhibits proliferation of human SCC cells via programmed necrosis.
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Conditional Cyld mutation induces epidermal cell lineage-specific abnormalities due to dereg-
ulation of NF-kB and c-Myc gene regulators
J Jin,1 S Wang,1 J Cho,1 G Mosiolas2 and J Zhang1 1 Dermatology, Duke University, Durham, NC
and 2 Aristotle University of Thessaloniki, Thessaloniki, Greece
Genetic mutations in Cyld are linked to multiple pathological conditions including skin cancer.
The molecular mechanisms underlying the pathogenesis are still unclear. Here, we generated a con-
ditional CYLD mutant (CYLDm) knock-in mouse model through K14-Cre-mediated deletion of
cyld exon 9 (hereafter refer to Cylde9/9). Cylde9/9 mice were born alive but developed a coarse
hair phenotype accompanied with sebaceous gland hyperplasia, elongated incisor teeth and toe
nails. Upon challenge with DMBA/TPA, these animals displayed reduced growth of papilloma but
increased growth of sebaceous nevi and basaloid tumor nodules. Molecular analysis revealed that
CYLDm sustained NF-kB activity which in turn maintains CYLDm-gene expression. In addition,
CYLDm resulted in an elevated level of c-Myc and c-Myc-K63-ubiquitination in keratinocytes. Top-
ical treatment of Cylde9/9 mice with pharmacological inhibitors of NF-kB and c-Myc significantly
increased sebaceous gland cell apoptosis. Taken together, these results indicate that endogenous
CYLDm forms a positive feedback loop with NF-kB, and activates c-Myc to promote epidermal cell
lineage-specific defects. Thus, our findings identify NF-kB and c-Myc as potential therapeutic tar-
gets for pathological conditions associated with Cyld mutation.
385
Enhanced MET signaling in mouse epidermis activates EGFR and initiates squamous car-
cinogenesis
SH Yuspa, F Liu, L Wright, A Zhuang, G Merlino and C Cataisson Laboratory of Cancer Biology
and Genetics, National Cancer Institute, Bethesda, MD
Activation of MET signaling is associated with multiple cancers but its function in the process of
carcinogenesis has not been elucidated. The multistage induction of tumors on mouse skin was used
to address this question. Double transgenic mice were generated by crossing K5-PKCalpha mice
that overexpress PKCalpha in basal keratinocytes and are tumor promotion sensitive with MT1-HGF
mice that overexpress the MET ligand HGF under a metallothionein promoter to create MT1-HGF/
K5-PKCalpha (DT) mice and their respective controls. DT animals developed six fold more squa-
mous tumors than other genotypes when exposed to a single tumor initiating application of dimethyl-
benz(a)anthracene followed by six applications of tumor promoting 12-O-tetradecanoyl-13-phor-
bol acetate (TPA). Both DT and MT1-HGF keratinocytes in vitro displayed MET-mediated autonomous
conversion to a morphological and biochemical phenotype characteristic of initiation by oncogenic
H-Ras. Enhanced MET signaling activated EGFR through specific upregulation of EGFR ligands, a
common pathway downstream from oncogenic Ras initiation. Inhibition of EGFR activity reversed
many of the biochemical changes resulting from enhanced MET signaling. In vitro and in vivo, MT1-
HGF keratinocytes and mice responded to TPA like wildtype keratinocytes while DT keratinocytes
and mice responded to TPA like promotion sensitive K5-PKCalpha keratinocytes. Thus, enhanced
MET signaling alone did not influence tumor promotion. In vivo without chemical initiation, DT
mice developed multiple squamous papillomas when promoted by TPA while none of the three
other genotypes developed tumors. Mutations were not detected in any Ras allele in DT tumors.
Together these results indicate that enhanced keratinocyte MET activity can initiate skin tumor for-
mation through autocrine activation of EGFR, and the synergistic activity of MET and PKCalpha in
epidermal keratinocytes can substitute for the lack of Ras mutations during skin carcinogenesis.
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Cutaneous SCC and the RAS controversy
AT McHugh,1 K Purdie,2 C Pourreyron,1 S Watt,1 A Rose,1 I Leigh,1 C Harwood,2 A South1 and
C Proby1 1 Skin Tumour Laboratory, Division of Cancer Research, Ninewells Hospital &
Medical School, University of Dundee, Dundee, United Kingdom and 2 Centre for Cutaneous
Research, Barts & the London Queen Mary, University of London, London, United Kingdom
Cutaneous squamous cell carcinoma (SCC), the second most common cancer worldwide, is increas-
ing by at least 5% per annum in Scotland. SCC is now responsible for 25% of skin cancer-related
deaths with a lack of targeted treatments for recurrent/metastatic disease because the molecular
drivers of cutaneous SCC are poorly understood. Activating mutation of HRAS is the initiating event
in the chemical carcinogenesis model of cutaneous SCC, but the role of RAS mutation in UV-initi-
ated SCC is unclear. The development of keratoacanthoma-like SCC skin tumours in patients treated
with BRAF inhibitors and the availability of targeted therapies to MEK and EGFR revisit the ques-
tion of RAS activation in cutaneous SCC. We performed whole exome sequencing on 10 well dif-
ferentiated (WD) and 10 poorly differentiated (PD) SCC using the Illumina Hi-Seq platform (EASIH,
Cambridge), identifying a single codon 12 KRAS mutation in 1/20 tumours. Targeted sequencing of
HRAS, KRAS and NRAS was performed using the Fluidigm / Roche 454 GS-Junior platform on a
validation series of 82 SCC plus 20 SCC cell lines. Five codon 13 HRAS mutations were identified
in 4 WD-SCC and 1 SCC cell line confirming a 5% mutation rate. Ras activation was measured using
the Ras GTPase Chemi ELISA Kit with only 1 in10 of the SCC cell lines displaying any activation of
Ras. These data, together with low levels of pERK and pAKT in the majority of cell lines, imply a
less central role for Ras in UV-induced SCC compared with vemurafenib-induced skin tumours.
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The role of Retinoblastoma protein (Rb) in cell cycle control by TH1-cytokines in mouse and
human cancers
K Braungart, M Hahn, A Sonja, H Braumüller, E Brenner, S Weidemann, T Wieder and M Röcken
Department Of Dermatology, University Medical Center, Tübingen, Germany
Regulation of the cell cycle progression via the p16Ink4a/Rb-pathway is a central mechanism that is
impaired in several types of cancer. RIP1-Tag2 mice expressing the T antigen (Tag) under the con-
trol of the rat insulin promoter (RIP) develop β-cell cancers due to a partial inhibition of the p16Ink4a/Rb
pathway and a complete inactivation of p53. Our previous studies showed that Tag-specific, inter-
feron-γ (IFNγ)- and tumor necrosis factor (TNF)-producing T helper 1 (TH1) cells doubled the sur-
vival of RIP1-Tag2 mice and strongly reduced cell proliferation. MHC class II restricted TH1 cells are
unable to directly interact with β-cancer cells or to kill the cancer cells, as β-cancer cells do express
MHC class II neither in vitro nor in vivo. We therefore focused on the effects of the soluble TH1
cytokines IFNγ and TNF on β-cancer cells. In vitro, IFNγ and TNF both exerted an anti-proliferative
effect on β-cancer cells and arrested them in the G0/G1 phase of the cell cycle, as shown by flow
cytometry. These effects strongly increased when the two cytokines were combined. We next focused
on the effects of TH1-cytokines on the p16Ink4a/Rb-pathway in β-cancer cells, first by Western Blot
and immunofluorescence. IFNγ and TNF caused within 48h strong dephosphorylation of Rb, while
it did not affect Rb protein in the cytoplasm. Thus, TH1-cytokines caused a stabilization of Rb-medi-
ated cell cycle control. To confirm the functional importance of the p16Ink4a/Rb-pathway in cytokine-
mediated cell cycle control, we performed a knockdown of Rb in β-cancer cells via lentiviral trans-
fection with shRNA. First experiments already confirmed that silencing of Rb in β-cancer cells
decreased the responsiveness to TH1-cytokine treatment. Similarly, IFNγ and TNF caused dephos-
phorylation of Rb in a human sarcoma. Thus, Rb is a central target of TH1-cytokine induced cell cycle
control in cancers of mouse and human origin.
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The detection of novel KIT mutations in mastocytosis
I Chan and MD Tharp Department of Dermatology, Rush University Medical Center, Chicago,
IL
KIT is a receptor tyrosine kinase (RTK) that consists of a ligand-binding extracellular domain (ECD),
a transmembrane domain (TMD), a cytoplasmic juxtamembrane regulatory domain (JMD), and a
tyrosine kinase domain (TKD). Activating KIT mutations are associated with mastocytosis. Sequence
analysis targeting the KIT mutational hot spots have shown that while most adult-onset patients
express the autoactivated KITD816V mutation in the TKD, most childhood mastocytosis patients have
mutations within the ECD; however, not all patients express KIT mutations. We speculate that addi-
tional KIT activation results from alternative splicing. Thirty-eight mastocytosis subjects (28 adults
and 10 children) were evaluated for KIT transcript variations using a long-range PCR amplification
targeting the full-length cDNA and direct DNA sequencing. Seventy-nine percent of adult patients
(22 out of 28) had the D816V (T>A) mutation, 18% (4 out of 28) had the M541L (C>A) mutation
within the TMD, 14% (4 out of 28) had the V560G (G>T) mutation located in the JMD, but 0% had
a mutation in the ECD. Forty percent of children (4 out of 10) had mutations at the 816 locus, 10%
expressed the M541L mutation, 70% had mutations in the ECD, but 0% had the V560G mutation.
Thus, in our mastocytosis patient group, we have detected a higher percentage (14%) of patients
expressing the KITV560G mutation, which has been previouosly reported to be rare. Additionally, a
novel Q515H mutation at the ECD glucosamine linking site was identified in two children, and a
novel truncated KIT transcripts was found in two other children. One of the truncated KIT results
from a nonsense mutation at Q947, while another results from a deletion of exons 3 to 13. The
results of this study demonstrate the importance of full-length KIT DNA sequencing in the identifi-
cation of novel KIT mutations and transcript variants, which may provide additional information
into the pathophysiology and treatment of mastocytosis.
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Epigenetic regulation of malignant peripheral nerve sheath tumor development
AJ Patel, C Liu and LQ Le Dermatology, UT Southwestern Medical Center, Dallas, TX
Patients with Neurofibromatosis type I (NF1), a common tumor predisposition genetic disorder of
the nervous system, develop multiple malignancies, including the Malignant Peripheral Nerve Sheath
Tumors (MPNSTs). Previously, we showed that a population of neural crest-related stem/progenitor
cells residing in the dermis termed Skin-Derived Precursors (SKPs) as the cell of origin of NF1-asso-
ciated dermal neurofibromas and generated a novel mouse model for this complex tumor that
recapitulates the progressive nature of its human counterpart. We demonstrated that Nf1-deficient
SKPs can give rise to neurofibromas, and further loss of p53 robustly generates MPNSTs in vivo.
However, the tumorigenic potential of Nf1-/- p53-/- SKPs pales in comparison to the cells derived
from developed MPNSTs, suggesting loss of the tumor suppressors Nf1 and p53 is required but insuf-
ficient for MPNST development and pointing to the critical roles of further genetic and/or epige-
netic changes for MPNST development. Here we show that upon comparative transcriptome analy-
sis, we identified a profound upregulation of HMTases (histone methyltransferase) in MPNSTs. The
emerging role of HMTases in cancer development prompted us to determine their exact roles in
MPNST development. We found that inhibiting the levels of HMTase attenuates both MPNST pro-
liferation in vitro and tumorigenesis in vivo. However, we unexpectedly found that HMTase inhi-
bition accelerates malignant transformation of Nf1-/- p53-/- SKPs to MPNSTs in mice, suggesting
that HMTase regulates in vivo tumor suppression. These findings suggest a dual role for HMTases at
distinct stages of MPNST development. Our studies highlight the utility of novel mouse tumor mod-
els that allow dissection of gene function during tumor evolution. More importantly, while epige-
netic enzymes are promising therapeutic targets, our findings suggest preclinical evaluation of epi-
genetic therapies at earlier stages of cancer development as a means to personalize cancer therapy
based on the stage of cancer progression.
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Expression of microRNAs in Merkel cell carcinoma
MS Ning and T Andl Department of Medicine / Division of Dermatology, Vanderbilt University
Medical Center, Nashville, TN
Merkel cell carcinoma (MCC) is a primary neuroendocrine carcinoma of the skin. Although not as
prevalent as other skin cancers, MCC is more aggressive than melanoma and has a higher mortal-
ity rate, with reviews citing an overall five-year survival of sixty percent. Unfortunately, while the
incidence of MCC increases, our knowledge of these tumors remains limited. In an attempt to expand
our understanding, we focus our attention on microRNAs, small single-stranded RNA molecules
that participate in the negative regulation of gene expression. MicroRNAs have been implicated in
the pathogenesis of various skin cancers, including melanoma, squamous cell carcinoma (SCC),
and basal cell carcinoma (BCC). Through their unique role in posttranscriptional regulation, they
can function as important regulators of tumor growth and metastasis; however, the differential expres-
sion of microRNAs and their role in pathogenesis have yet to be explored in MCC. To identify microR-
NAs specific to MCC (MCC-miRs), high-throughput sequencing (HTS) of small RNA libraries was
performed on several tissue samples: MCC, melanoma, SCC, BCC, normal skin, and normal lymph
node. Comparison of the sequencing profiles identified several microRNAs upregulated (≥3-fold)
in MCC versus other tissues. To validate some of these candidates, their expression was measured
via qRT-PCR in a larger group of MCC samples (n=20) and in a comparison group (n=23) com-
posed of other cutaneous tumors (melanoma, SCC, BCC) and normal skin. Out of those evaluated,
five microRNAs were confirmed to be upregulated in MCC: miR-7 (11.3-fold), miR-9 (9.9-fold), miR-
340 (6.3-fold), miR-502-3p (4.7-fold), and miR-182 (3.3-fold). Several of these have been impli-
cated in the pathogenesis of other cancers and may play a role in the development, progression,
and metastasis of MCC. We present data regarding their functional significance, including poten-
tial target genes, derived from initial studies in the MCC13 cell line.
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Genetic background of mastocytosis, a synopsis of cooperative studies conducted by ECNM
B Nedoszytko,1 M Niedoszytko,2 M Lange,1 B Wasag,3 M Zablotna,1 J Glen,1 J van Doormaal,5
J Varkonyi,6 I Aladzsity,6 E Rausz,6 J Roszkiewicz,1 M Zmijewski,4 R Nowicki1 and P Valent7 1
Dermatology, Medical University of Gdansk, Gdansk, Poland, 2 Allergology, Medical
University of Gdansk, Gdansk, Poland, 3 Medical Genetics, Medical University of Gdansk,
Gdansk, Poland, 4 Histology, Medical University of Gdansk, Gdansk, Poland, 5 Allergology,
University Groningen, Groningen, Netherlands, 6 Internal Medicine, Semmelweis University,
Budapest, Hungary and 7 Internal Medicine, Medical University of Vienna, Vienna, Austria
Mastocytosis (MC)is a clonal disorder of the hematopoietic progenitor cells that give rise to mast
cells and other myeloid and lymphoid lineages and occurs in two general forms: cutaneous (CM)
and systemic (SM). The majority of adult and pediatric MC could be characterized by somatic
mutations of genes coding KIT or other receptors with kinase activity. In more aggressive form of
SM some specific mutations of oncogenes (JAK2V617F, AML1/ETO, BCR/ABL, FLT3) were found.
Our study involving 247 MC patients and 175 healthy individuals indicated that single nucleotide
polymorphisms (SNP) detected in genes coding cytokines (IL-13,TNF-α, IL-6, IL-10), their receptors
(IL-4R, IL-6R) and other proteins including: TLR-2,FcεRI – β, and TAP-1 were associated with devel-
opment of the disease. Progression of MC could be correlated with inherited SNPs in cytokine genes
(IL-13, TLR-2, IL-6, IL-10), activation of Btk/Lyn, N-RAS and inactivation TET-2 genes. Whole genome
expression profiles indicate in SM overexpression in blood and bone marrow of genes coding: α-
tryptase, carboxypeptidase A as well as regulators of transcription, proliferation, apoptosis, signal
transduction, protein transport and ubiquitin mediated proteolysis. SM patients with a history of IVA
showed additional alteration indicating more pronounced mast cells dysfunction in this group. Addi-
tional somatic mutations deregulating epigenetic mechanisms were found to be frequent in aggres-
sive SM. Finally, mi-RNA depending mechanisms involved in KIT-dependent mast cells activation,
MITF synthesis and may probably influence on tryptase production are newly described pathways
in MC.
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ΔNp63α drives mutagen-induced skin tumor initiation and progression to malignancy
M Devos,1,2 G Denecker,1,2 B Gilbert,1,2 K Leurs,1,2 K Lemeire,1,2 T Hochepied,1,2 J Haigh,1,2
G Berx,1,2 S Lippens,1,2 P Vandenabeele1,2 and W Declercq1,2 1 DMBR, VIB, Ghent, Belgium and
2 DMB, Ghent University, Ghent, Belgium
P63 is a transcription factor crucial for ectodermal development and the formation of stratifying
epithelia. Unlike its family member p53, the p63 gene is rarely mutated in human cancers, but it is
often overexpressed. Squamous Cell Carcinoma (SCC) is a common and treatment-refractory form
of human cancer in epithelial tissues were the p63 locus is frequently targeted for genomic ampli-
fication, leading to increased levels of the ΔNp63α isoform. To investigate the contribution of ΔNp63α
in the initiation, promotion and progression of SCC, we developed K5-Cre/LoxP-controlled ROSA26
promoter-driven ΔNp63α conditional transgenic mice. These mice develop epidermal hyperplasia
and hair abnormalities, eventually leading to alopecia. Interestingly, spontaneous benign tumors
occur in 25% of the transgenic mice. When subjected to two different models of chemical car-
cinogenesis (DMBA/TPA and DMBA/DMBA), we found that ΔNp63α transgenic mice were more
prone to the onset of tumor formation, and display more tumors compared to control mice and this
in a gene dosage-dependent manner. Moreover, progression to malignant carcinoma was only
observed in the ΔNp63α transgenic lines. In vitro experiments with primary keratinocytes derived
from wild-type and ΔNp63α transgenic mice demonstrate enhanced cell survival upon ΔNp63α
overexpression. No differences were observed in genotoxic stress-induced apoptosis, instead ΔNp63α
was able to block cellular senescence, marked by lower levels of p16Ink4a. In addition, ectopic
transgenic ΔNp63α expression was detected in the bile duct epithelium, leading to severe dilata-
tion of the intrahepatic bile ducts and cholangitis, leading to biliary cyst formation and the devel-
opment of cholangiocarcinoma (CC). Taken together, we generated a new mouse model for SCC
and CC and clearly show a causal relationship between p63 gene amplification and tumor devel-
opment.
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Analysis of pdgfrαmutations and survivin expression in merkel cell polyomavirus positive and
negative merkel cell carcinomas
M Batinica,1 P Zigrino,1 B Akgül,2 H Pfister2 and C Mauch1 1 Dermatology, University of
Cologne, Cologne, Germany and 2 Virology, University of Cologne, Cologne, Germany
Merkel Cell Carcinoma (MCC) is a rare neuroendocrine and highly aggressive cancer of the skin.
Little is known on MCC pathogenesis and oncogenesis, more recently a viral involvement has been
questioned. We have analyzed 63 MCC specimens for Merkel Cell Polyomavirus (MCPyV) positiv-
ity and load. Out of these, 68% of patients were MCPyV positive with viral load ranging from 0.006
to 943 virus DNA copies/beta globin. Viral DNA was found in patients with and without metasta-
tic disease, however patients with distant metastases presented higher loads. This data might indi-
cate a correlation between strong viral positivity and poorer disease outcome. Further, we have
investigated whether mutations in PDGFRα gene and expression of Survivin, previously shown to
be highly expressed in MCCs, might be the consequence of viral infection and correlate to disease
progression. More than one mutation was detected within PDGFRα exons 10, 12 and 18, whereas
at least one mutation in the PDGFRα gene was found in 35% of MCPyV positive and 60% of MCPyV
negative tumors. This suggests that the presence of mutations is not correlated with the viral posi-
tivity. PDGFRα protein expression was detected in all tumors and 11% of analyzed samples showed
low expression of this protein. Interestingly the majority of patients with metastatic disease showed
low PDGFRα expression. 73% of the patients displayed Survivin with a strong to moderate expres-
sion pattern. No correlation was found between Survivin expression and viral positivity. Yet, cellu-
lar localization may be correlated to disease progression being nuclear expression of Survivin a neg-
ative prognostic factor. In conclusion, our data indicate that strong viral positivity correlates with
poor disease outcome but not with mutations of the PDGFRα gene or with Survivin expression sug-
gesting that these three factors independently contribute to Merkel Cell Carcinoma development.
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In vivo role of TPL2 activation in squamous cell carcinoma, keratoacanthoma-type develop-
ment and progression
J Suh,1 J Lee,1 J Jung2 and J Jeong1 1 Dermatology, Medical College of Wisconsin, Milwaukee,
WI and 2 Microbiology, USC, Los Angeles, CA
Skin cancer is the most common cancer in the United States with more than 3.5 million new cases
diagnosed every year. Although basal cell carcinoma is more common, squamous cell carcinoma
(SCC) with an estimated 700,000 new annual cases result in far more fatalities. In fact, deaths
resulting from SCC are only surpassed by melanoma in terms of cancers arising in the skin. Squa-
mous cell carcinoma, keratoacanthoma-type (SCC, KA-type) resembles SCC, but it is unique can-
cer because of its rapid growth. Currently, we do not know how SCC, KA-type arises, but the occur-
rence of this type of SCC is clinically important since it is a known side effect of a recently-approved
drug (Vemurafenib) for advanced melanoma. Previously, our laboratory made a special mouse in
which a cancer-related gene (TPL2) was inserted into the mouse DNA to over-express the gene in
all mouse tissues. Surprisingly, these mice developed SCC, KA-type. These findings tell us that TPL2
over-expression may be one of causes underlying SCC development. Therefore, we seek to prove
that SCC development in these mice has clinical features similar to those in humans. If so, these
mice will be able to serve as a new mouse model system to study SCC in the future. Most impor-
tantly, we will be able to take advantage of this mouse model to test new anti-cancer drugs for the
treatment of SCC.
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Comprehensive analysis of the basal cell carcinoma functional methylome
T Brinkhuizen,1 S Denil,5 G Trooskens,5 W van Criekinge,5,6 V Winnepenninckx,3 K Mosterd,1
M van Engeland3,2 and M van Steensel1,4,2 1 Dermatology, ; Maastricht University Medical
Center, Maastricht, Netherlands, 2 GROW-School for Oncology and Developmental Biology,
; Maastricht University Medical Center, Maastricht, Netherlands, 3 Pathology, ; Maastricht
University Medical Center, Maastricht, Netherlands, 4 Clinical Genetics, ; Maastricht
University Medical Center, Maastricht, Netherlands, 5 Mathematical Modeling, Statistics and
Bioinformatics, Ghent University, Ghent, Belgium and 6 MDX-Health, Liege, Belgium
Introduction Basal cell carcinoma (BCC) is the most common malignancy. Its genetic basis BCC is
well defined. However, its epigenetics have not been fully charted and might reveal additional car-
cinogenic pathways. We used the latest tools for methylation and transcriptome analysis to obtain
a detailed map of the BCC functional methylome with a view to unraveling BCC tumorigenesis.
Methods DNA and total RNA were extracted from primary BCC and matched healthy control skin
samples. Methylated DNA was MBD2 isolated and used for library preparation. After rRNA deple-
tion, a cDNA library was generated from the total RNA. Both libraries were sequenced on an Illu-
mina Genome Analyzer II. Sequence assembly and bio-informatics analysis were performed with
open source tools and in-house developed algorithms. Results Our initial analysis indicates global
hypomethylation in BCC compared to healthy skin, previously reported for other malignancies.
Some genomic areas were significantly hypermethylated. Interestingly, sun-exposed skin did not
share the BCC methylation signature. The methylome and RNA-Seq data were matched to deter-
mine whether the observed methylation led to gene silencing (functional methylome). Of note,
Hedgehog signaling did not emerge as a primary target from our analysis. We targeted the path-
ways predicted to be active by our data in a translational trial and obtained a dramatic therapeutic
response. A thorough understanding of the BCC functional methylome leads to innovations in BCC
treatment. Our results warrant high-throughput analysis of BCC responses to known medical inter-
ventions in order to uncover their mechanisms of action.
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Expression microarray analysis identifies key processes in the transition from actinic kerato-
sis to cutaneous squamous cell carcinoma
SR Lambert,1 N Mladkova,1 A Gulati,1 R Hamoudi,2 KJ Purdie,1 R Cerio,1 IM Leigh,3 CM Proby3,1
and CA Harwood1 1 Centre for Cutaneous Research, Blizard Institute, Barts and the London
School of Medicine and Dentistry, Queen Mary University of London, London, United
Kingdom, 2 Research Department of Pathology, Cancer Institute, University College London,
London, United Kingdom and 3 Cancer Research UK Skin Tumour Laboratory, Medical
Research Institute, Ninewells Hospital & Medical School, University of Dundee, Dundee,
United Kingdom
Cutaneous squamous cell carcinoma (SCC) is one of the most common malignancies in fair skinned
populations worldwide and its incidence is increasing by at least 5% per annum in the UK. Despite
previous observations of multiple genetic abnormalities in SCC, the oncogenic process remains elu-
sive. The purpose of this study was to investigate the transcriptome of SCC and actinic keratoses
(AK), to elucidate key molecular events associated with the progression of precursor AK lesions to
invasive carcinoma. We have used laser capture microdissection combined with the Affymetrix
HGU133 Plus 2.0 microarrays to examine the transcriptome of 30 SCC and 10 AK. We have iden-
tified a core set of 196 genes that are differentially expressed between AK and SCC, and are enriched
in processes including epidermal differentiation, cell migration, cell cycle regulation and metabo-
lism. Gene set enrichment analysis highlighted a key role for the MAPK pathway in SCC progres-
sion from AK. Furthermore, the histological subtype of the SCC influenced the gene expression pro-
file, which may have implications for drug sensitivity and response in clinical trials. These data
indicate that progression to SCC is associated with a complex pattern of molecular changes. We
have identified relevant pathways involved in this process, in particular that the MAPK pathway may
be pivotal to the transition from AK and may represent a potential therapeutic target.
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Organ transplant recipients with Merkel cell carcinoma have reduced overall, disease-spe-
cific, and progression-free survival independent of stage at presentation
TN Canavan, ST Arron and SS Yu Dermatology, University of California, San Francisco, San
Francisco, CA
Background: Merkel cell carcinoma (MCC) is an aggressive cutaneous malignancy. Various forms
of immunosuppression have been associated with increased incidence of MCC and decreased MCC-
specific survival. We sought to identify whether solid organ transplant recipients (SOTR) with MCC
had decreased progression-free, disease-specific, and overall survival compared to immunocom-
petent (IC) MCC patients. Methods: This is a retrospective cohort study examining 103 cases of MCC
diagnosed between 1991 and 2012. Diagnosis and clinical data was collected from medical records.
Progression-free, disease-free, and overall survival were visualized with Kaplan-Meier methods. Cox
regression models were generated for the outcomes of progression, MCC-specific death, and death
from any cause, adjusted for patient sex, age at diagnosis, and stage at presentation. Results: 8 SOTR
and 95 IC MCC patients were followed for a median followup time of 24.2 months (range 1.5-152.4).
There were 31 deaths from all causes among the IC patients (33.0%) and 5 in the SOTR (62.5%).
Median time to death was 6 and 1.7 years in each group, respectively. SOTR had a 9-fold increased
hazard for all-cause death (95% confidence interval (CI) 2.7-30.5, p<0.0001) and an 8-fold increased
hazard for MCC-specific death (95% CI 1.9-32.7, p=0.004), when adjusted for sex, age, and stage
at presentation. SOTR also had a 4-fold increased hazard for progression (95% CI 1.5-10.3, p<0.0001).
SOTR had a significant reduction in 1-year overall survival compared to IC patients, 46.9% (95%
CI 12.0-76.3) vs. 86.9% (95% CI 77.5-92.5, logrank p=0.0018). 1-year MCC-specific survival was
similarly reduced in SOTR, 56.3% (95% CI 14.7-84.2) vs. 95.2% (95% CI 87.6-98.2, logrank
p=0.0001). Conclusions: SOTR have a significant reduction in overall survival, MCC-specific sur-
vival, and progression-free survival compared to IC patients with MCC, even when adjusted for stage
at presentation. More research is needed in order to improve MCC outcomes for SOTR.
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High frequency of PTEN mutations in pre-malignant and malignant pigmented lesions in xero-
derma pigmentosum 
T Masaki,1,3 Y Wang,1,5 JJ DiGiovanna,1 CR Lee,4 SG Khan,1 M Raffeld,4 TJ Hornyak,1 TN Darling2
and KH Kraemer1 1 Dermatololgy Branch, NCI, Bethesda, MD, 2 Dermatology, USUHS,
Bethesda, MD, 3 Dermatology, Kobe University, Kobe, Japan, 4 Pathology, NCI, Bethesda, MD
and 5 Dermatology, Peking University First Hospital, Peking, China
We examined the relationship between pre-malignant pigmented skin lesions and melanomas in
xeroderma pigmentosum (XP) patients who have defective DNA excision repair and 1000-fold
increase in melanomas. Unlike freckles, the XP lesions had a lentiginous appearance with markedly
increased numbers of melanocytes clinically and histologically. Using laser capture microdissec-
tion, we performed DNA sequencing on 18 pre-malignant pigmented lesions (benign and atypical
nevi) and 75 melanomas (melanomas in situ and invasive melanomas) from 10 XP patients. We
found a similar high frequency of PTEN mutations in nevi and in melanomas [61% (11/18) vs 53%
(39/73)]. Both had a very high proportion of UV type mutations (occurring at adjacent pyrimidines)
[91% (10/11) vs 92% (36/39)]. However, fewer of the PTEN mutations were missense in the XP
nevi than in the melanomas [33%(7/21) vs 66% (41/62) p<0.05]. Immunostaining of the lesions
using an antibody to phospho-S6 indicated activation of the mTOR pathway in the atypical nevi and
melanomas but not in the benign nevi. In contrast to melanomas in the general population, the fre-
quency of BRAF mutations (11%, 7/61), NRAS mutations (21% 13/62) and KIT mutations (21% 6/28)
in the XP patients was lower than for PTEN, and the BRAFV600E mutation hotspot was not detected.
Thus the clinical and histological appearances and the molecular pathology of XP nevi and
melanomas were different from nevi and melanomas in the general population. The increased fre-
quency of PTEN mutations and activation of the mTOR pathway in the XP patients may offer an
opportunity for melanoma control by use of PTEN/ mTOR pathway inhibitors.
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Soluble adenylyl cyclase alters cellular metabolism to reflect a cancer-like phenotype
M Park1,2 and J Zippin1 1 Dermatology, Weill Cornell Medical College, New York, NY and 2
Albert Einstein College of Medicine, New York, NY
Cancer cells have an altered metabolic state whereby they rely heavily on glycolysis even though
they are provided with adequate oxygen levels. This metabolic state is called the Warburg effect and
is essential for the growth of cancer. Soluble adenylyl cyclase (sAC) is a novel metabolic sensor that
influences many cellular functions, primarily cell growth and proliferation, through its generation
of cyclic AMP. Recent publications demonstrate the importance of sAC in hyperproliferative ker-
atinocyte skin diseases such as squamous cell carcinoma. Our lab is interested in studying the role
of sAC in cancer. sAC knockout (KO) cells are more easily transformed as compared to wild type
(WT) cells likely due to activation of Ras. We wanted to examine whether sAC also influenced the
ability of cells to respond to changes in nutrients as this might also influence cellular transforma-
tion. sAC KO and WT mouse embryonic fibroblast (MEF) cell lines were grown in different con-
centrations of glucose over one week and cell number was counted using a Beckman Coulter Counter.
At the highest concentrations of glucose, KO cells grew at a faster rate resulting in a 2-fold increase
in total cell number. Repeated measures ANOVA revealed a significant difference between KO and
WT cell growth (p = 0.0007). Below 3 mM glucose, KO cells grew more slowly than WT cells, and
over time cell death occurred. These results suggest that KO cells are more sensitive to glucose avail-
ability than WT cells. Incubation in 2-deoxyglucose led to a dose-dependent decrease in cellular
growth in both KO and WT cells with an identical IC50; however, KO cells had a greater extent of
inhibition (20% in WT cells and 75% in KO cells; p<0.0008). Increased sensitivity to glucose con-
centration and inhibitors of glycolysis is a hallmark of cancer cell metabolism and suggests that
sAC KO cells exhibit a metabolic state consistent with cancer. Better understanding of the role of
sAC in metabolic control may provide a more complete understanding of cancer development and
insight into novel drug targets.
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The covert stages of cancer immunoediting provide prevention targets
BJ Kubick and DR Roop University of Colorado Anschutz Medical Campus, Aurora, CO
The earliest events of multistage cancer development remain a mystery, especially regarding ele-
ments of the pre-cancer microenvironment. While a cell-intrinsic understanding has taken shape,
several intercellular interactions that precede clinical presentation remain largely uninvestigated.
In part, this is due to the difficulty of modeling and observing primary carcinogenesis. One process
that precedes the onset of malignancy is immunoediting, whereby effectors of the immune system
exert selective pressure on a burgeoning neoplasm. To emerge from this pruning process and pro-
ceed to malignancy, a clone(s) of cells must acquire immune-evasive characteristics. We hypothe-
size that this is a rate-limiting step in carcinogenesis and a barrier against cancer cell heterogene-
ity in most cancer types. The drastic increase in Squamous Cell Carcinoma (SCC) incidence among
immunosuppressed organ transplant recipients suggests that intact immune function can limit skin
malignancies. There have also been striking case reports detailing the transfer of malignant melanoma
from organ donors to recipients. While there was no clinical evidence of cancer in the donors, the
recipients experienced immediate outgrowth of melanomas from transplanted organs upon receiv-
ing immunosuppressant drugs. This suggests that the donor immune systems were able to restrict
the outgrowth of micrometastatic lesions. Since an understanding of these immunologically restricted
neoplasms may provide opportunities for cancer prevention, we have developed an in vivo model
of carcinogenesis that allows tracking of pre-malignant clones in immunocompetent microenvi-
ronments. Using inducible Cre-lox technology, we are able to activate common initiating muta-
tions of SCC in combination with fluorescent reporters. This enables us to trace the entire process
of carcinogenesis via whole animal imaging and intravital microscopy. More importantly, we are
able to isolate immune-controlled cells for further expression profiling, assessment of cellular hier-
archy, relative heterogeneity measurement, and screening for drug/small molecule sensitivity.
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Suppression of autophagy is associated with enhanced regression of skin tumors in mice
C Barresi,1 J Pammer,2 I Steiner,3 M Buchberger,1 H Rossiter,1 L Eckhart1 and E Tschachler1 1
Research Division of Biology and Pathobiology of the Skin, Department of Dermatology,
Medical University of Vienna, Vienna, Austria, 2 Institute of Clinical Pathology, Medical
University of Vienna, Vienna, Austria and 3 Center for Medical Statistics, Informatics, and
Intelligent Systems, Section for Medical Statistics, Medical University of Vienna, Vienna,
Austria
Autophagy has been implicated in the pathogenesis of cancer, but whether it acts as a repressor or
promoter of tumorigenesis in the skin has not yet been investigated. We have thus performed a mul-
tistage skin carcinogenesis study in mice deficient of epidermal expression of the essential autophagy-
related gene Atg7 (K14-Cre ATG7 F/F) and in control mice (ATG7 F/F). 7, 12-
dimethylbenz(a)anthracene was used as carcinogen and 12-O-tetradecanoylphorbol-13-acetate
(TPA) was applied as tumor promoter for 25 weeks. Skin papillomas arose with similar kinetics in
mice of both genotypes. However, papillomas in the K14-Cre ATG7 F/F mice were significantly
smaller than in ATG7 F/F mice (p=0, 05). Moreover, deficiency of keratinocyte autophagy was asso-
ciated with significantly higher incidence of tumor regression at all time points between week 12
and week 45. There was no difference in the rate of conversion from papillomas to carcinomas.
Histological analysis of tumors revealed that the suppression of epithelial autophagy led to a sub-
stantial accumulation of p62, a multifunctional protein involved in the control of protein turnover
and pro-inflammatory signaling. Together, these data suggest that autophagy does not protect from
tumor formation but rather supports the survival of established tumors in the epidermis.
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Gene expression profiling demonstrates that the effects of PTCH1 suppression are not fully
reversed upon pharmacological inhibition of SMOOTHENED in human keratinocytes
M Rahman,1 J Selway,2 D Herath,1 A Hazan,1 A Roy,2 K Langlands,2 S Edmunds,1 D Kelsell,1
C Harwood,1 MP Philpott1 and GW Neill1 1 Centre for Cutaneous Research, Queen Mary
University of London, London, United Kingdom and 2 Clore Laboratory, University of
Buckingham, Buckingham, United Kingdom
BCC is predominantly associated with mutational inactivation of the PTCH1 gene product result-
ing in hyper-activation of the HEDGEHOG developmental pathway. Tumour formation is linked to
induction of the GLI (GLI1 and GLI2) transcription factors via a pathway that is thought to require
the transmembrane protein SMOOTHENED (SMO); accordingly, SMO is attracting much interest
as a therapeutic drug target. Although there has been a certain degree of success in treating BCC
with anti-SMO compounds, many tumours are only partially or unresponsive indicating that SMO-
independent mechanisms may contribute to tumour viability. To further understand how reduced
PTCH1 function contributes to BCC, RNAi was employed to suppress PTCH1 in immortalised NEB-
1 human keratinocytes. Compared to control NEB1-shCON cells, NEB1-shPTCH1 cells displayed
more compact colony formation and increased GLI1 (but not GLI2) expression; however, whereas
GLI1 was suppressed by the SMO antagonists KAAD-Cyclopamine and SANT-1 in NEB1-shCON
cells, its increased expression was maintained in NEB1-shPTCH1 cells. Indeed, cDNA microarray
profiling revealed that over 80% of transcripts that were differentially expressed in NEB1-shPTCH1
cells (>2-fold, p<0.01) remained differentially expressed in the presence of KAAD-CYC and included
CXCL10 and CXCL11 which have recently been shown to be expressed at high levels in BCC.
These data indicate that many of the effects of PTCH1 loss are SMO-independent (or they are unre-
sponsive to anti-SMO drugs) in cultured human keratinocytes and, therefore, the mechanism(s) lead-
ing to BCC formation may be more complex than current dogma purports.
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Romidepsin, but not Pralatrexate, alters expression of a genetic signature in CTCL
BO Dulmage, LD Falo and LJ Geskin Dermatology, University of Pittsburgh, Pittsburgh, PA
Romidepsin, a histone deacetylase (HDAC) inhibitor, was recently FDA-approved in the US for the
treatment of CTCL. HDACs exhibit increased activity in cancer; they both catalyze the removal of
acetyl groups from histone lysine residues and deacetylate transcription factors, together produc-
ing a modulation of gene expression. HDAC inhibitors thus work to correct altered gene expres-
sion. The specific mechanism by which romidepsin changes gene expression in CTCL has not been
characterized. To determine the effects of romidepsin on gene expression in CTCL, we isolated
peripheral blood mononuclear cells from six Sézary syndrome (SS) patients. PBMCs were cultured
overnight, and romidepsin was added at three concentrations. Pralatrexate, a folate analog meta-
bolic inhibitor that competitively inhibits dihydrofolate reductase and halts DNA synthesis by deplet-
ing thymidine was used as a control for drug-specific alteration of gene expression. Cells were har-
vested at 24 and 48 hours following treatment. RNA was isolated, and qRT-PCR was performed on
a set of genes identified by our group and others as dysregulated in CTCL. RNA isolated from healthy
controls was used as a negative control. To ensure that the observed changes in gene expression
were attributable to changes within malignant cells and not the result of decrease in cell numbers
due to death during culture with the drugs, we performed flow cytometry on selected samples to
confirm that the proportion of live malignant cells in the cultures was constant. Romidepsin induced
significant gene expression alterations of many genes, including but not limited to PLS3, TOX, and
RUNX3. Many of these changes resulted in normalization of gene expression. PLS3 expression,
which can be greater than 1000 times normal in SS was decreased by over 80%. Pralatrexate, how-
ever, did not induce changes in expression of these genes. This work provides new insight into the
mechanism of action of romidepsin. The observed changes in selected genes may be considered in
the future studies for validation as markers predictive of response to romidepsin.
S68 Journal of Investigative Dermatology (2013), Volume 133
IID13_Abstracts-5  3/25/13  3:00 PM  Page S68
Carcinogenesis and Cancer Genetics | ABSTRACTS
404
K-homology (KH)-type splicing regulatory protein (KSRP) protects against inflammation-medi-
ated cutaneous carcinogenesis by destabilization of inflammatory mediators
I Ahmad,1 KM Muneer,1 C Chou,2 C Chen2 and N Yusuf1 1 Dermatology, University of Alabama
at Birmingham, Birmingham, AL and 2 Biochemistry and Molecular Genetics, University of
Alabama at Birmingham, Birmingham, AL
Progressive research has enlightened the association of inflammation and the development of can-
cer. K-homology (KH)-type splicing regulatory protein (KSRP) plays an important role in the control
of inflammatory gene expression by modifying the post-transcriptional mechanisms. KSRP triggers
rapid degradation of mRNAs for various cytokines, chemokines, and other inflammation-related
proteins by interacting with adenylate-uridylate rich element elements (AREs) in their 3′-untrans-
lated regions. To determine the role of KSRP with respect to inflammation mediated tumor devel-
opment, KSRP knockout (KSRP-/-) and wild type (WT) mice were subjected to a standard two-stage
7,12-dimethylbenz[a]anthracene (DMBA) and 12-O-tetradecanoylphorbol-13-acetate (TPA) model,
for initiation and promotion respectively, in which inflammation plays a central role. The percent-
age of mice with tumors was much greater (p<0.05) in KSRP-/- mice than in WT mice. Similar results
were obtained when the data were evaluated as the cumulative number of tumors per group. A sig-
nificantly high (p<0.05) rate of conversion from benign papillomas to malignant carcinomas in KSRP-
/- mice was observed compared to the WT mice. Absence of KSRP caused significant up-regulation
(p<0.05) of pro-inflammatory cytokines like IL-1β, IL-6, and TNF-α in KSRP-/- mice compared to
WT mice. Moreover, inflammation induced skin hyperplasia and pro-inflammatory mediators such
as, COX-2 and iNOS were substantially upregulated (p<0.05) in KSRP-/- mice compared to WT
mice. These results demonstrate that KSRP has a vital role in regulation of inflammation. Thus, com-
pounds that can enhance the ability of KSRP to bind to inflammatory mRNAs can be screened and
used to develop therapeutic strategies for inflammation-mediated carcinogenesis.
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Screening for cellular binding partners of the Merkel cell polyomavirus-small t antigen by
yeast two-hybrid system
HP Nguyen, A Agranayak, PL Rady and SK Tyring Dermatology, University of Texas at Houston
Medical School, Houston, TX
The purpose of this study was to investigate the role of the Merkel Cell Polyomavirus (MCpyV)
Small t antigen (St) in Merkel Cell Carcinoma (MCC) through the determination of its cellular bind-
ing partners using the yeast two-hybrid system. MCpyV, which was recently identified as an infec-
tious etiology of MCC, expresses two “early” proteins: the large T (LT) and St antigens. The LT anti-
gen is truncated in MCC, resulting in loss of its helicase activity and putative inactivation of its p53
tumor suppressor binding capacity, suggesting the St antigen has a more significant role in car-
cinogenesis. To characterize the role of the St antigen, yeast two-hybrid technology was employed
using full-length MCPyV St antigen as “bait”, which was then introduced to Universal Human and
Bone Marrow libraries. The quantitative α-Gal Assay was utilized to determine differences in the
relative strength of binding between mutant forms of interacting proteins. The screening experiments
using a Universal Human Normalized library revealed six human proteins as binding partners of
MCPyV St antigen. Four clones showed cereblon (CRBN) sequences suggesting that CRBN is a pri-
mary binding partner for MCPyV St antigen in our experiments. Co-transformation experiment in
Y2H Gold yeast cells and the α-Gal assay confirmed the CRBN-St interaction. CRBN may act as a
DDB2 competitor component of E3 protein ligase complex and may have a putative role of response
to ultraviolet exposure and for subsequent DNA repair. Additionally, the human bone marrow library
revealed further notable protein-protein interactions with the St, including PP2A and β-Hemoglo-
bin. The findings of these experiments are currently being confirmed through co-immunoprecipi-
tation and pull-down assays. We expect that the results will identify human proteins affected by St,
which will aid in the design of new therapies that can be used to combat the highly malignant
MCC.
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Fc gamma receptor II (CD32) as novel regulator of keratinocyte proliferation and differenti-
ation
SN Freiberger, PJ Dziunycz, G Iotzova-Weiss, LE French and GF Hofbauer Department of
Dermatology, University Hospital Zurich, Zurich, Switzerland
During the process of maturation there are critical steps that have to be strictly regulated. Two of
them are cell proliferation and differentiation. Alterations or defects in these steps of keratinocyte
maturation cause increased proliferation and impaired differentiation leading to cancer develop-
ment including cutaneous squamous cell carcinoma (SCC). We showed previously, that the Fc
gamma receptor II (CD32) that is commonly known to be expressed on immune cells is also pres-
ent on keratinocytes. We found all CD32 isoforms (A, B and C) expressed on primary human ker-
atinocytes as well as on the immortalized keratinocyte cell line HaCaT and the cutaneous squa-
mous cell carcinoma cell line SCC13. All isoforms were higher expressed on cancer cells than on
keratinocytes. Additionally we found a correlation of CD32 expression and differentiation of pri-
mary human keratinocytes. Blocking of CD32 by a specific antibody leads to an increase of ker-
atinocyte proliferation while the proliferation of SCC13 cells is not altered. New data provide fur-
ther evidence that CD32 plays a role in proliferation and differentiation of keratinocytes. We
overexpressed CD32 in SCC13 cells and saw decreased proliferation in these cells. Preliminary data
show the same also for primary keratinocytes. Since human IgG is the natural ligand of CD32 we
challenged primary keratinocytes and SCC13 cells with doses from 1 ng/ml to 1 ug/ml of human
IgG. While SCC13 cell did not show any reaction primary keratinocytes showed an increased pro-
liferation at the highest treatment concentration. To address the involved signaling pathways we
treated primary human keratinocytes with CD32 blocking antibody and looked for phospho-ERK
activation. After 15 minutes we were able to detect activation of ERK. These data provide evidence
that CD32 plays a role in the regulation of proliferation and differentiation of keratinocytes via ERK
signaling.
407
A comparative study of Langerhans Cell Histiocytosis (LCH) and non-melanoma skin cancer
transcriptional profiles
P Harikumar, J Selway, A Chu and K Langlands Clore Laboratory, University of Buckingham,
Buckingham, United Kingdom
LCH is a rare and potentially fatal disorder of unknown aetiology, although recent reports of fre-
quent BRAFV600E mutations are consistent with neoplasia. We hypothesized that comparison of
LCH gene expression profiles with basal and squamous cell carcinoma (BCC and SCC) might reveal
common processes in cutaneous tumourigenesis, or identify biomarkers of clinical relevance. We
profiled gene expression in biopsies of cutaneous LCH and normal epidermal LCs, whereas SCC
and BCC data were retrieved from the Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo; BCC
GSE6520 and SCC GSE2503). A combination of open access and proprietary software, including
MetaCore (www.genego.com/metacore.php), were used to identify transcripts discriminating dis-
ease and normal compartments for each dataset (fold change thresholds >1.5, p<0.05), followed
by analysis between disease datasets. 772 genes were shared between LCH and SCC, 407 between
LCH and morphoeic BCC, and 93 were common to all datasets. Enrichment analysis revealed sig-
nificant common pathways, including oxidative phosphorylation (LCH v SCC: p=4.3x10-8; LCH v
BCC: p=1.1x10-8) and MAPK-associated RAN regulation pathway (LCH v SCC: 1.6x10-5; LCH v
BCC: p=2.8x10-3). We also observed an overall alteration in ECM remodelling, although constituent
transcripts varied across disorders. For example, MMP1 expression increased 13 fold in LCH and
74 fold in SCC, but decreased 9 fold in BCC. SPARC expression was up 3 fold in LCH and 20 fold
in BCC, with no change in SCC. IL8 expression decreased 11 fold in LCH but increased 51 fold in
SCC, with no change in BCC. Histological evaluation of ECM organisation confirmed active colla-
gen and elastic fibre remodelling in the microenvironment of all diseases studied. As the oncogenic
BRAFV600E mutation has been linked to suppression of oxidative phosphorylation and ECM remod-
elling in other disease states, we are currently investigating the relationship between ECM remod-
elling, mitochondrial dysregulation and BRAF mutation status in LCH.
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Laser cancer prevention: Is the ablative laser for rejuvenation preventive against ultraviolet-
induced skin cancer?
J Gye,1 J Yoo,1,2 J Kim,1 J Kim,1 B Park,1 M Kim1 and S Hong1 1 Department of Dermatology,
College of Medicine, Dankook University, Cheonan, Republic of Korea and 2 Department of
Dermatology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea
Non-melanoma skin cancers, one of the most commonly diagnosed cutaneous malignancies in
human, are mainly caused by prolonged ultraviolet(UV) exposure. However, there is no effective
prevention other than avoiding sun exposure. Recently, ablative fractional photothermolysis (FP)
laser treatment is actively being carried out for facial rejuvenation. We elucidated whether the occur-
rence of skin tumor caused by exposure to ultraviolet light can be decreased by with multi-sessions
of ablative FP with CO2 laser. Two groups of hairless mice were treated with either FP or nothing
at 3-weeks interval during the 20 weeks of UV exposure period, simultaneously exposed to 60
mJ/cm2 of UVB and 1.8 J/cm2 of UVA three times per week for first 20 weeks. The other group was
treated with only FP without UV exposure. In the following 10 weeks, mice were examined for
tumor development every 2 weeks without any treatments. At the 30-week, termination of the exper-
iment, representative tumors were taken to evaluate the type of tumor. In addition, we evaluated
the change of skin barrier function, thickness, elasticity at 12 week, 20week. At 30weeks, FL treated
group showed significantly lower average size and the number of tumors than UV exposed group.
Tumor occurred in FL treated group 2~3 weeks later than UV exposed group. There was no tumor
development in the FL-only treated group, and their skin looked more smooth, tightened. All mice
of UV exposed group developed skin tumor, but 64.3% mice of FL treated group developed skin
tumor. And UV exposed group showed significantly increased in trans-epidermal water loss, than
FL-treated group. In conclusion, Ablative FP can be effective for not only the rejuvenation but also
the prevention against skin tumors induced by UV.
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Three siblings with epidermodysplasia verruciformis caused by an aberrant splicing of the
TMC8 gene
B Burger,1 Z Yüksel,2 I Spoerri,1 J DeMesmaeker,1 W Kempf3 and PH Itin4,1 1 Department of
Biomedicine, University Hospital Basel, Basel, Switzerland, 2 Medical Genetics Department,
Eskisehir Osmangazi University, Eskisehir, Turkey, 3 Kempf and Pfaltz Histological Diagnostics,
Zurich, Switzerland and 4 Department of Dermatology, University Hospital Basel, Basel,
Switzerland
Epidermodysplasia verruciformis (EV) is a rare inherited skin disease. Patients with EV develop
cutaneous squamous skin cancer (SCC) under the influences of HPV infection and UV irradiation.
Majority of patients are carrier of homozygous or compound heterozygous mutations in the TMC6
or TMC8 gene. In consequence of these mutations patients with EV are susceptible to skin infec-
tions by particular types of human papilloma viruses (HPV) that are considered to be innocuous for
the general population. To date mutations of only 14 families with EV are described in the litera-
ture. We investigated a large family with at least three clinically affected children and identified a
novel splice site mutation in TMC8, which was homozygously present in all affected children but
heterozygously in both parents. Analysis of cDNA revealed an aberrant spliced product in all affected
children and both parents;the parents showed the wildtype spliced product additionally. In this
report we describe the first splice site mutation within TMC8 leading to EV in all homozygous car-
rier.
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Loss of collagen VII increases aggressive tumor behavior in Col7al hypomorphic mice
V Mittapalli, A Nyström, A Fritsch and L Bruckner-Tuderman Department of Dermatology,
University Medical Center, Freiburg, Germany
Recessive dystrophic epidermolysis bullosa (RDEB) is an inherited severe skin fragility disorder that
is caused by abnormalities or absence of collagen VII. This collagen is one of the major proteins
that stabilize the dermal-epidermal junction in the skin. Its lack is associated with trauma-induced
skin blistering and healing with scarring. Patients with RDEB often develop partial or total mitten
deformities of the hands and feet and are also at greater risk of developing squamous cell carcino-
mas (SCC), which are aggressive and often lethal. The molecular events leading to the development
of aggressive SCC tumors in RDEB remain elusive. In this study, we investigated the susceptibility
of Col7al hypomorphic mice (a mouse model for RDEB with only 10% of functional collagen VII)
to induced tumor formation by means of chemical carcinogenesis. Wildtype mice produced benign
papillomas, whereas Col7al hypomorphic mice developed aggressive, invading tumors within a 20-
week treatment period with DMBA and TPA. Immunofluorescence staining of the tumors revealed
the characteristic features associated with high risk tumors such as increased proliferation, elevated
epithelial to mesenchymal transition (EMT), high invasion of proliferating keratinocytes, and high
inflammatory infiltrates, in the hypomorphic mice, in contrast to the wildtype tumors. Our findings
uncovered a molecular mechanism involving TGFβ1 in aggressive behavior of tumors in hypomor-
phic Col7al mice. Absence of collagen VII increases TGFβ1 and TGFβ1, in turn, increases tissue
stiffness by increasing collagen I synthesis and myofibroblast maturation, and thereby activating the
FAK-AKT-MMP9 pathway leading to highly invading, aggressive carcinomas. Moreover, our results
also suggest that targeting TGFβ signaling may have therapeutic potential and reduce the risk of
RDEB-associated aggressive squamous cell carcinomas.
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Distinct mechanisms mediate cellular proliferation by p63 and p73 in human skin squamous
cell carcinoma
T Mattiello, D Antonini and C Missero CEINGE, Center for Genetic Engineering, Napoli, Italy
Skin squamous cell carcinomas (SCCs) arise on sun-exposed areas and may behave aggressively,
rapidly invading the surrounding tissue and resulting in recurrence or metastasis. In this study we
investigated the role of the p53 family members p63 and p73 in early stages of SCC development
using two cell lines derived from facial SCCs carrying a mutant p53 allele. In head and neck SCC
(HNSCC) p63 has been shown to play a crucial role in promoting cell survival, as p63 depleted cells
undergo apoptosis in a p73-dependent manner. Here we show that in contrast to HNSCC, in skin
SCCs both p63 and p73 depletion induced cell cycle arrest without affecting cell survival, whereas
p53 depletion had no effect on cell proliferation. In SCCs the major p63 isoform is the DNp63alpha,
which has been reported to act primarily as a transcriptional repressor in the context of cancer
cells. Here we show that both DNp63alpha and p73 acted primarily as activators rather than repres-
sors in the context of cutaneous SCCs. Identification of differentially regulated genes in p63 or p73
depleted cells revealed that many early target genes were in common, however a significant frac-
tion was regulated specifically by either p63 or p73, while only very few genes were controlled in
the opposite fashion. Among this latter gene category, the cell cycle inhibitor CDKN1A was repressed
by p73, while it was modestly induced by p63. Consistently concomitant depletion of both p73
and p21 resulted in cell cycle progression, whereas p21 depletion was unable to rescue cell cycle
arrest in p63 depleted cells. p63 positively regulated several ERBB ligands by direct transcriptional
activation. Consistently treatment with ERBB ligands was able to rescue cell proliferation in p63
depleted cells, but not in the p73 depleted ones. These data provide the first evidence that p63 and
p73 play crucial and partially independent roles in sustaining cell proliferation during early stages
of skin tumorigenesis.
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Molecular analysis of primary cutaneous aggressive T-cell lymphomas
D Fanoni,1 CP Tensen,2 F Novara,3 L Venegoni,4 L Corti,1 S Alberti Violetti,1 F Onida,1,4 M Paulli,3
R Willemze2 and E Berti5,1 1 Fondazione IRCCS Ca’ Granda, Milan, Italy, 2 Leiden University
Medical Center, Leiden, Netherlands, 3 Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy, 4
Università degli Studi di Milano, Milan, Italy and 5 Università degli Studi di Milano Bicocca,
Milan, Italy
We explore genomic alterations possibly involved in tumorigenesis of aggressive primary cutaneous
T-cell lymphomas (CTCL). In particular we focused on 17 cases of CD8+ aggressive epidermotropic
cytotoxic T-cell lymphoma (AECTCL), 8 of peripheral T-cell lymphoma, not otherwise specified (PTL-
NOS) with CD4+ (4) or CD8+ (4) phenotype, as well as 4 cutaneous gamma-delta lymphoma (CGDL).
By array-based comparative genomic hybridization investigations, we found the presence of exten-
sive gains and losses of both large and small chromosomal regions; copy number gains were more
frequent than losses. We found some alterations present in all entities such as loss of 9p21.3 and
gains of 11q12.3-q13.2 and 17q21.31. Some aberrations seems to be more frequent in CD8+ lym-
phomas (both AECTCL and PTL-NOS-CD8+) (gains of 3p21.33-p21-2, 7q11.23, 7q21.2-q22.1,
8q24.3, 9q33.3-q34.2, 11pter, 17q25 and trisomy 19) while others were found only in CD4+ lym-
phomas (losses of 2p24.2-p21, 6q24.2-q27, 10p and 10q). Gains of 7q36.1-q36.3, 16p13.3 and
trisomy 22 as well as loss of 8p22 were found only in AECTCLs and should be related to epider-
motropism, while loss of 13q were observed only in PTL-NOS (both CD8+ and CD4+). In CGDL,
recurrent copy number alterations (observed in 50% to 75% of cases) were gain of 2q13-qter and
loss of 6q23.3. Loss of 9p21.3, harbouring CDKN2A and CDKN2B genes, and gain of 17q21.1
(STAT3 and STAT5) regions were imbalanced in all four entities studied and they may be involved
in aggressiveness of tumors and poor outcome. Trisomy of chr19 (JAK3) was shared by CD8+ lym-
phomas suggesting a possible role of JAK3/STATs pathway in the pathogenesis of these malignan-
cies. Although some genetic aberrations detected in our study have been described in tumoral
stage of mycosis fungoides, we suggest that the combination of aberrations appear characteristic in
these aggressive disorders.
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Mutant p53 in cutaneous squamous cell carcinoma
H Saundh,1 IM Leigh,1,2 AP South1 and MK Saville1 1 Division of Cancer Research, University
of Dundee, Dundee, United Kingdom and 2 Barts and the London School of Medicine,
University of London, London, United Kingdom
p53 mutation results in loss of its normal tumour suppressor activity and in some circumstances
can result in tumour-promoting gain of function. Upregulation of mutant p53 protein levels is thought
to be required for this gain of function activity. Mutant p53 accumulation is not simply due to
intrinsic properties of the mutants but also requires other cellular events. The mutation and accu-
mulation of p53 are early steps in cutaneous squamous cell carcinoma (cSCC) development. We
are investigating the potential of targeting mutant p53 for cSCC therapy. Low passage cSCC cell lines
were transfected with individual siRNA complementary to different sequences in p53 and the effect
on cell growth was assessed. Knockdown of mutant p53 inhibits the proliferation of SCCIC1 cells.
Reducing the level of mutant p53 may consequently be a therapeutic approach for cSCC. Mutant
p53 protein levels are high in cSCC cell lines compared with wild-type p53 in normal human ker-
atinocytes. To identify therapeutically tractable ways to reduce mutant p53 protein levels we are
investigating the mechanism(s) of mutant p53 accumulation in cSCC. We have verified that mutant
p53 accumulation in cSCC is due to a reduction in p53 protein degradation. The general deubiq-
uitinating enzyme (DUB) inhibitor PR-619 reduces the levels of p53 in cSCC cell lines. The pro-
teasome inhibitor bortezomib blocks the effect of PR-619 on mutant p53 expression. This is con-
sistent with an involvement of DUBs in the stabilisation of mutant p53 through protection against
proteasomal degradation. The role of individual DUBs in mutant p53 stabilisation in cSCC is cur-
rently being investigated.
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Immunohistochemical assessment of MRG-binding protein and polo-like kinase 1 over-expres-
sion in human cutaneous SCC
C Harkins, SA Watt, C Pourreyron, IM Leigh, CM Proby and AP South Division of Cancer
Research, University of Dundee, Dundee, United Kingdom
Cutaneous squamous cell carcinoma (cSCC) is the second most common cutaneous neoplasm affect-
ing Caucasian populations and can cause significant morbidity and mortality. We have recently
shown MRG-binding protein (MRGBP) and Polo-like Kinase 1 (PLK1) to be up-regulated in cSCC
compared with normal and psoriatic skin and that siRNA knockdown induces apoptosis in cSCC
keratinocytes with no effect on normal cells. The aim of this study was to assess the extent of pro-
tein expression of MRGBP and PLK1 in cSCC by immunohistochemistry using two anti-MRGBP anti-
bodies (raised against the N- and C-termini respectively) and a commercial anti-PLK1 antibody. A
total of 43 tumour samples with different histological grades were stained and compared with non-
UV exposed normal skin samples. PLK1 was detected in mitotic cells in both cSCC and normal skin
samples. MRGBP antibodies were validated previously with Western blotting and overexpression
constructs as well as siRNA. MRGBP is expressed in the nucleus of proliferative keratinocytes
localized in the basal layer of the normal epidermis and in the non-differentiated areas within cSCC.
Nuclear staining was also observed in fibroblasts and endothelial cells in both normal and tumour
samples. Both antibodies showed similar nuclear localization but the N-terminal anti-MRGBP anti-
body also readily bound within the cytoplasm of differentiated keratinocytes in normal skin and
regions of cSCC undergoing notable differentiation suggesting that MRGBP localizes to two distinct
cellular compartments. In conclusion we demonstrate that MRGBP and PLK1 are overexpressed in
cSCC compared with normal skin and that MRGBP localizes to the nucleus in dividing keratinocytes
and stromal cells as well as the cytoplasm of differentiating keratinocytes.
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Depletion of MRG-binding protein invokes TIP60 histone acetyltransferase-dependent apop-
tosis in cutaneous squamous cell carcinoma cells
SA Watt, K Arrand, IM Leigh and AP South Division of Cancer Research, University of Dundee,
Dundee, United Kingdom
Cutaneous squamous cell carcinoma (cSCC), the most frequent skin neoplasm with malignant poten-
tial, is responsible for 1 in 4 skin cancer related deaths. A targeted therapy for cSCC remains an
unmet clinical need. C20orf20, encoding the TIP60 histone acetyltransferase (HAT) complex mem-
ber MRG-binding protein (MRGBP), is overexpressed in cSCC versus normal keratinocytes and RNAi-
mediated depletion induces apoptosis in vitro and attenuates tumour growth in vivo. Normal ker-
atinocytes are unaffected. Lactate dehydrogenase release and caspase activation assays reveal a
profound induction of cell death following knockdown (up to 3-fold increase in cytotoxicity com-
pared to control siRNA, n=20) in a caspase 3/7 dependent manner (5-fold increase in caspase
activity, n=4). A RNAi screen of putative MRGBP interacting partners identified 6 proteins (4 TIP60
related, 2 unrelated) where knockdown invoked a similar response (TRRAP, DMAP1, EPC1, VPS72,
RSL1D1 and VAV2). However, depletion of the HAT catalytic subunit, TIP60, had little effect. Inter-
estingly, parallel knockdown of both MRGBP and TIP60 resulted in significantly attenuated cell
death compared to siMRGBP alone (151% ± 4.1 vs 227% ± 0.06 increase in cytotoxicity relative
to control siRNA, n= 7) indicating a TIP60-dependent mode of death. Finally, gene expression pro-
filing of siMRGBP cells revealed a 3.45-fold increase in expression of ACSL4, the gene responsible
for the synthesis of the precursor to acetyl-CoA, the sole source of acetyl group used by HATs.
Together these data suggest that a MRGBP-containing complex confers a pro-survival drive in cSCC
through regulation of TIP60. Our data show that RNAi depletion of MRGBP unleashes caspase-
dependent apoptosis through disruption of the MRGBP/TIP60 balance resulting in pro-death HAT
activity. Regulation of MRGBP and the TIP60 complex may therefore provide an effective strategy
for future cSCC-specific therapies.
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UISO cell line is not representative of Merkel cell carcinoma tumors
K Daily,1 A Coxon,1 JS Williams,1 C Lee,1 DG Coit,2 KJ Busam2 and I Brownell1,2 1 National
Cancer Institute, NIH, Bethesda, MD and 2 Memorial Sloan-Kettering, New York, NY
When using a cell line to study cancer, phenotypic similarity to the original tumor is paramount.
Multiple cell lines have been used to study the cutaneous neuroendocrine tumor Merkel cell car-
cinoma (MCC), but little has been done to characterize how closely they model native MCC tumors.
The cell line UISO has been used extensively in the research of MCC since it was first character-
ized in 1993. To determine its similarity to MCC tumor samples, we characterized the UISO cell
line and two other commonly used MCC cell lines (Mkl-1 and WaGa) with gene expression microar-
rays. Using whole transcriptome gene expression signatures and a computational bioinformatic
approach, we identified significant differences between the UISO cell line and the two other MCC
cell lines. Furthermore, we identified significant differences between the UISO cell line and fresh
frozen MCC tumors, irrespective of the Merkel cell polyomavirus status in the tumors. In compari-
son, the Mkl-1 and WaGa cell lines more closely approximated the global transcriptome of MCC
tumors. Next, we characterized UISO cells grown as xenografts in immunocompromised mice. His-
tologically and immunophenotypically UISO tumors did not resemble typical MCC tissue. In con-
trast, WaGa xenograft tumors showed immunohistological features consistent with MCC. Spectral
karyotyping (SKY) and short tandem repeat (STR) analysis of the UISO cell line matched that of the
originally described UISO cells, ruling out contamination by another cancer cell line. Our results
indicate that the UISO cell line is not representative of MCC tumors, whereas the Mkl-1 and WaGa
cell lines more closely model MCC tumors.
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IQGAP1 and IQGAP3 are required for invasive epidermal tumorigenesis but are relatively
dispensable for normal epidermal homeostasis
C Monteleon, A McNeal and T Ridky Dermatology, University of Pennsylvania, Philadelphia,
PA
Proteins required for neoplastic transformation, but dispensable for normal tissue function are poten-
tial therapeutic targets. In this regard, the IQGAP family of ubiquitously-expressed molecular scaf-
folds may be ideal. IQGAPs are frequently highly expressed in tumors, and regulate a number of
cell processes related to receptor-ligand signaling, cytoskeletal-rearrangement, cell-cell communi-
cation, proliferation and invasion. Despite these critical functions, IQGAP1 knockout mice are devel-
opmentally normal, suggesting functional redundancy with other IQGAP proteins. IQGAP3 null
murine tissue has not yet been generated. We sought to understand the roles of IQGAP1/3 in
human epidermal maintenance and tumor progression through shRNA-mediated IQGAP 1/3 antag-
onism in primary human keratinocytes. Engineered IQGAPi human skin tissue was xenografted on
mice with and without concurrent oncogenic Ras signaling sufficient to drive invasive SCC in con-
trol grafts. Wild-type levels of both IQGAP1 and IQGAP3 were required for invasive tumor forma-
tion, indicating that in the cancer setting, they are not functionally redundant. In contrast, IQGAP3
was dispensable for normal epidermal function, highlighting a tumor-specific requirement. How-
ever, IQGAP1 and IQGAP3 are not completely functionally redundant in normal human epider-
mis, as high efficiency IQGAP1 knockdown alone caused profound proliferation arrest in ker-
atinocytes accompanied by hypophosphorylation of Rb. This result contradicts IQGAP1 dispensability
in the murine model, indicating that IQGAP requirements may differ between mouse and human.
The IQGAP1 effect was dose dependent, as partial knockdown of IQGAP1 in human keratinocytes
was well-tolerated both in vitro and in vivo. Importantly, this partial IQGAP1 knockdown tissue still
did not support tumor formation when challenged with active Ras. These findings demonstrate a
role for IQGAPs in epithelial tissue maintenance and tumor development, and identify IQGAP1 and
3 as potential therapeutic targets for human tumors.
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Combination of histone acetylation and dna demethylation is synergistic in ctcl treatment
S Rozati, P Cheng, A Fettelschoss, MP Leveque and R Dummer Dermatology, University hospi-
tal of Zurich, Zurich, Switzerland
Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of malignancies derived from skin-
homing T cells. CTCL is a chronic and at times debilitating disease with many open questions regard-
ing its pathogenesis and treatment. The current moderate success of histone deacetylase inhibitors
(HDACi) in the clinical practice for CTCL treatment encourages the investigation of combinational
therapy in order to increase the response rate. To determine the effect of the combination treatment
with Romidepsin and Azacytidine compared to single agent or untreated cells, we performed MTT
assays for cell viability and Annexin V staining via flow cytometry for apoptosis. CTCL cell lines
(MyLa2973 and SeAx) were cultured in the presence/ or absence of Romidepsin 1.25nM and/ or
Azacytidine 2.5uM for 48hrs. The combination treatment showed an increase in apoptosis and necro-
sis in a time and dose dependent manner compared to single agent treated. Increase in cell cycle
regulators such as p15, p16, p21 as well as down-regulation of CDK4 in the combination treatment
suggests this combination treatment counteracts the loss of cell cycle control more efficiently in
CTCL. This combination triggers an increase in cleaved caspase 9 as well as cleaved caspases 3 and
7 and an increased in the cleavage of PARP1 compared to Romidepsin or Azacytidine single treat-
ment. Analysis of the Cancer Drug Target PCR array of the CTCL cell lines treated demonstrated a
significant re-expression of a GTP binding protein from the Rho protein family, RhoB, in the com-
bination treatment. We validated this data by PCR analysis and western blot of RhoB expression at
an RNA and protein level. Defective regulation of apoptosis has been considered as a main cause
for accumulation of clonal T cells and therefore we hypothesize based on our current results RhoB
might have an important role in the sensitization of the tumor cells to DNA damage and subse-
quent apoptosis. Furthermore, peripheral blood lymphocytes (PBLs) from Sezary Syndrome patients
were used to validate the results we attained in vitro.
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Targeting Merkel cell carcinoma dependence on Bcl-2 family members promotes efficient
cell death in vitro and in vivo
ME Verhaegen, JW Weick, TD Vozheiko, DM Mangelberger, JC Pero, TM Johnson, CK Bichakjian
and AA Dlugosz Dermatology, University of Michigan, Ann Arbor, MI
Merkel cell carcinoma (MCC), a rare but aggressive cutaneous neoplasm, has a poor prognosis at
late stages of disease with no proven chemotherapeutic regimens. Although the Merkel cell poly-
omavirus (MCPyV) is emerging as a potential key contributor to MCC tumorigenesis, signaling path-
ways modulating progression and survival have not yet clearly been defined. Here we provide both
genetic and pharmacological evidence that the anti-apoptotic Bcl-2 family members (Bcl-2, Bcl-xL
and Mcl-1) act as key survival factors that impart a point of vulnerability in MCC that can be exploited
for rational drug therapy. Based on immunoblot analysis of 19 tumors, most MCCs expressed high
levels of Bcl-2 and Bcl-xL(94% of tumors) and Mcl-1 (79% of tumors). In a panel of 12 novel MCC
cell lines we established for functional studies, 9 of which are tumorigenic in nude mice, expres-
sion patterns of the Bcl-2 family members mimicked those seen in human tumors. We inactivated
individual Bcl-2 family members by short hairpin-driven RNA interference which promoted MCC
cell line death, indicating a dependence on these proteins for survival. In parallel, we analyzed the
impact of targeted inhibition of Bcl-2/Bcl-xL by the small molecule ABT-263 (Navitoclax). A dose-
dependent decrease in cell proliferation was observed in 11 of 12 MCC lines treated with ABT-263.
Detailed analysis of four lines indicated that regardless of MCPyV status or Mcl-1 levels, ABT-263
induced p53-independent apoptosis (>83% death, 5μM ABT, 72h), characterized by rapid cleav-
age of caspase-3 and PARP. Furthermore, ABT-263 treatment of mice with established MCC xenografts
(>250mm3) led to a rapid and sustained halt in tumor growth (p<0.004), which was accompanied
by a dramatic increase in the number of apoptotic tumor cells. Our results indicate that the use of
Bcl-2 family antagonists may provide a valuable addition to MCC treatment regimens by reversing
an intrinsic resistance to cell death in these aggressive malignancies.
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Cyclosporine A polarizes T cells toward T22 and induces IL-22 receptor in human SCC cells
in vitro: A mechanism driving IL-22 induced SCC proliferation
VR Yanofsky,1 H Mitsui,2 CQ Wang,2 J Gonzalez,3 JG Krueger,2 D Felsen4 and JA Carucci1 1
Department of Dernatology, NYU Medical Center, New York, NY, 2 Lab for Investigative
Dermatology, Rockefeller, New York, NY, 3 Translational Immunology Resource Center,
Rockefeller, New York, NY and 4 Institute for Pediatric Urology, Rockefeller, New York, NY
Solid organ transplant recipients (OTR) often develop hundreds of SCC lesions prone to recurrence
and metastasis. Many OTR are immunosuppressed with Cyclosporine A (CsA). Previously, we showed
transplant-associated SCC (TSCC) contain a higher percentage of IL-22 producing CD8+ T cells rel-
ative to immune competent SCC (SID 2012, Abs. 615). Herein, we stimulated PBMC derived T cells
with or without CsA and determined T cell phenotype by intracellular cytokine staining. We also
studied the effect of CsA on IL-22 receptor (IL-22R) expression in the SCC cell line A-431 using RT-
PCR. Finally, we evaluated the role of IL-22 on SCC proliferation in vitro through Ki67 expression
and cell counts. We found that the number of CD4+ and CD8+ IL-22 producing cells remained con-
stant following incubation with CsA (100ng/mL, 24h), while the number of IFN-γ and IL-17 pro-
ducing cells was dramatically reduced. This resulted in an elevated proportion of T22 cells within
the total CD4+ (8.8% vs 26.4%) and CD8+ (5.8% vs 19.2%) T cell population (p<0.001). Addi-
tionally, CsA upregulated mRNA expression of both subunits of the IL-22R, IL-22RA1 and IL-10R2B,
in normal epidermal keratinocytes and A-431 cells. Further, IL-22 treatment of A-431 cells (100ng/mL,
48h, 0.1% FBS) significantly increased SCC cell proliferation, as reflected by Ki67 staining and an
8-fold increase in cell counts (p<0.001). CsA thus increased the percentage of T22 cells and induced
IL-22R expression on SCC cells, while IL-22 increased proliferation of SCC cells. CsA may there-
fore drive accelerated SCC growth in transplant patients via polarization toward T22 and induction
of IL-22R. Targeting the IL-22 axis may provide a novel means of TSCC therapy with a focused
attack on tumor proliferation without jeopardizing allograft survival.
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A mutational storm revealed by Exome sequencing: Dramatic increase of UV signature muta-
tions during development of skin cancer in Xeroderma pigmentosum patients
P Bauer,1 Y Kamenisch,2 M Sturm,1 C Schröder,1 C Bauer,1 M Röcken,2 O Riess1 and M Berneburg2
1 Genetics, Eberhard Karls University, Tübingen, Germany and 2 Dermatology, Eberhard Karls
University, Tübingen, Germany
Xeroderma pigmentosum (XP) is a rare autosomal recessive disease clinically characterized by
photosensitivity, xerosis cutis and a 1000-fold increased risk to develop skin cancer. Patients with
XP have defects in a DNA repair system, responsible for removal of bulky helix-distorting DNA dam-
age mainly induced by ultraviolet (UV) radiation. Unrepaired UV-induced DNA damage can give
rise to UV-signature mutations such as C to T and CC to TT transitions. This is the first study ana-
lyzing the complete exome of humans in this context. Here, we identified somatic mutations in
DNA from three patients, suffering from in Germany the most frequent XP complementation group
C. Skin samples of non-sun-exposed, sun-exposed and manifest skin tumors at UV-exposed body
sites were compared to the respective germline genomes derived from patient blood as well as
samples from individuals with normal DNA repair. Exome-sequencing was performed by next-gen-
eration sequencing with average exome coverage of >50 reads per base and >90% total target cov-
erage, covering 36Mbp and 30.000 genes. The mutations which were only present in sun exposed
or tumor tissue are called differential mutations. The load of differential mutations, especially UV
signature mutations, was dramatically increased only in XP patients and not in control groups of
elderly people. The highest level of differential mutations with approximately 8000 transitions was
observed only in XP tumor tissue and not in other tumors of non XP patients. Interestingly exces-
sive cancer risk in XP patients correlates well with excessive differential mutations in the XP tumors,
linking UV induced mutational load and skin cancer. Annotation analysis will reveal relevant path-
ways with UV signature mutations to carcinogenesis. These findings can help solving the questions
of the existence and magnitude of mutational threshold levels sufficient for cancer formation.
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RNAi depletion of PRSS21 in cutaneous squamous cell carcinoma keratinocytes induces maspin
dependent apoptosis
KS Robinson, SA Watt, IM Leigh and AP South Division of Cancer Research, University of
Dundee, Dundee, United Kingdom
Cutaneous Squamous Cell Carcinoma (cSCC) is the most frequent skin cancer with the propensity
to metastasise contributing to 1 in 4 skin cancer deaths in the UK. Currently there are no molecu-
lar targets clinically available for cSCC. Gene expression analysis identified Protease, Serine, 21
(PRSS21) to be overexpressed in cSCC in vivo (average fold change of 1.5 over three independent
data sets) compared with normal skin and in vitro (7.4 fold, p<0.0005, n=8). Overexpression of
PRSS21 was confirmed in a panel of cSCC cell lines (n=7) by qPCR, Western blotting and immuno-
fluorescence. PRSS21 is frequently overexpressed in other malignancies and has been shown to pro-
mote tumour progression and metastasis in breast and ovarian cancers. We show that PRSS21 is
essential for cSCC cell survival. RNAi knockdown of PRSS21 significantly decreases cSCC cell via-
bility (40%±5% vs. non-targeting control siRNA, P<0.005, n=3), as determined by MTS assay, through
increased cytotoxicity (20%±5.1% PRSS21 vs. non-targeting control siRNA, n=4) as measured by
LDH release. Normal primary keratinocytes are unaffected (n=3). Cell death is via apoptosis as
detected by a 2.3 (SD±0.4) fold increase in cytoplasmic nucleosomes a 25% (SD±5.2) increase in
Annexin V/7AAD positive cells (p<0.05, n=2) and a 1.9 fold increase in caspase activity (p<0.001,
n=3). PRSS21 has been shown to interact with the serine protease inhibitor maspin, a known tumour
suppressor. Using the Proximity Ligation Assay, PRSS21 interacts with maspin in cSCC cells. Addi-
tionally, we show that knockdown of PRSS21 resulted in a concurrent 60% increase in expression
of maspin and that increased caspase activity induced by PRSS21 depletion is dependent on maspin
(P<0.001, n=3). In conclusion, we show that PRSS21 negatively regulates maspin induced caspase
activity in cSCC cells and that maspin and PRSS21 are promising molecular targets in cSCC.
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Perifosine, an alkylphospholipid inhibitor of Akt1, a downstream target of the sonic hedge-
hog (Shh) pathway, suppresses growth of basal cell carcinomas (BCC) cells
AL Kim,1 Y Zhu,1 JH Back,1 N Yardley,1 M Athar2 and DR Bickers1 1 Dermatology, Columbia
University, New York, NY and 2 University of Alabama at Birmingham, Birmingham, AL
Targeted blockade of Shh pathway components like smoothened (SMO) suppresses the growth of
BCCs in patients with basal-cell nevus syndrome (BCNS); however tumors frequently recur follow-
ing cessation of treatment hence the need to find novel targets. One such target is Akt1 whose dys-
regulation drives the growth of sporadic and hereditary cancers in human populations. We have
shown that Akt1 activation is essential for the growth of BCCs and partial genetic ablation of Akt1
effectively abrogates the formation of BCCs in Ptch1+/-/SKH-1 mice, a murine model of BCNS. Here,
we compared the impact of Akt1 activation in primary Ptch1+/-/SKH-1 and Ptch1+/+/SKH-1 ker-
atinocytes, and the efficacy of targeted Akt1 inhibition on BCC growth. Ptch1+/- keratinocytes
resist UV-induced apoptosis whereas Ptch1+/+ keratinocytes do not. Akt1 phosphorylation at S473
in Ptch1+/- keratinocytes, blocked apoptosis and was accompanied by inhibitory phosphorylation
of pro-apoptotic Bad at S136, an Akt1 substrate. Overexpression of Akt1 (myr-Akt1) in UV-sensitive
Ptch1+/+ keratinocytes restored resistance to UV-induced apoptosis. Moreover, sequence analysis
of the Ptch1 gene from UV-resistant myr-Akt1-expressing Ptch1+/+ keratinocytes identified frequently
repeated mutations (e.g., Phe1315Leu and frame shift deletion 4148C), suggesting that Akt1 acti-
vation facilitates the survival of UV-irradiated mutant keratinocytes thereby providing a survival
advantage for cells harboring Ptch1 mutations. Screening of various PI3K and Akt inhibitors revealed
that perifosine, an alkylphospholipid targeted Akt inhibitor previously shown to be nontoxic and
well-tolerated in Phase I/II clinical trials for other human cancers, abrogated S473 Akt1 phospho-
rylation, cyclin D1 expression, and induced apoptosis in Ptch1+/-/SKH-1 keratinocytes and ASZ001
murine BCC cells. Targeting Akt1 may offer an alternative therapeutic approach for treating BCCs
in BCNS patients.
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Loss of p38δmitogen-activated protein kinase (MAPK) expression reveals a stage-specific reg-
ulation of skin inflammation and malignant progression in a two-stage chemical skin car-
cinogenesis model
A Kiss,1 AC Koppel,1 GE Kissling2 and T Efimova1 1 Medicine/Dermatology, Washington
University School of Medicine, St. Louis, MO and 2 Biostatistics Branch, National Institute of
Environmental Health Sciences, Research Triangle Park, NC
p38δ MAPK expression and/or activity are increased in human cutaneous malignancies including
invasive squamous cell carcinoma (SCC) and head and neck SCC, but the role of p38δ in cuta-
neous carcinogenesis has not been well-defined. We have previously reported that mice with germline
loss of p38δ exhibit a reduced susceptibility to skin tumor development compared with wild-type
mice in the two-stage 7,12-dimethylbenz(a)anthracene (DMBA)/12-O-tetradecanoylphorbol-13-
acetate (TPA) chemical skin carcinogenesis model. Additionally, we have reported that while ker-
atinocyte-specific p38δ loss impairs growth of tumors arising from v-rasHa-transformed keratinocytes
in skin orthografts to nude mice, conditional epidermal-specific p38δ gene targeting does not result
in significant changes in tumor latency, incidence or multiplicity during the promotion stage, reveal-
ing a context-dependent regulation of skin carcinogenesis in these two distinct experimental mod-
els of tumor induction in mouse skin. We now report that mice with keratinocyte-specific deletion
of p38δ show reduced overall tumor incidence during the progression stage of the DMBA/TPA reg-
imen, as well as reduced incidence of clinically defined invasive SCCs, indicating that keratinocyte
p38δ contributes to malignant conversion of DMBA/TPA-induced papillomas. Notably, skin of mice
with globally deleted p38δ exhibits enhanced inflammation in response to a short-term DMBA/TPA
regimen compared with skin of wild-type mice, as assessed by measuring expression of pro-inflam-
matory cytokines, including IL-1β, IL-6, IL-17, and TNFα, in vivo, underscoring a correlation between
increased inflammation during the initial phases of the DMBA/TPA treatment and the resistance to
DMBA/TPA-induced skin tumor development. Studies examining the molecular mechanisms under-
lying this regulation are underway.
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FRIZZLED7 and ERBB3 regulate distinct metastatic properties in melanoma
S Tiwary,1 M Preziosi,1 S Mohanti,1 B Martin,1 N Zeitouni2 and L Xu1 1 Biomedical genetics,
University of Rochester Medical Center, Rochester, NY and 2 Roswell Park Cancer Institute,
Buffalo, NY
Melanoma is a highly aggressive cancer. The low 5-year survival of late-stage melanoma patients
(~15%) treated with current methods calls for novel interventions. ~70% of melanomas express a
consitutively active form of BRAF (BRAF-CA); the remaining ~30% express wild type BRAF. Recently,
a BRAF-CA inhibitor, vemurafenib, has provided some initial benefits in patients, but resistance
quickly developed. Also, the drug was ineffective in melanomas expressing wild type BRAF, beg-
ging for alternative therapeutic strategies. Previously we showed that highly metastatic melanoma
cells differentially express a gene signature relative to low metastatic cells, which correlated with
poor patient survival. We analyzed two of these genes, FZD7 (WNT receptor) and ERBB3 (receptor
tyrosine kinase), in metastasis. The expression of both genes correlated with poor survival in melanoma
patients. We found that shRNA knockdown of FZD7 or ERBB3 reduced the metastatic potential of
multiple cell lines expressing BRAF-CA irrespective of their sensitivity for vemurafenib, providing
preclinical evidence for using FZD7 and ERBB3 as intervention points to treat both vemurafenib-
sensitive and -resistant melanomas. Further analyses indicated that, though both FZD7 and ERBB3
affected the number of lung metastases, only FZD7 knockdown affected the tumor initiating fre-
quency, and ERBB3 but not FZD7 was important for the seeding capacity of melanoma cell lines
in lung after injected into the tail vein of mice. These results suggested that ERBB3 and FZD7 reg-
ulate distinct metastatic steps. We are in the process of examining the signaling pathways mediated
by these factors. We hope our work will reveal the mechanisms by which distinct steps of metasta-
sis are regulated and provide the foundation for combinatorial therapies that more effectively treat
metastatic melanoma.
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Cutaneous squamous cell carcinoma carries the highest burden of mutation of any human
tumor type and harbors prevalent mutations in CARD11 and CREBBP
AP South,1 SA Watt,1 KJ Purdie,2 CM Proby,1 CA Harwood2 and IM Leigh1 1 Division of Cancer
Research, University of Dundee, Dundee, United Kingdom and 2 Centre For Cutaneous
Research, Barts and The London School of Medicine and Dentistry, London, United Kingdom
To assess genetic mutation in cutaneous squamous cell carcinoma (cSCC) we sequenced 20 tumors
with agilent 50Mb whole exome capture and illumina technology. We followed this by a focused
PCR amplicon based approach in a further 82 independent fresh frozen cSCC using Roche 454
pyrosequencing. In total we sequenced 102 micro-dissected fresh frozen cSCC of varying histo-
logical grade. Specialist sequencing and bioinformatics for the exome study were provided by the
EASIH - University of Cambridge supported by NIHR - Cambridge BRC. Our data show that muta-
tion (determined by variation present in tumor and absent in germ line DNA) across 20 cSCC exomes
ranged from 0.8 to 3.9 mutations per 30,000 base pairs with an overall average of 2.2. Such a
mutation burden is higher than any previously reported tumor type; an order of magnitude greater
than Ovarian Cancer (0.06), 9 times greater than Lung SCC (0.24) and 3.5 times greater than
Melanoma (0.62 average of 4 published studies). C > T transition base substitutions were by far the
most common change (>78%), consistent with UV damage. In addition to confirming known muta-
tion rates in TP53 (57%), NOTCH1 (59%), NOTCH2 (52%) and RAS (5%), we identify significant
missense mutation in CARD11 (38%) and CREBBP (35%). cSCC CREBBP variants were frequent
within the HAT domain but absent from the bromodomain, the large region reported to interact with
the nuclear factor TRERF1 and the Creb binding domain. Mutations were present in all domains of
CARD11, including the coiled-coiled domain where variants in Lymphoma are shown to increase
NF-kB activation. Here we show the cSCC variant P833L (within the SH3 domain) significantly
increases NF-kB activation in the absence of TNF-alpha stimulation compared with wild type, demon-
strating prevalent CARD11 mutation in cSCC potentially increases NF-kB activation.
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The Bmi-1 helix-turn and ring-finger domains are required for Bmi-1 antagonism of (-) epi-
gallocatechin-3-gallate suppression of skin cancer cell survival
S Balasubramanian, TM Scharadin, B Han, W Xu and RL Eckert Departments of Biochemistry
and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD
The Bmi-1 Polycomb Group (PcG) protein is an important epigenetic regulator of chromatin status.
Elevated Bmi-1 expression is observed in skin cancer cells and contributes to cancer cell survival.
(-)Epigallocatechin-3-gallate (EGCG), an important green tea-derived cancer prevention agent,
reduces Bmi-1 level resulting in reduced skin cancer cell survival. This is associated with increased
p21 and p27 expression, reduced cyclin (cyclin D1 and E), and cyclin dependent kinase (cdk2,
cdk4) expression, and increased cleavage of apoptotic markers. These EGCG-dependent changes
are attenuated by vector-mediated maintenance of Bmi-1 expression. In the present study, we iden-
tify Bmi-1 functional domains that are required for this response. We confirm that Bmi-1 expres-
sion reverses the EGCG-dependent reduction in SCC-13 cell survival but, in contrast, Bmi-1 mutants
lacking the helix-turn-helix-turn-helix-turn (Bmi-1ΔHT) or ring finger (Bmi-1ΔRF) domains do not
reverse the action of EGCG. Immunofluorescence studies confirm that the mutant and wild-type
Bmi-1 proteins are in the nucleus. We further show that these mutants act in a dominant-negative
manner to inhibit Bmi-1 function. Our results suggest that the HT and RF domains are required for
Bmi-1 activity and ability to maintain skin cancer cell survival upon challenge with stress agents.
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Bone marrow-derived epithelial cells as well as hair follicle bulge-derived cells contribute to
skin tumors and ulcer-associated dysplasia mediated by tumor promotion in the mouse
H Park,2,3,4 N Readio,1 G Jin,4 S Asfaha,4 A Singh,1 A Singh,1 X Yang,4 KS Patterson,4 CS Trempus,5
TC Wang4 and RJ Morris1,2,3 1 The Hormel Institute/University of Minnesota, Austin, MN, 2
Dermatology, Columbia University, New York, NY, 3 Pathology and Cell Biology, Columbia
University, New York, NY, 4 Medicine, Columbia University, New York, NY and 5 Matrix
Biology Group, NIEHS, Research Triangle Park, NC
A stem cell origin for tumors was postulated nearly 200 years ago; however, a critical role for ker-
atin-15 expressing hair follicle stem cells in skin tumorigenesis has only recently been established.
Here, we examined skin-homing, bone marrow-derived cells (BMDCs) in cutaneous papillomas
during chemically induced carcinogenesis (a single application of 200 nmol of 7, 12-dimethyl-
benz[a]anthracene and thrice weekly application of 17 nmol of 12-O-tetradecanoylphorbol-13-
acetate) following gender-mismatched allogeneic bone marrow transplantation in mice. First, we
detected proliferating green fluorescent protein labeled, keratin immunoreactive BMDCs in the basal
epithelium of papillomas in numbers approaching 25% of tumor area in 17 of 45 papillomas. Sec-
ond, an enhanced contribution of Y-chromosome positive bone marrow-derived epithelial cells
was observed in 26 of 49 ulcer-associated skin lesions in numbers approaching 35% of lesional
area. Third, keratin expression was induced in a subset of plastic adherent bone marrow cells fol-
lowing co-culture with primary keratinocytes and treatment with bone morphogenetic protein 5 in
the absence of cellular contact. These results demonstrate that BMDCs participated as an epithelial
cell source in chronically damaged skin lesions including papillomas and ulcers. We conclude that
BMDCs as well as bulge-derived cells contribute to the pathogenesis of skin tumors and associated
lesions induced by skin tumor promotion.
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Phospholipase C-beta 4 regulates proliferation and invasion in cutaneous SCC
EL Ruban,1 VL Martins,1 M Caley,1 C Raimondi,2 M Falasca2 and EA O’Toole1 1 Centre for
Cutaneous Research, Queen Mary University of London, London, United Kingdom and 2
Centre for Diabetes, Queen Mary University of London, London, United Kingdom
Phospholipase C beta 4 (PLC-β4) belongs to the phospholipase C family of enzymes, known to play
a central role in intracellular signalling pathways regulating cell growth, differentiation and migra-
tion through activation of protein kinase C (PKC) and intracellular calcium release. We found using
gene expression arrays that PLCB4 is highly expressed in SCC cells with knockdown of type VII col-
lagen, modelling recessive dystrophic epidermolysis bullosa (RDEB) known to be associated with
aggressive SCC. Our hypothesis is that PLC-beta4 may play a regulatory role in SCC tumourigene-
sis. Immunostaining of cutaneous SCC samples demonstrated nuclear staining of PLC-β4 in mod-
erately-differentiated tumours and RDEB SCC while well-differentiated (grade I) tumours exhibited
cytoplasmic localisation. Using RNAi technology, we achieved transient and lentiviral stable knock-
down (KD) of PLC-β4 (siPLC-β4 and shPLC-β4) in cutaneous SCC cell lines. SCC cells with KD of
PLC-β4 had decreased proliferation without altering differentiation or inducing apoptosis. KD 3D
cultures had decreased Ki-67 expression. A phospho-array demonstrated decreased phosphoryla-
tion of Stat3, confirmed by Western blotting. Live-imaging confocal microscopy demonstrated that
PLC-β4 KD cells had absent intracellular calcium-release following specific activation of the PLC-
β4 pathway. Moreover, various functional assays, including monolayer scratch, Transwell® and
organotypic 3D cultures, revealed significantly decreased cell migration and invasion in SCC cells
with KD of PLC-β4 with reduced cell adhesion. PLC-β4 KD cells had decreased β1 integrin expres-
sion, alterations in FAK activation and decreased Rho GTPase expression. These findings suggest
that PLC-β4 regulates SCC cell proliferation, migration and invasion through the Rho/integrin/FAK/Stat
signaling pathway and likely intracellular calcium regulation. The recent finding of mutations in
PLCB4 in melanoma suggests that this will be an attractive therapeutic target.
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EGFR/Ras-induced CCL20 production is a critical factor within the tumor microenviron-
ment
A Hippe,1 A Schoor,1 A Müller-Homey,1,2 A van Lierop,1 S Seeliger,3 A Pivarcsi,4 B Buhren,1
S Müller,1 A Gerber,1 JP Sleeman,5 NH Stoecklein,6 F Alves,7 TK Hoffmann,8 A Zlotnik9 and
B Homey1 1 Dermatology, University Hospital Düsseldorf, Düsseldorf, Germany, 2 Radiation
Oncology, University Hospital Düsseldorf, Düsseldorf, Germany, 3 Pediatric Cardiology and
Intensive Care, Georg-August-University Göttingen, Göttingen, Germany, 4 Center for
Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden, 5 Centre for
Biomedicine and Medical Technology, Medical Faculty Mannheim, Mannheim, Germany, 6
General-, Visceral- and Pediatric Surgery, University Hospital Düsseldorf, Düsseldorf,
Germany, 7 Hematology and Oncology, Georg-August-University Göttingen, Göttingen,
Germany, 8 Otorhinolaryngology, University Hospital Essen, Essen, Germany and 9
Physiology and Biophysics, University of California, Irvine, CA
The activation of the EGFR/Ras signaling pathway in tumor cells induces a distinct chemokine reper-
toire, which in turn modulates the tumor microenvironment. In particular, we show that tumors facil-
itate progression by the EGFR/Ras-induced production of CCL20. Enhanced expression of the
chemokine CCL20 in tumors correlates with advanced tumor stage (P<0.001) and increased lymph
node metastasis (P<0.05) in several types of cancer, and was associated with decreased survival in
breast cancer patients (P<0.05). Endothelial cells (EC) abundantly express the specific CCL20 recep-
tor CCR6. Activation of CCR6 signaling in EC induces directional migration and enhanced vessel
formation. In vivo, CCL20 promoted vascularization of Matrigel plugs in wild-type mice, but not in
CCR6-deficient mice. Furthermore, tumor growth and tumor-associated vascularization in CCR6-
deficient mice were decreased compared to wild-type mice. Experiments with bone marrow chimeras
indicates that the observed phenotype is dependent on CCR6 deficiency in stromal cells but not
within the immune system. Taken together, our findings underscore the importance of tumor-stroma
interactions and identify a novel chemokine-driven mechanism that critically modulates the tumor
environment and affects survival of cancer patients.
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mTOR, a potential molecular target for the chemoprevention of non-melanoma skin cancer
in organ transplant recipients
SC Chaudhary,1 SB Walsh,1 XW Tang,2 AL Kim,2 D Kurundkar,1 RK Srivastva,1 Z Weng,1
DR Bickers,2 CA Elmets,1 L Kopelovich3 and M Athar1 1 Dermatology, UAB, Birmingham, AL, 2
Columbia University, NY, NY and 3 NCI, Bethesda, MD
Non-melanoma skin cancers (NMSCs) are the most common neoplasm in organ transplant recipi-
ents (OTRs). Rapamycin, a specific mTOR inhibitor has been demonstrated to be an effective chemo-
preventive agent against a variety of cancers both in humans and in experimental animals. Here,
we show that both topically and parenterally administered rapamycin reduced UVB-induced p-
mTOR, cyclin D1and PCNA in SKH-1 hairless mice. Intraperitoneally administered rapamycin blocks
UVB-induced BCCs and SCCs by 60% and 76%, respectively in genetically engineered Ptch+/-
/SKH-1 hairless mice. A significant reduction both in number and size of tumors was noted. Topi-
cally administered rapamycin lead to regression of UVB-induced SCCs in SKH-1 mice. Rapamycin
reduced the expression of proliferation markers, PCNA and cyclin D1, other cell cycle regulatory
proteins and increased apoptosis both in Ptch+/-/SKH-1 and SKH-1 mice. As expected, an inhibi-
tion in mTOR signaling was common in tumors and tumor-adjacent skin of rapamycin-treated ani-
mals. Similarly, a dose-dependent reduction in tumor growth was noted in rapamycin-treated to
nu/nu mice carrying A431 xenograft tumors. To understand the mechanism of tumor growth in chron-
ically immuno-suppressed OTRs, mice carrying A431 xenograft tumors were treated with cyclosporine
(CsA) alone or in combination with rapamycin. CsA-augmented tumor growth was attenuated by
rapamycin. These tumors were less invasive and aggressive as compared to CsA-treated tumors a
response similar to that reported in OTRs receiving CsA+rapamycin. Decreased tumor invasiveness
was correlated with the reduced expression of mesenchymal markers and increased E-cadherin in
residual tumors in rapamycin-treated mice. The exact mechanism by which rapamycin blocks EMT
in CsA-treated tumors is unclear, but, reduced MAPK/Akt kinases in rapamycin-treated tumors appear
to be involved in this process.
433
Yin and Yang: IL-1β promotes, while IL-1α inhibits, lymphoma and melanoma tumor growth
in mice
T Tian, RC Fuhlbrigge and TS Kupper Dermatology, Brigham and Women’s Hospital, Boston,
MA
The roles of Interleukin 1α and 1β have long been controversial in tumor immunity. We showed
earlier that transgenic mice overexpressing IL-1α in the epidermis were completely resistant to chem-
ical carcinogenesis; however, the mechanism was elusive. In the present study, we used mice injected
with EL4 lymphoma and B16 melanoma tumor cells to further explore the roles of these ancient IL-
1 family members. To our surprise, mice deficient only in IL-1β had dramatically reduced growth
of both tumors. In contrast, mice deficient in IL-1α, or the IL-1R type I (through which both IL-1α
and IL-1β signal) showed normal (poor) tumor resistance. To explore this paradoxical finding in a
different fashion, we treated mice with an IL-1β blocking antibody; this treatment inhibited tumor
growth dramatically, while antibody depletion of IL-1α did not. This presented a unique puzzle,
since both IL-1α and β are thought to signal solely through the same (type I) IL-1 receptor. We next
fashioned bone marrow chimeras between IL-1β and wild type mice. Only the mice with wild type
bone marrow placed into IL-1β deficient recipients showed resistance to tumor growth—IL-1β defi-
cient bone marrow did not confer this protective effect. Depletion of both CD4 and CD8 T cells
demonstrated that the protective effect of IL-1β deficiency could be completely abrogated by T cell
depletion, indicating a T cell mediated immune mechanism mediating protection. Taken together,
these results indicate that the simultaneous absence of IL-1β and the presence of IL-1α creates a
tumor-resistant milieu that is strongly influenced by T cell immunity. This fascinating translational
observation requires further study, especially given the recent introduction of IL-1β blocking anti-
bodies as a therapeutic agent for both pediatric and adult inflammatory conditions.
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Topical rapamycin inhibits tumor formation in a murine model of cutaneous T-cell lym-
phoma
X Wu, J Garner, W Kittipongdaja, ST Hwang and SM Schieke Dermatology, Medical College of
Wisconsin, Milwaukee, WI
The mTOR signaling pathway is a central regulator of cellular proliferation, growth, and metabo-
lism which has been demonstrated to be important for tumor formation and growth. Herein, we
characterize the antitumor effect of topically applied rapamycin, an mTOR pathway inhibitor, in a
murine model of cutaneous T-cell lymphoma (CTCL). In our experimental model, MBL2 murine T
lymphoma cells were injected subcutaneously into ears of C57BL/6 mice followed immediately by
a single topical application of dinitrofluorobenzene (DNFB), a contact sensitizing agent, to the injec-
tion site. From day 6 on, rapamycin 0.1% in petrolatum base (n=8 mice) or petrolatum alone (n=6
mice) was applied daily. At day 14, the rapamycin-treated mice showed markedly decreased tumor
size as assessed by ear thickness compared to control animals (0.78 mm vs. 2.26 mm, p<0.05). H&E
staining of ear tissue revealed a striking decrease in tumor cells in rapamycin-treated ears. This anti-
tumor effect was correlated with decreased activation of mTOR signaling as assessed by an approx-
imately fourfold decrease in phosphorylation of p70S6K, S6, and Akt (Ser473) in Western blots
from ear tissues of treated animals. To characterize the effect of rapamycin on MBL-2 cells, in vitro
studies were performed. Incubation of MBL2 cells with rapamycin (5 nM) attenuated mTOR path-
way activity as determined by phosphorylation of downstream targets such as S6K, S6, and Akt
(Ser473) in Western blot assays. Furthermore, rapamycin also decreased the proliferation of MBL2
cells as well as human Hut78 CTCL cells. In summary, we were able to demonstrate for the first
time that topical rapamycin is sufficient to inhibit development of tumors in a murine model of
CTCL. Moreover, we demonstrate the anti-proliferative effects of rapamycin on murine and human
T lymphoma cells in vitro. Future clinical trials will characterize the clinical efficacy and therapeutic
potential of topically applied rapamycin in patients with early stage CTCL.
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Topical platelet activating factor receptor (PAF-R) agonist treatment suppresses PMA induced
inflammatory effects and cutaneous chemical carcinogenesis: Effects on inflammation requires
both the PAF-R and mast cells
R Konger,1,2 R Sahu,1 S DaSilva-Arnold,1,2 J Travers2 and S Rezania1 1 Pathology & Lab Medicine,
Indiana University, Indianapolis, IN and 2 Dermatology, Indiana University, Indianapolis, IN
Platelet activating factor (PAF) is a well known mediator of acute edema responses. We have pre-
viously reported that PAF-R knockout mice (Pafr-/- mice) exhibit an enhanced chronic inflamma-
tory response to repetitive PMA treatment. Pafr-/- mice also exhibited augmented chemical car-
cinogenesis that was not associated with DMBA-induced DNA damage responses or PMA-induced
epidermal hyperplasia. In this study, we examined the effects of topical CPAF on PMA-induced
inflammation. Given the known vasoactive effects of PAF, it was not surprising that topical CPAF (2,
6, and 20 nmole) induced a modest dose-dependent increase in ear thickness that peaked at 2 hrs
and resolved within 8 hrs. PMA induced both a rapid acute inflammatory reaction after initial
application, an augmented acute response to a second application, and a sustained chronic inflam-
matory phase with repeated treatments. Cotreatment of mouse ears with both PMA and 6 nmole
CPAF resulted in a significant reduction in both acute and chronic PMA-induced ear thickness
changes. The effects of topical CPAF were abolished in both Pafr-/- mice and Mast cell deficient
mice. In dorsal epidermis treated with both repeated PMA applications, co-administration of topi-
cal CPAF suppressed both PMA-induced skin thickness and myeloperoxidase activity. Given the
known association between PMA-induced inflammation and tumor promotion, as well as the
increased DMBA/PMA-induced tumorigenesis in Pafr-/- mice, it is notable that we also show that
topical CPAF suppresses DMBA/PMA-induced tumor formation by 37%. Our data indicate that
PAF has potent immunosuppressive effects on PMA-induced skin inflammation. Thus, PAF-R acti-
vation may play a more complex immunomodulatory role on cutaneous inflammatory responses
than previously appreciated. Moreover, these inflammatory effects appear to be mediated by der-
mal Mast cells.
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Genetic loss of Srcasm promotes oncogenic signaling and cell growth after UVB exposure
X Yang,1 K Tsukamoto,1,2 M Gober,1 C Marshall,1 L Wang,1 T Dentchev1 and J Seykora1 1
Dermatology, Perelman School of Medicine UPenn, Philadelphai, PA and 2 Rohto
Pharmaceutical, Kyoto, Japan
Cell growth is regulated through a coordination of oncogenic and anti-oncogenic signals. Tyrosine
kinases are primary drivers of cell growth and are negatively regulated by Srcasm through lysoso-
mal degradation in transgenic overexpression models. We hypothesized that genetic downregula-
tion of Srcasm by gene deletion or shRNA knockdown would promote oncogenic signaling and
cell growth. To test this hypothesis Srcasm null mice and Srcasm lentiviral knockdown in human
keratinocytes were generated and studied. Western blotting of epidermal lysates from Srcasm null
mice demonstrates that loss of Srcasm promotes activation of EGFR and Src kinases and decreases
levels of p53, NICD and p21. Activation of the canonical Erk1/2, STAT-3 and PDK-1 oncogenic path-
ways also was seen in Srcasm null lysates. The epidermis of Srcasm null mice exhibits a higher Ki-
67 index of 8.7 +/- 2.0 compared to 1.5 +/- 1.1 in controls (p<0.001). UVB irradiation (500 mJ/cm2
x 15 doses) produced precancerous lesions in Srcasm null mice but not in controls; the precancer-
ous lesions show an increased Ki-67 index and activation of Src kinases, STAT-3 and PDK-1. Acute
UVB (1200 mJ/cm2 x 1 dose) of Srcasm null mice induced prominent erythema, epidermal necro-
sis and a prominent increase in the TUNEL-positive index (14.0 vs 1.3). Srcasm knockdown in human
keratinocytes accelerated keratinocyte growth 130%; it also increased levels of EGFR and acceler-
ated the kinetics of EGFR and MAPK activation in response to EGF stimulation. In human ker-
atinocytes, Srcasm knockdown promoted cell growth after UVB exposure. These data show that
loss of Srcasm is associated with increased oncogenic signaling, impaired p53 function and ker-
atinocyte proliferation. Loss of Srcasm promotes keratinocyte proliferation post-UVB exposure and
promotes the early stages of UVB-induced cutaneous neoplasia.
437
Human basal cell carcinoma tumor-initiating cells are resistant to etoposide killing
CS Colmont,1 A BenKetha,1 R Errington,1 C Yee,2 MC Udey2 and GK Patel3 1 School of Medicine,
Cardiff University, Cardiff, United Kingdom, 2 Dermatology Branch, National Cancer Institute,
NIH, Bethesda, MD and 3 School of Biosciences, Cardiff University, Cardiff, United Kingdom
The creation of an in vivo orthotopic xenograft model for primary human basal cell carcinoma (BCC)
led to the recent identification of CD200+ BCC tumour-initiating cells (TICs) (Colmont et al., 2013).
The methodology used to reproducibly propagate BCC in vivo was similar to that for primary human
squamous cell carcinoma propagation, but in addition necessitated administration of intraperitoneal
etoposide to immunocompromised recipient mice 1 day prior to BCC grafting. We sought to deter-
mine if etoposide exerted selection bias by killing BCC cells or otherwise adversely affecting the
TIC frequency or expansion. Addition of 60 or 100μM etoposide to freshly-plated or established
BCC colonies in culture led to a DNA damage response, resulting in nuclear accumulation of H2AX,
stabilisation of p53, cell cycle arrest and DNA repair in viable cells - similar to that which occurred
with human osteosarcoma U2OS cells. At etoposide concentrations > 60μm, BCC colonies were
reduced in size by 5% but their numbers were unaffected. Because cancer cell resistance to etopo-
side can result from expression of transmembrane pumps, we assessed BCC tumors and cells for
these proteins. BCC tissue samples (n=6) expressed MDR1, MRP1, MRP3 and MRP4, whereas cul-
tured BCC cells (n=5) expressed only MDR1, in the presence and absence of etoposide. Although
MDR1 is not expressed by normal keratinocytes, we confirmed its expression by BCC cells by RT-
PCR and FACS analysis and verified activity using a rhodamine dye extrusion assay. MDR1 was
expressed by 2-3% of all BCC cells and ~50% of CD200+CD45- BCC cells. Both MDR1+ CD200+
CD45- and MDR1- CD200+ CD45- BCC subpopulations initiated tumors in vivo (n=3 BCC sam-
ples). In conclusion, BCC TIC’s are resistant to etoposide killing, perhaps because they express MDR
proteins. This is consistent with previous clinical observations and establishes the appropriateness
of etoposide use in this newly developed human skin cancer model.
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NKp46 specific expression on skin-resident CD4+ lymphocytes of mycosis fungoides (MF)
and Sézary syndrome (SS) 
P Schneider,1,2 L Verneuil,3 M Battistella,1,3 A Bensussan,2 M Bagot1,2 and A Janin1,3 1 hopital
Saint-Louis, paris, France, 2 inserm U976, paris, France and 3 inserm U728, paris, France
In SS, and MF, because the morphological features of malignant T cells are not specific enough for
an unequivocal detection of the tumoral cells, specific markers are required. Here, we report the
NKp46 expression on the malignant skin resident CD4+ T cells of CTCL. 15 CTCL (5 MF, 5 TMF, 5
SS) were included. Controls were 10 inflammatory skin diseases (5 eczema, 4 psoriasis, 1 drug erup-
tion), 5 primary cutaneous diffuse large B-cell lymphoma, leg type and 5 normal-skin. All patients
were treatment-naive before cutaneous biopsies. Immunohistochemistry were performed on for-
malin-fixed sections using monoclonal antibodies against human CD4, CD8, CD56 or CD30 as
primary antibodies. Molecular analyses were performed on frozen skin samples and on CD4+ laser-
microdissected cells. Conventional RT-PCR was made on frozen skin samples to value the NKp46
transcript. On the laser-microdissected cells, we used RT-PCR after a preamplification step to con-
trol the presence of CD4+ and the absence of CD8+ transcripts. Phenotypic analyses showed that
CD3+ CD4+ lymphocytes were prominent in dermal infiltrate of all CTCL. Molecular analyses
showed a significant over-expression of NKp46 in the 15 CTCLscompared to the ISD (p<0.05), CBCL
(p<0.05), or normal-skin (p<0.05). No significant difference was found between SS, MF and TMF.
Using quantitative RT-PCR on CD4+ laser-microdissected cells, NKp46 was detected in the 15 CTCL,
without significant difference across MF-TMF-SS. Moreover, NKp46 gene expression levels were
significantly higher in CD4+ laser-microdissected cells from CTCL than those from CBCL (p<0.05).
To note T-plastin mRNA was not expressed in CD4+ T-lymphocytes from SS, MF and TMF patients.
NKp46 expression on CD4+ circulating Sézary cells has been recently identified. Here we charac-
terized NKp46 expression on CD4+ resident skin cells and showed that this expression was not
restricted to SS, but also present in MF.
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Defining and targeting differentiation pathways in non-melanoma skin cancer
A BenKetah,1 SH Reed,1 PE Bowden1 and GK Patel2 1 School of Medicine, Cardiff University,
Cardiff, United Kingdom and 2 School of Biosciences, Cardiff University, Cardiff, United
Kingdom
Human cancer stem cells are proposed to play a critical role in tumor initiation and maintenance
by their exclusive ability to regenerate the tumor. Thus cancer stem cells share many of the proper-
ties of normal stem cell including self-renewal and ability to give rise to progeny which undergo
tissue-specific differentiation. The aim of this project is to determine whether both inward and upward
differentiation patterns observed in the normal tissue (hair follicle) are conserved in cancer (basal
cell carcinoma). To test this hypothesis we analyzed 6 different human BCC samples with normal
hair follicle tissue as controls for 20 different hair follicle specific differentiation keratins using RT-
PCR. For the 12 specific keratin genes expressed in the BCC, we analyzed expression by immuno-
fluorescence on 20 different BCC samples, using hair follicle samples as positive controls. Our
findings suggest that human BCC demonstrates both inward and upward differentiation patterns sim-
ilar to the hair follicle, with expression of: outer root sheath (K5,14,16,and k17), companion layer
(K75), inner root sheath (K26,27,28,71,72,and k74), and cuticle (K32,35,82,and k85); but not hair
shaft (K31) markers. We also observed the mutually exclusive relationship between expression of
the early differentiation marker K19 and cell proliferation in the hair follicle and BCC, in keeping
with the shared functional characteristics of these cells. Similarly, expression of the outer root sheath
keratins coincided with nuclear translocation of both Gli1 and NFIL-6 suggesting that regulation
was also similar. To further test the hypothesis that normal tissue factors observed in the hair folli-
cle regulated BCC differentiation we have developed an in vitro BCC assay. Using this tissue cul-
ture model we have tested the hypothesis that BCCs are “stuck” in a refractory telogen hair follicle
differentiation pattern, by inducing BCC differentiation.
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The expression of IL-1 family cytokines is perturbed in non-melanoma cancers of the skin
A Aphale, M Riblett, C Bichakjian, T Johnson, A Johnston and J Gudjonsson Department of
Dermatology, University of Michigan, Ann Arbor, MI
Non-melanoma skin cancers, including basal cell carcinoma (BCC) and squamous cell carcinoma
(SCC) are the most common malignancies of the skin. While keratinocyte damage is causal, alter-
ation of immune responses may contribute to their pathophysiology. The IL-1 family comprises 11
ligands and 9 receptors forming several distinct signaling systems; aberrancies in which are seen in
several diseases, including malignancies. The objective of this study was to delineate differences in
expression of IL-1 family members among SCC, BCC and normal skin (NN). SCC and BCC tissue
was obtained from Mohs surgery excisions and NN tissue from healthy patient donors. RNA and
protein expression was analyzed using microarray, quantitative real time PCR (QRT-PCR) and immuno-
histochemistry. Overall, SCCs showed greater changes in expression of IL-1 members than BCCs.
QRT-PCR data showed the pro-inflammatory genes IL1A and IL1B were up-regulated in SCCs ver-
sus NN 9.6-fold (p=0.001) and 10.5-fold (p=0.006) respectively whereas their receptor, IL1R1, was
down-regulated 2.4-fold (p=0.001) and their antagonist, IL1RN, was up-regulated 2.2-fold (p=0.03).
In contrast, BCCs had 4.2-fold down-regulation of IL1A (p=0.009) while there were no significant
differences in IL1B, IL1R1, or IL1RN expression. Of the members of the novel IL-36 family, IL36A
was unchanged, whereas IL36B and its antagonist IL36RN were up-regulated 8.8-fold (p=0.03) and
3.3-fold (p=0.0001) respectively in SCCs. These findings were not mirrored in BCCs as there were
no significant changes in the expression of IL-36 ligands or antagonists. Immunohistochemistry con-
firmed these findings. These data are consistent with prior observations that SCCs are more inflam-
matory in nature than BCCs, and demonstrate for the first time abnormalities in the IL-36 system in
these cutaneous malignancies.
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A miR-34a-SIRT6 axis in the squamous cell differentiation network
K Lefort,1,2 Y Brooks,3 P Ostano,4 M Cario-André,5 V Calpini,1 A Albinger-Hegyi,6
W Hoetzenecker1 and G Dotto1,3 1 Biochemistry, University of Lausanne, Epalinges,
Switzerland, 2 Medicine, CHUV, Lausanne, Switzerland, 3 Cutaneous Biology Research
Center, Massachusetts General Hospital, Charlestown, MA, 4 Laboratory of Cancer Genomics,
Fondazione Edo ed Elvo Tempia Valenta, Biella, Italy, 5 Inserm U876 and National Reference
Centre for Rare Skin Diseases, Bordeaux hospital, Bordeaux, France and 6 HNO Praxis, HNO
Zuerich Fraumünster, Zurich, Switzerland
Squamous Cell Carcinomas (SCCs) are highly heterogeneous tumours, resulting from deranged
expression of genes involved in squamous cell differentiation. Here we report that microRNA-34a
(miR-34a) functions as a novel node is the squamous cell differentiation network, with SIRT6 as
critical target. miR-34a expression increases with keratinocyte differentiation, while it is suppressed
in skin and oral SCCs, SCC cell lines, and aberrantly differentiating primary human keratinocytes
(HKCs). Expression of this miRNA is restored in SCC cells, in parallel with differentiation, by rever-
sion of genomic DNA methylation or wild-type p53 expression. In normal HKCs, the pro-differen-
tiation effects of increased p53 activity or UVB exposure are miR-34a-dependent, and increased
miR-34a levels are sufficient to induce differentiation of these cells both in vitro and in vivo. SIRT6,
a sirtuin family member not previously connected with miR-34a function, is a direct target of this
miRNA in HKCs, and SIRT6 down-modulation is sufficient to reproduce the miR-34a pro-differen-
tiation effects. The findings are of likely biological significance, as SIRT6 is oppositely expressed to
miR-34a in normal keratinocytes and keratinocyte-derived tumors.
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Defining the roles of p53, Myc, and Aurora kinase A in skin squamous cell carcinomas from
organ transplant recipients
EC Torchia,1 T Terzian,1 M Salazar,2 F Arbab3 and DR Roop1 1 Dermatology and Gates Center
for Regenerative Medicine and Stem Cell Biology, University of Colorado Anschutz Medical
Campus, Aurora, CO, 2 School of Medicine, University of Colorado Anschutz Medical
Campus, Aurora, CO and 3 Pathology, West Houston Medical Center, Houston, TX
Organ transplant recipients (OTRs) are highly susceptible to the development of skin Squamous Cell
Carcinomas (SCCs) that are likely to recur or metastasize. We have previously shown that skin spe-
cific expression of a gain-of-function mutant form of p53 in mice resulted in metastasis-prone SCCs
that display high levels of genomic instability as well as preferential gene amplification of Myc and
altered expression of Aurora Kinase A (Aurora-A) (Oncogene (2012) 31: 2680-90). To define how
these oncogenes contribute to the formation of high-risk SCCs in OTRs, we examined the staining
pattern of p53, Myc and Aurora-A in 53 SCCs resected from 22 OTR patients. Tumor grade was
assessed using the National Institute for Health diagnostic criterion (Grade I=well-differentiated to
IV=poorly differentiated). The mitotic index was ascertained in at least 10 high-powered fields from
Hematoxylin and Eosin stained sections. A cumulative score for immunoreactivity was determined
by multiplying the staining intensity by the percentage of positively stained cells in at least three
separate fields. Immunoreactivity for p53, Myc and Aurora-A was detected in all samples. The per-
centage of p53 positive cells in tumors ranged from 19% to 97% with a mean of 68.6% (95% CI=65.1,
72.0). p53 expression was significantly increased with tumor grade (p<0.0001). Mitotic index was
positively correlated with tumor grade (p<0.03) and with p53 expression (p<0.05). High-level expres-
sion of p53 is consistent with the expression of mutant forms of p53, not loss of p53. Our results
indicate that mutant p53 may contribute to the development of high-risk tumors in OTRs.
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Expression of epidermal growth factor receptor and detection of mutant EGFR (EGFRvIII) in
human cutaneous squamous cell carcinoma
PJ Dziunycz,1 Z Lazarova,2 N Duncan,2 S Wong,3 M Neuburg,2 GF Hofbauer1 and EB Olasz2 1
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland, 2 Department
of Dermatology, Medical College of Wisconsin, Milwaukee, WI and 3 Department of
Oncology, Medical College of Wisconsin, Milwaukee, WI
Epidermal growth factor receptor (EGFR) is overexpressed in large percentage of cutaneous squa-
mous cell carcinomas (SCC). Therapeutic trials using EGFR blockade to treat high-risk or metasta-
tic SCCs are ongoing. The most common form of mutant EGFR called EGFRvIII has been described
in several cancers. It has been shown that EGFRvIII contributes to enhanced growth of SCC and
resistance to EGFR inhibitor drugs. Our goal was to assess expression of wild type EGFR and EGFRvIII
in SCC and correlate it with tumor biology. SCC specimens from patients were collected consecu-
tively. Tumor specimens were embedded in paraffin and assessed for EGFR expression by immuno-
histochemistry while EGFRvIII expression was determined by RT-PCR. A representative SCC cell line
stably transfected with an EGFRvIII expression construct served as a positive control. Fifteen of the
tumors (20%) were collected from solid organ transplant patients. All tumors (100%) expressed
EGFR, with variation in intensity and proportion of labeled cells. EGFR expression, however, was
not correlated with tumor differentiation, anatomic location or transplant status. Surprisingly, none
of the tumors (0%) expressed EGFRvIII mRNA. To verify these results tissue microarray with 275 SCC
samples (138 received from solid organ transplant recipients) was stained for the EGFRvIII protein
expression. Similarly to the previous results, none of these tumors expressed the mutated form of
the receptor. The lack of mutant EGFRvIII expression may have implications on the design of future
clinical trials using EGFR inhibitors for treatment of high risk cutaneous SCC.
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Oncogene addiction distinguishes malignant from benign skin tumors caused by deregulated
Hedgehog signaling
M Grachtchouk, D Wilbert, J Pero, K Fiehler, J Crowley, A Photenhauer, AN Ermilov and
AA Dlugosz University of Michigan, Ann Arbor, MI
High-level oncogenic Hedgehog (Hh) signaling underlies the development of basal cell carcino-
mas (BCCs) whereas low-level signaling leads to the formation of benign basaloid follicular hamar-
tomas (BFHs). The great majority of BCC tumor cells are strictly dependent on Hh pathway activity
for growth and survival (“oncogene addicted”), based on studies performed in experimental ani-
mals and clinical data from patients treated with Hh pathway antagonists. To determine whether
benign tumors caused by low-level Hh signaling are similarly dependent on continued signaling,
we used a novel mouse model to reversibly activate expression of the Hh pathway oncogene SmoA1
in skin of adult mice using doxycycline (doxy). SmoA1-expressing mice developed slow-growing
BFHs composed of anastomosing cords and strands of bland-appearing epithelial cells, but lesions
resembling BCCs, either grossly or histologically, were never observed. Hamartomas expressed fol-
licle outer root sheath markers (K17, Sox9) and HA-tagged SmoA1 in nearly all epithelial cells, but
expression of Hh target genes (Gli1, Ptch1, Ptch2, Cyclin D1), proliferative activity (Ki67 immunos-
taining), and the hair matrix marker CDP were largely limited to cells at the tumor periphery. This
pattern differs strikingly from the diffuse expression of markers in BCCs arising in GLI2*-expressing
mice with high-level Hh signaling. Withdrawal of doxy led to rapid loss of SmoA1 expression and
reduced Ki67 immunostaining, but remarkably, most BFH tumor masses were still present after 7
weeks. Persistent hamartomas expressed the follicle marker K17 and to a lesser extent Sox9, but the
peripheral CDP-positive population of tumor cells was lost, suggesting that only those cells with
elevated Hh signaling regress upon SmoA1 inactivation. Our findings underscore the molecular and
biological differences between malignant BCC and benign BFH, and strongly suggest that tumors
with low-level oncogenic Hh signaling activity are not likely to be responsive to treatment with Hh
pathway antagonists.
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Lgr5+ stem cells give rise to Hedgehog pathway-driven gastric adenocarcinomas
LJ Syu, X Zhao, M Grachtchouk, A Ermilov, J Greenson, X Zheng, A Kaatz, J Pero, D Wilbert,
D Gumucio, L Samuelson, J Merchant and AA Dlugosz University of Michigan, Ann Arbor, MI
Deregulated Hedgehog (Hh) signaling drives basal cell carcinoma (BCC) development and has been
linked to several internal malignancies, including gastric adenocarcinoma, but studies testing a
causal role for Hh signaling in this malignancy have not been reported. In preliminary experiments,
mosaic expression of the activated Hh pathway transcription factor GLI2 (GLI2*) led to gastric ade-
nocarcinoma development. To investigate the potential cell of origin of these cancers we targeted
GLI2* expression to Lgr5+ stem cells in the gastric antrum of adult mice. Induction of GLI2* led to
the development of large antral tumors within 4-6 weeks. At 3 days post-induction, GLI2* was
detected in small groups of cells at the base of antral glands near the stem cell compartment, and
by day 14 these had expanded to fill the thickened antral mucosa. Tumors were frequently over one
cm in size, with occasional submucosal invasion. They consisted of an admixture of disorganized
glands comprising GLI2*+ cells which expressed canonical Hh target genes (Gli1,Ptch1), hyper-
plastic gastric epithelium, an inflammatory infiltrate, and an increased number of SMA+ myofi-
broblasts. Expression of proliferation markers was markedly increased, and pSTAT3, which has been
strongly implicated in gastric adenocarcinoma development in humans and other mouse models,
was highly expressed in epithelial and stromal cell populations. GLI2*-expressing mice also devel-
oped BCCs, as previously reported, but epithelial tumors were strikingly absent in intestine, despite
GLI2* expression in Lgr5+ intestinal stem cells. Our findings establish that deregulated Hh/Gli sig-
naling can function as an oncogenic driver to produce invasive gastric adenocarcinomas in adult
mice; identify Lgr5+ gastric stem cells as the likely cells of origin for these tumors; support the con-
cept that STAT3 activation is a key signaling event in gastric cancer; and underscore the importance
of tissue context in defining responsiveness to oncogenic signaling.
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ΔNp63α in squamous cancer pathogenesis
KE King,1 L Ha,1 RM Ponnamperuma,1 S Jay2 and WC Weinberg1 1 Laboratory of Molecular
Oncology, Division of Monoclonal Antibodies, Center for Drug Evaluation and Research/FDA,
Bethesda, MD and 2 SAIC Frederick, Inc., Frederick, MD
ΔNp63α, the predominant p63 isoform in epidermis, is expressed in basal keratinocytes and over-
expressed in human squamous cell carcinomas. To delineate the biological contribution and iden-
tify downstream mediators of ΔNp63α in keratinocyte growth regulation, differentiation, survival,
and cancer development, we have used adenoviral and lentiviral vectors to drive transient and sus-
tained overexpression of ΔNp63α.in primary mouse keratinocytes. We previously established that
transient overexpression of ΔNp63α inhibits Ca2+-mediated growth arrest and biochemical differ-
entiation of primary murine keratinocytes, and that the block in growth arrest is mediated via the
NF-κB subunit c-Rel. c-Rel accumulates in a phosphorylated form in the nucleus of ΔNp63α-over-
expressing cells and binds in complex with ΔNp63α to a p63 binding site on the p21waf1 promoter.
Consistent with these findings, keratinocytes expressing lenti-ΔNp63α demonstrate enhanced pro-
liferation rates over 15 days in culture relative to lenti-GFP control cultures. These cultures also
exhibit a block in senescence associated with decreased levels of p16 and p19. Following grafting
to nude mice, keratinocytes expressing lenti-ΔNp63α in combination with oncogenic v-rasHa form
undifferentiated carcinomas, in contrast to the well-differentiated papillomas observed with onco-
genic v-rasHa alone. Lentivirus-driven ΔNp63α overexpression also results in sustained nuclear
accumulation of c-Rel. Lentiviral c-Rel shRNAs have been developed to knock down c-Rel in ΔNp63α-
overexpressing keratinocytes and provide a model system for elucidating the contribution of NFkB/c-
rel to ΔNp63α /v-rasHa-driven carcinogenesis.
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